Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2015 | Apr. 29, 2015 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | COMMUNITY HEALTH SYSTEMS INC | |
Entity Central Index Key | 1108109 | |
Document Type | 10-Q | |
Document Period End Date | 31-Mar-15 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q1 | |
Current Fiscal Year End Date | -19 | |
Trading Symbol | CYH | |
Amendment Flag | FALSE | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 118,034,114 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Income (Loss) (USD $) | 3 Months Ended | |
In Millions, except Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Condensed Consolidated Statements of Income (Loss) [Abstract] | ||
Operating revenues (net of contractual allowances and discounts) | $5,646 | $4,875 |
Provision for bad debts | 735 | 699 |
Net operating revenues | 4,911 | 4,176 |
Operating costs and expenses: | ||
Salaries and benefits | 2,257 | 1,992 |
Supplies | 762 | 632 |
Other operating expenses | 1,099 | 1,019 |
Government settlement and related costs | 8 | |
Electronic health records incentive reimbursement | -26 | -40 |
Rent | 116 | 98 |
Depreciation and amortization | 296 | 255 |
Amortization of software to be abandoned | 42 | |
Total operating costs and expenses | 4,512 | 3,998 |
Income from operations | 399 | 178 |
Interest expense, net | 241 | 224 |
Loss from early extinguishment of debt | 8 | 73 |
Equity in earnings of unconsolidated affiliates | -18 | -11 |
Impairment of long-lived assets | 24 | |
Income (loss) from continuing operations before income taxes | 168 | -132 |
Provision (benefit) for income taxes | 56 | -56 |
Income (loss) from continuing operations | 112 | -76 |
Discontinued operations, net of taxes: | ||
Loss from operations of entities sold or held for sale | -11 | -4 |
Impairment of hospitals sold or held for sale | -1 | -18 |
Loss on sale, net | -1 | |
Loss from discontinued operations, net of taxes | -13 | -22 |
Net income (loss) | 99 | -98 |
Less: Net income attributable to noncontrolling interests | 20 | 14 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | $79 | ($112) |
Basic earnings (loss) per share attributable to Community Health Systems, Inc. common stockholders: | ||
Continuing operations | $0.80 | ($0.84) |
Discontinued operations | ($0.11) | ($0.21) |
Net income (loss) | $0.69 | ($1.05) |
Diluted earnings (loss) per share attributable to Community Health Systems, Inc. common stockholders: | ||
Continuing operations | $0.79 | ($0.84) |
Discontinued operations | ($0.11) | ($0.21) |
Net income (loss) | $0.68 | ($1.05) |
Weighted-average number of shares outstanding: | ||
Basic | 114,419,590 | 106,601,997 |
Diluted | 115,057,668 | 106,601,997 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Condensed Consolidated Statements of Comprehensive Income (Loss) [Abstract] | ||
Net income (loss) | $99 | ($98) |
Other comprehensive (loss) income, net of income taxes: | ||
Net change in fair value of interest rate swaps, net of tax | -9 | 9 |
Net change in fair value of available-for-sale securities, net of tax | 1 | |
Amortization and recognition of unrecognized pension cost components, net of tax | 1 | |
Other comprehensive (loss) income | -7 | 9 |
Comprehensive income (loss) | 92 | -89 |
Less: Comprehensive income attributable to noncontrolling interests | 20 | 14 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | $72 | ($103) |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Current assets: | ||
Cash and cash equivalents | $222 | $509 |
Patient accounts receivable, net of allowance for doubtful accounts of $3,628 and $3,504 at March 31, 2015 and December 31, 2014, respectively | 3,606 | 3,409 |
Supplies | 561 | 557 |
Prepaid income taxes | 30 | |
Deferred income taxes | 341 | 341 |
Prepaid expenses and taxes | 189 | 192 |
Other current assets (including assets of hospitals held for sale of $7 and $38 at March 31, 2015 and December 31, 2014, respectively) | 507 | 528 |
Total current assets | 5,426 | 5,566 |
Property and equipment | 14,400 | 14,264 |
Less accumulated depreciation and amortization | -4,309 | -4,095 |
Property and equipment, net | 10,091 | 10,169 |
Goodwill | 8,954 | 8,951 |
Other assets, net (including assets of hospitals held for sale of $36 and $90 at March 31, 2015 and December 31, 2014, respectively) | 2,648 | 2,735 |
Total assets | 27,119 | 27,421 |
Current liabilities: | ||
Current maturities of long-term debt | 229 | 235 |
Accounts payable | 1,192 | 1,293 |
Income tax payable | 13 | |
Deferred income taxes | 23 | 23 |
Accrued interest | 157 | 227 |
Accrued liabilities (including liabilities of hospitals held for sale of $2 and $10 at March 31, 2015 and December 31, 2014, respectively) | 1,547 | 1,811 |
Total current liabilities | 3,161 | 3,589 |
Long-term debt | 16,740 | 16,681 |
Deferred income taxes | 844 | 845 |
Other long-term liabilities | 1,694 | 1,692 |
Total liabilities | 22,439 | 22,807 |
Redeemable noncontrolling interests in equity of consolidated subsidiaries | 520 | 531 |
Community Health Systems, Inc. stockholders' equity: | ||
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued | ||
Common stock, $.01 par value per share, 300,000,000 shares authorized; 119,000,326 shares issued and 118,024,777 shares outstanding at March 31, 2015, and 117,701,087 shares issued and 116,725,538 shares outstanding at December 31, 2014 | 1 | 1 |
Additional paid-in capital | 2,101 | 2,095 |
Treasury stock, at cost, 975,549 shares at March 31, 2015 and December 31, 2014 | -7 | -7 |
Accumulated other comprehensive loss | -70 | -63 |
Retained earnings | 2,056 | 1,977 |
Total Community Health Systems, Inc. stockholders' equity | 4,081 | 4,003 |
Noncontrolling interests in equity of consolidated subsidiaries | 79 | 80 |
Total equity | 4,160 | 4,083 |
Total liabilities and equity | $27,119 | $27,421 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Parenthetical) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, except Share data, unless otherwise specified | ||
Condensed Consolidated Balance Sheets [Abstract] | ||
Allowance for doubtful patient accounts | $3,628 | $3,504 |
Other current assets of hospitals held for sale | 7 | 38 |
Noncurrent assets of hospitals held for sale | 36 | 90 |
Current liabilities of hospitals held for sale | $2 | $10 |
Preferred stock, par value per share | $0.01 | $0.01 |
Preferred stock, shares authorized | 100,000,000 | 100,000,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value per share | $0.01 | $0.01 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 119,000,326 | 117,701,087 |
Common stock, shares outstanding | 118,024,777 | 116,725,538 |
Treasury stock, shares | 975,549 | 975,549 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements of Cash Flows (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Cash flows from operating activities: | ||
Net income (loss) | $99 | ($98) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
Depreciation and amortization | 296 | 302 |
Government settlement and related costs | 8 | |
Stock-based compensation expense | 14 | 11 |
Loss on sale, net | 1 | |
Impairment of long-lived assets and hospitals sold or held for sale | 2 | 42 |
Loss from early extinguishment of debt | 8 | 73 |
Excess tax benefit relating to stock-based compensation | -3 | |
Other non-cash expenses, net | -7 | 6 |
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures: | ||
Patient accounts receivable | -202 | -171 |
Supplies, prepaid expenses and other current assets | 14 | 14 |
Accounts payable, accrued liabilities and income taxes | -284 | -83 |
Other | -10 | -28 |
Net cash (used in) provided by operating activities | -61 | 65 |
Cash flows from investing activities: | ||
Acquisitions of facilities and other related equipment | -13 | -2,774 |
Purchases of property and equipment | -241 | -181 |
Proceeds from disposition of hospitals and other ancillary operations | 62 | |
Proceeds from sale of property and equipment | 3 | |
Purchases of available-for-sale securities | -59 | -78 |
Proceeds from sales of available-for-sale securities | 56 | 76 |
Increase in other investments | -39 | -99 |
Net cash used in investing activities | -231 | -3,056 |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 17 | 6 |
Repurchase of restricted stock shares for payroll tax withholding requirements | -20 | -11 |
Deferred financing costs and other debt-related costs | -20 | -269 |
Excess tax benefit relating to stock-based compensation | 3 | |
Redemption of noncontrolling investments in joint ventures | -7 | -5 |
Distributions to noncontrolling investors in joint ventures | -23 | -19 |
Borrowings under credit agreements | 1,251 | 7,079 |
Issuance of long-term debt | 4,000 | |
Proceeds from receivables facility | 75 | 133 |
Repayments of long-term indebtedness | -1,268 | -7,686 |
Net cash provided by financing activities | 5 | 3,231 |
Net change in cash and cash equivalents | -287 | 240 |
Cash and cash equivalents at beginning of period | 509 | 373 |
Cash and cash equivalents at end of period | 222 | 613 |
Supplemental disclosure of cash flow information: | ||
Interest payments | -300 | -175 |
Income tax (payments) refunds, net | ($1) | $79 |
Basis_of_Presentation_and_Sign
Basis of Presentation and Significant Accounting Policies | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Basis of Presentation and Significant Accounting Policies [Abstract] | ||||||
Basis of Presentation and Significant Accounting Policies Disclosure | 1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES | |||||
The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2015 and December 31, 2014 and for the three-month periods ended March 31, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of Health Management Associates, Inc. (“HMA”) are included from January 27, 2014, the date of the HMA merger. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2015. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2014, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2015. | ||||||
Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets. | ||||||
During the three months ended March 31, 2014, the Company made the decision to sell several smaller hospitals and entered into definitive agreements to sell two hospitals. Since March 31, 2014, the Company made the decision to sell two additional hospitals. The condensed consolidated statement of income for the three months ended March 31, 2014 has been restated to reclassify the results of operations for these hospitals that were owned or leased in 2014 to discontinued operations. | ||||||
Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc. | ||||||
Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses. | ||||||
The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. For all other non-self-pay payor categories, the Company reserves 100% of all accounts aging over 365 days from the date of discharge. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies. | ||||||
Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions. | ||||||
Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2015 and 2014, were as follows (in millions): | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Medicare | $ | 1,398 | $ | 1,261 | ||
Medicaid | 586 | 459 | ||||
Managed Care and other third-party payors | 2,946 | 2,450 | ||||
Self-pay | 716 | 705 | ||||
Total | $ | 5,646 | $ | 4,875 | ||
Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment. | ||||||
Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. | ||||||
Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available. | ||||||
In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met. | ||||||
Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers. | ||||||
The Company recognized approximately $26 million and $40 million for the three months ended March 31, 2015 and 2014, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology. These incentive reimbursements are presented as a reduction of operating costs and expenses on the condensed consolidated statements of income. The Company received cash related to the incentive reimbursement for HITECH incentives of approximately $54 million and $62 million for the three months ended March 31, 2015 and 2014, respectively. The Company recorded $75 million and $93 million as deferred revenue in connection with the receipt of these cash payments at March 31, 2015 and March 31, 2014, respectively, as all criteria for gain recognition had not been met. | ||||||
New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently decided to defer the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows. | ||||||
Accounting_for_StockBased_Comp
Accounting for Stock-Based Compensation | 3 Months Ended | |||||||||
Mar. 31, 2015 | ||||||||||
Accounting for Stock-Based Compensation [Abstract] | ||||||||||
Accounting for Stock-Based Compensation Disclosure | * | |||||||||
2. ACCOUNTING FOR STOCK-BASED COMPENSATION | ||||||||||
Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. 2009 Stock Option and Award Plan, amended and restated as of March 19, 2014 (the “2009 Plan”). | ||||||||||
The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock. Persons eligible to receive grants under the 2000 Plan include the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 have a 10-year contractual term, options granted in 2005 through 2007 have an eight-year contractual term and options granted in 2008 through 2011 have a 10-year contractual term. The Company has not granted stock option awards under the 2000 Plan since 2011. Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan. | ||||||||||
The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term. As of March 31, 2015, 3,192,176 shares of unissued common stock were reserved for future grants under the 2009 Plan. | ||||||||||
The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date. | ||||||||||
The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): | ||||||||||
Three Months Ended | ||||||||||
March 31, | ||||||||||
2015 | 2014 | |||||||||
Effect on income from continuing operations before income taxes | $ | -14 | $ | -11 | ||||||
Effect on net income | $ | -8 | $ | -7 | ||||||
At March 31, 2015, $103 million of unrecognized stock-based compensation expense related to outstanding unvested restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 29 months. There is no expense to be recognized related to stock options. There were no modifications to awards during the three months ended March 31, 2015 and 2014. | ||||||||||
Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows (in millions, except share and per share data): | ||||||||||
Weighted- | Aggregate | |||||||||
Average | Intrinsic | |||||||||
Weighted- | Remaining | Value as of | ||||||||
Average | Contractual | March 31, | ||||||||
Shares | Exercise Price | Term | 2015 | |||||||
Outstanding at December 31, 2014 | 1,953,727 | $ | 32.94 | |||||||
Granted | - | - | ||||||||
Exercised | -452,959 | 38.77 | ||||||||
Forfeited and cancelled | - | - | ||||||||
Outstanding at March 31, 2015 | 1,500,768 | $ | 31.18 | 4.7 years | $ | 32 | ||||
Exercisable at March 31, 2015 | 1,498,764 | $ | 31.19 | 4.7 years | $ | 37 | ||||
No stock options were granted during the three months ended March 31, 2015 and 2014. The aggregate intrinsic value (the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($52.28) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on March 31, 2015. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the three months ended March 31, 2015 and 2014 was $5 million and $1 million, respectively. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. | ||||||||||
The Company has also awarded restricted stock under the 2000 Plan and the 2009 Plan to its directors and employees of certain subsidiaries. The restrictions on these shares generally lapse in one-third increments on each of the first three anniversaries of the award date. Certain of the restricted stock awards granted to the Company’s senior executives contain a performance objective that must be met in addition to any time-based vesting requirements. If the performance objective is not attained, the awards will be forfeited in their entirety. Once the performance objective has been attained, restrictions will lapse in one-third increments on each of the first three anniversaries of the award date. In addition, 835,000 restricted stock awards granted March 1, 2014 have a performance objective that is measured based on the realization of synergies related to the HMA merger over a two-year period that began on February 1, 2014. The performance objective could be met in part in the first year or in whole or in part over such two-year period. Depending on the degree of attainment of the performance objective, restrictions may lapse on a portion of the award grant over the first three anniversaries of the award date at a level dependent upon the amount of synergies realized. If the synergies related to the HMA merger did not reach a certain level, then the awards would have been forfeited in their entirety. Based on the synergy levels attained in the first annual measurement period ending on January 31, 2015, the performance objective for the first measurement period was met, and one-third of the awards vested on March 1, 2015. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2000 Plan and the 2009 Plan will lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance standards that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied. | ||||||||||
Restricted stock outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows: | ||||||||||
Weighted- | ||||||||||
Average Grant | ||||||||||
Shares | Date Fair Value | |||||||||
Unvested at December 31, 2014 | 2,760,639 | $ | 39.82 | |||||||
Granted | 1,223,500 | 47.72 | ||||||||
Vested | -1,115,006 | 37.45 | ||||||||
Forfeited | - | - | ||||||||
Unvested at March 31, 2015 | 2,869,133 | 44.11 | ||||||||
Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2000 Plan and the 2009 Plan. On February 27, 2013, each of the Company’s outside directors received a grant under the 2009 Plan of 3,596 RSUs. On March 1, 2014, each of the Company’s outside directors received a grant under the 2009 Plan of 3,614 RSUs. On March 1, 2015, each of the Company’s outside directors received a grant under the 2009 Plan of 3,504 RSUs. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date. | ||||||||||
RSUs outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows: | ||||||||||
Weighted- | ||||||||||
Average Grant | ||||||||||
Shares | Date Fair Value | |||||||||
Unvested at December 31, 2014 | 49,362 | $ | 36.07 | |||||||
Granted | 21,024 | 47.70 | ||||||||
Vested | -27,708 | 31.76 | ||||||||
Forfeited | - | - | ||||||||
Unvested at March 31, 2015 | 42,678 | 44.59 | ||||||||
Cost_of_Revenue
Cost of Revenue | 3 Months Ended |
Mar. 31, 2015 | |
Cost of Revenue [Abstract] | |
Cost of Revenue Disclosure | 3. COST OF REVENUE |
Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office and Naples, Florida office, (which was the headquarters of HMA prior to the closing of the HMA merger), which collectively were $77 million for both the three months ended March 31, 2015 and 2014. During the three months ended March 31, 2015, corporate office costs from the Naples, Florida office were significantly lower than the three months ended March 31, 2014 due to the integration of the HMA corporate functions. Included in these corporate office costs is stock-based compensation of $14 million and $11 million for the three months ended March 31, 2015 and 2014, respectively. | |
Use_of_Estimates
Use of Estimates | 3 Months Ended |
Mar. 31, 2015 | |
Use of Estimates [Abstract] | |
Use of Estimates Disclosure | 4. USE OF ESTIMATES |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions. | |
Acquisitions_and_Divestitures
Acquisitions and Divestitures | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Acquisitions And Divestitures [Abstract] | ||||||
Acquisitions and Divestitures Disclosure | ||||||
5. ACQUISITIONS AND DIVESTITURES | ||||||
Acquisitions | ||||||
The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition. Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired. | ||||||
Approximately $3 million and $57 million of acquisition and related integration costs related to prospective and closed acquisitions were expensed during the three months ended March 31, 2015 and 2014, respectively, and are included in other operating expenses on the condensed consolidated statements of income. | ||||||
Effective November 1, 2014, the Company entered into and closed on a restructuring agreement related to the joint venture between an affiliate of the Company and an affiliate of Novant Health, Inc. (“Novant”), the non-profit joint venture partner. Through this joint venture, Novant owned an indirect noncontrolling interest in Lake Norman Regional Medical Center (“Lake Norman”), one of the former HMA hospitals. The HMA merger triggered a change in control provision in the operating agreement of this joint venture, requiring the Company to purchase the 30% noncontrolling interest in Lake Norman held by Novant for the higher of fair value or $150 million. As part of the restructuring agreement, on November 3, 2014, the Company paid Novant (1) $150 million for its 30% noncontrolling interest in Lake Norman, (2) approximately $4 million to acquire Upstate Carolina Medical Center (125 licensed beds) in Gaffney, South Carolina, and (3) approximately $5 million to settle prior claims with Novant. The amounts paid to Novant to acquire the noncontrolling interest in Lake Norman and to settle prior claims were recognized as part of the opening balance sheet in the purchase accounting for HMA. Based upon our preliminary purchase price allocation relating to this acquisition as of March 31, 2015, no goodwill has been recorded related to the acquisition of Upstate Carolina Medical Center. The preliminary allocation of the purchase price has been determined by us based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material. | ||||||
On October 1, 2014, one or more subsidiaries of the Company completed the acquisition of Natchez Regional Medical Center (179 licensed beds) in Natchez, Mississippi. The total cash consideration paid at closing for long-lived assets was $10 million. As part of the closing, the Company also paid $8 million as a prepayment for future property taxes that will be applied to the tax liability for the next 17 years. Based upon our preliminary purchase price allocation relating to this acquisition as of March 31, 2015, no goodwill has been recorded. The preliminary allocation of the purchase price has been determined by us based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material. | ||||||
Effective April 1, 2014, one or more subsidiaries of the Company completed the acquisition of Sharon Regional Health System in Sharon, Pennsylvania. This healthcare system includes Sharon Regional (258 licensed beds) and other outpatient and ancillary services. The total cash consideration paid for long-lived assets and working capital was approximately $67 million and $1 million, respectively, with additional consideration of $9 million assumed in liabilities, for a total consideration of $77 million. Based upon the Company’s purchase price allocation relating to this acquisition as of March 31, 2015, approximately $8 million of goodwill has been recorded. | ||||||
Effective April 1, 2014, one or more subsidiaries of the Company completed the acquisition of a 95% interest in Munroe Regional Medical Center (421 licensed beds) in Ocala, Florida and its other outpatient and ancillary services through a joint venture arrangement with an affiliate of a regional not-for-profit healthcare system, which acquired the remaining 5% interest. The total cash consideration paid for long-lived assets plus prepaid rent on the leased property and working capital was approximately $192 million and $4 million, respectively, with additional consideration of $11 million assumed in liabilities, for a total consideration of $207 million. The value of the noncontrolling interest at acquisition was $10 million. Based upon the Company’s purchase price allocation relating to this acquisition as of March 31, 2015, approximately $11 million of goodwill has been recorded. | ||||||
HMA Merger | ||||||
On January 27, 2014, the Company completed the HMA merger by acquiring all the outstanding shares of HMA’s common stock for approximately $7.3 billion, including the assumption of approximately $3.8 billion of existing indebtedness, for consideration for each share of HMA’s common stock consisting of $10.50 in cash, 0.06942 of a share of the Company’s common stock, and one contingent value right (“CVR”). The CVR entitles the holder to receive a cash payment of up to $1.00 per CVR (subject to downward adjustment but not below zero), subject to the final resolution of certain legal matters pertaining to HMA, as defined in the CVR agreement. At the time of the completion of the HMA merger, HMA owned and operated 71 hospitals in 15 states in non-urban communities located primarily in the southeastern United States. | ||||||
In connection with the HMA merger, the Company and CHS/Community Health Systems, Inc. (“CHS”) entered into a third amendment and restatement of its credit facility, providing for additional financing and recapitalization of certain of the Company’s term loans. In addition, the Company and CHS also issued in connection with the HMA merger: (i) $1.0 billion aggregate principal amount of 5.125% Senior Secured Notes due 2021 and (ii) $3.0 billion aggregate principal amount of 6.875% Senior Notes due 2022. | ||||||
The total consideration of the HMA merger has been allocated to the assets acquired and liabilities assumed based upon their respective fair values, resulting in $4.5 billion of goodwill resulting from the final purchase price allocation at December 31, 2014. The purchase price represented a premium over the fair value of the net tangible and identifiable intangible assets acquired for reasons such as: | ||||||
· the expansion of the number of markets in which the Company operates in existing states; | ||||||
· the extension and strengthening of the Company’s hospital and physician networks; | ||||||
· the centralization of many support functions; and | ||||||
· the elimination of duplicate corporate functions. | ||||||
Other Acquisitions | ||||||
During the three months ended March 31, 2015, the Company paid approximately $12 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during 2015, the Company allocated approximately $8 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. | ||||||
Discontinued Operations | ||||||
Effective January 1, 2015, one or more subsidiaries of the Company sold Carolina Pines Regional Medical Center (116 licensed beds) in Hartsville, South Carolina and related outpatient services to Capella Healthcare for approximately $74 million in cash, which was received at the closing on December 31, 2014. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger. | ||||||
Effective February 1, 2015, one or more subsidiaries of the Company sold Harris Hospital (133 licensed beds) in Newport, Arkansas and related healthcare services to White County Medical Center in Searcy, Arkansas for approximately $5 million in cash. | ||||||
Effective March 1, 2015, one or more subsidiaries of the Company sold Riverview Regional Medical Center (281 licensed beds) in Gadsden, Alabama to Prime Healthcare Services, LLC. (“Prime”) for approximately $25 million in cash. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger. | ||||||
Effective March 1, 2015, one or more subsidiaries of the Company sold Dallas Regional Medical Center (202 licensed beds) in Mesquite, Texas to Prime for approximately $25 million in cash. | ||||||
During the year ended December 31, 2014, the Company made the decision to sell and began actively marketing several smaller hospitals, which are classified as held for sale at March 31, 2015. In addition, HMA entered into a definitive agreement to sell Williamson Memorial Hospital (76 licensed beds) located in Williamson, West Virginia prior to the HMA merger. In connection with management’s decision to sell these facilities and the sale of the four hospitals noted above during 2015, the Company has classified the results of operations of the above mentioned hospitals as discontinued operations in the accompanying condensed consolidated statements of income, and classified these hospitals as held for sale in the accompanying condensed consolidated balance sheet. | ||||||
Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions): | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Net operating revenues | $ | 56 | $ | 89 | ||
Loss from operations of entities sold or held for sale | ||||||
before income taxes | -17 | -7 | ||||
Impairment of hospitals sold or held for sale | -1 | -22 | ||||
Loss on sale, net | -1 | - | ||||
Loss from discontinued operations, before taxes | -19 | -29 | ||||
Income tax benefit | -6 | -7 | ||||
Loss from discontinued operations, net of taxes | $ | -13 | $ | -22 | ||
Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment. | ||||||
In April 2014, FASB issued ASU 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that are recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. The Company adopted this ASU on January 1, 2015 and the adoption did not have a material impact on the Company’s consolidated financial position, results of operations and cash flows as of and for the three months ended March 31, 2015. | ||||||
Income_Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2015 | |
Income Taxes [Abstract] | |
Income Taxes Disclosure | |
6. INCOME TAXES | |
The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $5 million as of March 31, 2015. A total of approximately $2 million of interest and penalties is included in the amount of the liability for uncertain tax positions at March 31, 2015. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its condensed consolidated statements of income as income tax expense. | |
It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position. | |
The Company, or one of its subsidiaries, files income tax returns in the United States federal jurisdiction and various state jurisdictions. The Company has extended the federal statute of limitations through December 31, 2015 for Triad Hospitals, Inc. for the tax periods ended December 31, 1999, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, the Company is no longer subject to state income tax examinations for years prior to 2011. The Company’s federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2015 for Community Health Systems, Inc. for the tax periods ended December 31, 2007 and 2008, through June 30, 2015 for the tax periods ended December 31, 2009 and 2010, and through September 6, 2016 for the tax period ended December 31, 2011. | |
The Company’s effective tax rates were 33.2% and 42.5% for the three months ended March 31, 2015 and 2014, respectively. The decrease in the Company’s effective tax rate for the three months ended March 31, 2015 is primarily impacted by the increase in income from continuing operations before income taxes, and the impact of non-deductible transaction costs associated with the HMA merger affecting the tax provision for the three months ended March 31, 2014. | |
Cash paid for income taxes, net of refunds received, resulted in net cash paid of $1 million and a net cash refund of $79 million during the three months ended March 31, 2015 and 2014, respectively. | |
Goodwill_and_Other_Intangible_
Goodwill and Other Intangible Assets | 3 Months Ended | |||
Mar. 31, 2015 | ||||
Goodwill and Other Intangible Assets [Abstract] | ||||
Goodwill and Other Intangible Assets Disclosure | ||||
7. GOODWILL AND OTHER INTANGIBLE ASSETS | ||||
Goodwill | ||||
The changes in the carrying amount of goodwill for the three months ended March 31, 2015 are as follows (in millions): | ||||
Balance as of December 31, 2014 | $ | 8,951 | ||
Goodwill acquired as part of acquisitions during current year | 4 | |||
Consideration and purchase price allocation adjustments | ||||
for prior year’s acquisitions and other adjustments | -1 | |||
Balance as of March 31, 2015 | $ | 8,954 | ||
Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2015, the hospital operations reporting unit, the home care agency operations reporting unit, and the hospital management services reporting unit had approximately $8.9 billion, $44 million and $33 million, respectively, of goodwill. | ||||
Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2014. No impairment was indicated by this evaluation. The next annual goodwill evaluation will be performed during the fourth quarter of 2015. | ||||
The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions. | ||||
Intangible Assets | ||||
No intangible assets other than goodwill were acquired during the three months ended March 31, 2015. The gross carrying amount of the Company’s other intangible assets subject to amortization was $76 million at both March 31, 2015 and December 31, 2014, and the net carrying amount was $35 million at March 31, 2015 and $39 million at December 31, 2014. The carrying amount of the Company’s other intangible assets not subject to amortization was $128 million and $131 million at March 31, 2015 and December 31, 2014, respectively. Other intangible assets are included in other assets, net on the Company’s condensed consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions. | ||||
The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately four years. There are no expected residual values related to these intangible assets. Amortization expense on these intangible assets was $3 million and $1 million during the three months ended March 31, 2015 and 2014, respectively. Amortization expense on intangible assets is estimated to be $10 million for the remainder of 2015, $13 million in 2016, $3 million in 2017, $2 million in 2018, $2 million in 2019, $2 million in 2020 and $3 million thereafter. | ||||
The gross carrying amount of capitalized software for internal use was approximately $1.4 billion and $1.5 billion at March 31, 2015 and December 31, 2014, respectively, and the net carrying amount considering accumulated amortization was approximately $769 million and $790 million at March 31, 2015 and December 31, 2014, respectively. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, which is generally eight to ten years. There is no expected residual value for capitalized internal-use software. At March 31, 2015, there was approximately $33 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $53 million and $84 million during the three months ended March 31, 2015 and 2014, respectively. Amortization expense on capitalized internal-use software is estimated to be $146 million for the remainder of 2015, $167 million in 2016, $103 million in 2017, $75 million in 2018, $68 million in 2019, $65 million in 2020 and $145 million thereafter. | ||||
In connection with the HMA merger, the Company further analyzed its intangible assets related to internal-use software used in certain of its hospitals for patient and clinical systems, including software required to meet criteria for meaningful use attestation and ICD-10 compliance. This analysis resulted in management reassessing its usage of certain software products and rationalizing that, with the addition of the HMA hospitals in the first quarter of 2014, those software applications were going to be discontinued and replaced with new applications that better integrate meaningful use and ICD-10 compliance, are more cost effective and can be implemented at a greater efficiency of scale over future implementations. During the three months ended March 31, 2014, the Company recorded an impairment charge of approximately $24 million related to software in-process that was abandoned at March 31, 2014 and the acceleration of amortization of approximately $42 million related to shortening the remaining useful life of software abandoned by July 1, 2014. | ||||
Earnings_Per_Share
Earnings Per Share | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Earnings Per Share [Abstract] | ||||||
Earnings Per Share Disclosure | ||||||
8. EARNINGS PER SHARE | ||||||
The following table sets forth the components of the numerator and denominator for the computation of basic and diluted earnings per share for income (loss) from continuing operations, discontinued operations and net income attributable to Community Health Systems, Inc. common stockholders (in millions, except share data): | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Numerator: | ||||||
Income (loss) from continuing operations, net of taxes | $ | 112 | $ | -76 | ||
Less: Income from continuing operations attributable | ||||||
to noncontrolling interests, net of taxes | 20 | 14 | ||||
Income (loss) from continuing operations attributable to | ||||||
Community Health Systems, Inc. common | ||||||
stockholders — basic and diluted | $ | 92 | $ | -90 | ||
Loss from discontinued operations, net of taxes | $ | -13 | $ | -22 | ||
Less: Loss from discontinued operations attributable | ||||||
to noncontrolling interests, net of taxes | - | - | ||||
Loss from discontinued operations attributable to | ||||||
Community Health Systems, Inc. common | ||||||
stockholders — basic and diluted | $ | -13 | $ | -22 | ||
Denominator: | ||||||
Weighted-average number of shares outstanding — basic | 114,419,590 | 106,601,997 | ||||
Effect of dilutive securities: | ||||||
Restricted stock awards | 181,120 | - | ||||
Employee stock options | 452,659 | - | ||||
Other equity-based awards | 4,299 | - | ||||
Weighted-average number of shares outstanding — diluted | 115,057,668 | 106,601,997 | ||||
The Company generated a loss from continuing operations attributable to Community Health Systems, Inc. common stockholders for the three months ended March 31, 2014, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income from continuing operations during the three months ended March 31, 2014, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 578,587 shares. | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Dilutive securities outstanding not included in | ||||||
the computation of earnings per | ||||||
share because their effect is antidilutive: | ||||||
Employee stock options and restricted stock awards | - | 1,891,000 | ||||
Stockholders_Equity
Stockholders' Equity | 3 Months Ended | ||||||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||||||||||||||
Stockholders' Equity Disclosure | |||||||||||||||||||||||||
9. STOCKHOLDERS’ EQUITY | |||||||||||||||||||||||||
Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of March 31, 2015, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock. | |||||||||||||||||||||||||
On December 10, 2014, the Company adopted a new open market repurchase program for up to 5,000,000 shares of the Company’s common stock, not to exceed $150 million in repurchases. The repurchase program will expire at the earliest of three years from the commencement date, when the maximum number of shares has been repurchased, or when the maximum dollar amount of repurchases has been expended. During the three months ended March 31, 2015, the Company did not repurchase and retire any shares under this program. | |||||||||||||||||||||||||
With the exception of a cash dividend of $0.25 per share paid by the Company in December 2012, historically, the Company has not paid any cash dividends. The Company’s Credit Facility limits the Company’s ability to pay dividends and/or repurchase stock to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing the senior and senior secured notes also limit the Company’s ability to pay dividends and/or repurchase stock. As of March 31, 2015, under the most restrictive test under these agreements, the Company has approximately $461 million remaining available with which to pay permitted dividends and/or repurchase shares of stock or its senior and senior secured notes. | |||||||||||||||||||||||||
The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company, and equity attributable to the noncontrolling interests for the three-month period ended March 31, 2015 (in millions): | |||||||||||||||||||||||||
Community Health Systems, Inc. Stockholders | |||||||||||||||||||||||||
Redeemable Noncontrolling Interest | Common Stock | Additional Paid-In Capital | Treasury Stock | Accumulated Other Comprehensive Income (Loss) | Retained Earnings | Noncontrolling Interest | Total Stockholders’ Equity | ||||||||||||||||||
Balance, December 31, 2014 | $ | 531 | $ | 1 | $ | 2,095 | $ | -7 | $ | -63 | $ | 1,977 | $ | 80 | $ | 4,083 | |||||||||
Comprehensive income | 16 | - | - | - | -7 | 79 | 4 | 76 | |||||||||||||||||
Distributions to noncontrolling | |||||||||||||||||||||||||
interests, net of contributions | -17 | - | - | - | - | - | -6 | -6 | |||||||||||||||||
Purchase of subsidiary shares | |||||||||||||||||||||||||
from noncontrolling interests | -7 | - | - | - | - | - | - | - | |||||||||||||||||
Disposition of less-than-wholly | |||||||||||||||||||||||||
owned hospital | -8 | - | - | - | - | - | - | - | |||||||||||||||||
Other reclassifications of | |||||||||||||||||||||||||
noncontrolling interests | -1 | - | - | - | - | - | 1 | 1 | |||||||||||||||||
Adjustment to redemption | |||||||||||||||||||||||||
value of redeemable | |||||||||||||||||||||||||
noncontrolling interests | 6 | - | -6 | - | - | - | - | -6 | |||||||||||||||||
Issuance of common stock | |||||||||||||||||||||||||
in connection with the | |||||||||||||||||||||||||
exercise of stock options | - | - | 18 | - | - | - | - | 18 | |||||||||||||||||
Cancellation of restricted | |||||||||||||||||||||||||
stock for tax withholdings | |||||||||||||||||||||||||
on vested shares | - | - | -20 | - | - | - | - | -20 | |||||||||||||||||
Share-based compensation | - | - | 14 | - | - | - | - | 14 | |||||||||||||||||
Balance, March 31, 2015 | $ | 520 | $ | 1 | $ | 2,101 | $ | -7 | $ | -70 | $ | 2,056 | $ | 79 | $ | 4,160 | |||||||||
The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ equity (in millions): | |||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||
31-Mar-15 | |||||||||||||||||||||||||
Net income attributable to Community Health Systems, | |||||||||||||||||||||||||
Inc. stockholders | $ | 79 | |||||||||||||||||||||||
Transfers to the noncontrolling interests: | |||||||||||||||||||||||||
Net decrease in Community Health Systems, Inc. paid-in | |||||||||||||||||||||||||
capital for purchase of subsidiary partnership interests | - | ||||||||||||||||||||||||
Net transfers to the noncontrolling interests | - | ||||||||||||||||||||||||
Change to Community Health Systems, Inc. stockholders’ equity | |||||||||||||||||||||||||
from net income attributable to Community Health Systems, | |||||||||||||||||||||||||
Inc. stockholders and transfers to noncontrolling interests | $ | 79 | |||||||||||||||||||||||
Equity_Investments
Equity Investments | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Equity Investments [Abstract] | ||||||
Equity Investments Disclosure | ||||||
10. EQUITY INVESTMENTS | ||||||
As of March 31, 2015, the Company owned equity interests of 27.5% in four hospitals in Las Vegas, Nevada, and 26.1% in one hospital in Las Vegas, Nevada, in which Universal Health Systems, Inc. owns the majority interest, and an equity interest of 38.0% in three hospitals in Macon, Georgia, in which HCA Holdings Inc. owns the majority interest. | ||||||
Summarized combined financial information for these unconsolidated entities in which the Company owns an equity interest is as follows (in millions): | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Revenues | $ | 375 | $ | 332 | ||
Operating costs and expenses | 315 | 294 | ||||
Income from continuing operations before taxes | 60 | 39 | ||||
The summarized financial information was derived from the unaudited financial information provided to the Company by those unconsolidated entities. | ||||||
In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As part of the HMA merger, the Company acquired HMA’s ownership in HealthTrust. As of March 31, 2015, the Company had a 25.1% ownership interest in HealthTrust. | ||||||
The Company’s investment in all of its unconsolidated affiliates was $488 million and $470 million at March 31, 2015 and December 31, 2014, respectively, and is included in other assets, net in the accompanying condensed consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $18 million and $11 million for the three months ended March 31, 2015 and 2014, respectively. | ||||||
LongTerm_Debt
Long-Term Debt | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Long-term Debt [Abstract] | ||||||
Long-Term Debt Disclosure | ||||||
11. LONG-TERM DEBT | ||||||
Long-term debt consists of the following (in millions): | ||||||
March 31, | December 31, | |||||
2015 | 2014 | |||||
Credit Facility: | ||||||
Term A Loan | $ | 925 | $ | 950 | ||
Term D Loan | 4,544 | 4,555 | ||||
Term E Loan | - | 1,660 | ||||
Term F Loan | 1,700 | - | ||||
Revolving credit loans | 62 | - | ||||
8% Senior Notes due 2019 | 2,017 | 2,018 | ||||
7⅛% Senior Notes due 2020 | 1,200 | 1,200 | ||||
5⅛% Senior Secured Notes due 2018 | 1,600 | 1,600 | ||||
5⅛% Senior Secured Notes due 2021 | 1,000 | 1,000 | ||||
6⅞% Senior Notes due 2022 | 3,000 | 3,000 | ||||
Receivables Facility | 623 | 614 | ||||
Capital lease obligations | 215 | 228 | ||||
Other | 83 | 91 | ||||
Total debt | 16,969 | 16,916 | ||||
Less current maturities | -229 | -235 | ||||
Total long-term debt | $ | 16,740 | $ | 16,681 | ||
Credit Facility | ||||||
The Company’s wholly-owned subsidiary, CHS, has senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, the Company and CHS entered into a third amendment and restatement of its credit facility (the “Credit Facility”), providing for additional financing and recapitalization of certain of the Company’s term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019 (the “Revolving Facility”), (ii) the addition of a new $1.0 billion Term A facility due 2019 (the “Term A Facility”), (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which includes certain term C loans that were converted into such Term D facility (collectively, the “Term D Facility”)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the Company’s post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility included a subfacility for letters of credit. On March 9, 2015, CHS entered into a first amendment and incremental term loan assumption agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion dollars. | ||||||
The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term D Facility and the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term D Facility will be subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor. | ||||||
The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on the Company’s leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to the Company’s EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements. | ||||||
The borrower under the Credit Facility is CHS. All of the obligations under the Credit Facility are unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries. | ||||||
CHS has agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. CHS is obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility. | ||||||
The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s and its subsidiaries’ ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of the Company’s businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change the Company’s fiscal year. The Company is also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants. | ||||||
Events of default under the Credit Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility. | ||||||
As of March 31, 2015, the availability for additional borrowings under the Credit Facility, after consideration of the $62 million outstanding at that date, was approximately $1.0 billion pursuant to the Revolving Facility, of which $83 million was set aside for outstanding letters of credit. CHS has the ability to amend the Credit Facility to provide for one or more tranches of term loans or increases in the Revolving Facility in an aggregate principal amount of $1.5 billion, which CHS has not yet accessed. As of March 31, 2015, the weighted-average interest rate under the Credit Facility, excluding swaps, was 4.4%. | ||||||
8% Senior Notes due 2019 | ||||||
On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019 (the “8% Senior Notes”), which were issued in a private placement. The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes and related fees and expenses. On March 21, 2012, CHS completed the secondary offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%). The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes, to pay related fees and expenses and for general corporate purposes. The 8% Senior Notes bear interest at 8% per annum, payable semiannually in arrears on May 15 and November 15, commencing May 15, 2012. Interest on the 8% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. | ||||||
Except as set forth below, CHS is not entitled to redeem the 8% Senior Notes prior to November 15, 2015. | ||||||
Prior to November 15, 2015, CHS may redeem some or all of the 8% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 8% Senior Notes indenture. On and after November 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: | ||||||
Period | Redemption Price | |||||
November 15, 2015 to November 14, 2016 | 104.000 | % | ||||
November 15, 2016 to November 14, 2017 | 102.000 | % | ||||
November 15, 2017 to November 15, 2019 | 100.000 | % | ||||
Pursuant to a registration rights agreement entered into at the time of the issuance of the 8% Senior Notes, as a result of an exchange offer made by CHS, substantially all of the 8% Senior Notes issued in November 2011 and March 2012 were exchanged in May 2012 for new notes (the “8% Exchange Notes”) having terms substantially identical in all material respects to the 8% Senior Notes (except that the 8% Exchange Notes were issued under a registration statement pursuant to the Securities Act of 1933, as amended (the “1933 Act”)). References to the 8% Senior Notes shall also be deemed to include the 8% Exchange Notes unless the context provides otherwise. | ||||||
7⅛% Senior Notes due 2020 | ||||||
On July 18, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7⅛% Senior Notes due 2020 (the “7⅛% Senior Notes”). The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount plus accrued interest of CHS’ outstanding 8⅞% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes. The 7⅛% Senior Notes bear interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15, commencing January 15, 2013. Interest on the 7⅛% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. | ||||||
Except as set forth below, CHS is not entitled to redeem the 7⅛% Senior Notes prior to July 15, 2016. | ||||||
Prior to July 15, 2015, CHS is entitled, at its option, to redeem a portion of the 7⅛% Senior Notes (not to exceed 35% of the outstanding principal amount) at a redemption price equal to 107.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to July 15, 2016, CHS may redeem some or all of the 7⅛% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 7⅛% Senior Notes indenture. On and after July 15, 2016, CHS is entitled, at its option, to redeem all or a portion of the 7⅛% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: | ||||||
Period | Redemption Price | |||||
July 15, 2016 to July 14, 2017 | 103.563 | % | ||||
July 15, 2017 to July 14, 2018 | 101.781 | % | ||||
July 15, 2018 to July 15, 2020 | 100.000 | % | ||||
5⅛% Senior Secured Notes due 2018 | ||||||
On August 17, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5⅛% Senior Secured Notes due 2018 (the “2018 Senior Secured Notes”). The net proceeds from this issuance, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses. The 2018 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on August 15 and February 15, commencing February 15, 2013. Interest on the 2018 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2018 Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2018 Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. | ||||||
Except as set forth below, CHS is not entitled to redeem the 2018 Senior Secured Notes prior to August 15, 2015. | ||||||
Prior to August 15, 2015, CHS is entitled, at its option, to redeem a portion of the 2018 Senior Secured Notes (not to exceed 35% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to August 15, 2015, CHS may redeem some or all of the 2018 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2018 Senior Secured Notes indenture. On and after August 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 2018 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: | ||||||
Period | Redemption Price | |||||
August 15, 2015 to August 14, 2016 | 102.563 | % | ||||
August 15, 2016 to August 14, 2017 | 101.281 | % | ||||
August 15, 2017 to August 15, 2018 | 100.000 | % | ||||
5⅛% Senior Secured Notes due 2021 | ||||||
On January 27, 2014, CHS issued $1.0 billion aggregate principal amount of 5⅛% Senior Secured Notes due 2021 (the “2021 Senior Secured Notes”) in connection with the HMA merger, which were issued in a private placement. The net proceeds from this issuance were used to finance the HMA merger. The 2021 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 2021 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2021 Senior Secured Notes are secured by a first-priority lien, subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2021 Senior Secured Notes, on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. | ||||||
Except as set forth below, CHS is not entitled to redeem the 2021 Senior Secured Notes prior to February 1, 2017. | ||||||
Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 2021 Senior Secured Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain equity offerings. Prior to February 1, 2017, CHS may redeem some or all of the 2021 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2021 Senior Secured Notes indenture. On and after February 1, 2017, CHS is entitled, at its option, to redeem all or a portion of the 2021 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: | ||||||
Period | Redemption Price | |||||
February 1, 2017 to January 31, 2018 | 103.844 | % | ||||
February 1, 2018 to January 31, 2019 | 102.563 | % | ||||
February 1, 2019 to January 31, 2020 | 101.281 | % | ||||
February 1, 2020 to January 31, 2021 | 100.000 | % | ||||
Pursuant to a registration rights agreement entered into at the time of the issuance of the 2021 Senior Secured Notes, as a result of an exchange offer made by CHS, all of the 2021 Senior Secured Notes issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 2021 Senior Secured Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 2021 Senior Secured Notes shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise. | ||||||
6⅞% Senior Notes due 2022 | ||||||
On January 27, 2014, CHS issued $3.0 billion aggregate principal amount of 6⅞% Senior Notes due 2022 (the “6⅞% Senior Notes”) in connection with the HMA merger, which were issued in a private placement. The net proceeds from this issuance were used to finance the HMA merger. The 6⅞% Senior Notes bear interest at 6.875% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 6⅞% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. | ||||||
Except as set forth below, CHS is not entitled to redeem the 6⅞% Senior Notes prior to February 1, 2018. | ||||||
Prior to February 1, 2018, CHS is entitled, at its option, to redeem a portion of the 6⅞% Senior Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 106.875% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to February 1, 2018, CHS may redeem some or all of the 6⅞% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 6⅞% Senior Notes indenture. On and after February 1, 2018, CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: | ||||||
Period | Redemption Price | |||||
February 1, 2018 to January 31, 2019 | 103.438 | % | ||||
February 1, 2019 to January 31, 2020 | 101.719 | % | ||||
February 1, 2020 to January 31, 2022 | 100.000 | % | ||||
Pursuant to a registration rights agreement entered into at the time of the issuance of the 6⅞% Senior Notes, as a result of an exchange offer made by CHS, all of the 6⅞% Senior Notes issued in January 2014 were exchanged in October 2014 for new notes (the “6⅞% Exchange Notes”) having terms substantially identical in all material respects to the 6⅞% Senior Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 6⅞% Senior Notes shall be deemed to be the 6⅞% Exchange Notes unless the context provides otherwise. | ||||||
Receivables Facility | ||||||
On March 21, 2012, CHS and certain of its subsidiaries entered into an accounts receivable loan agreement (the “Receivables Facility”) with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent. On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries of the Company also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries of the Company also agreed to participate in the Receivables Facility as of that date. The existing and future non-self pay patient-related accounts receivable (the “Receivables”) for certain of the Company’s hospitals serves as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread. Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on March 21, 2017, subject to customary termination events that could cause an early termination date. The Company maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of the Company’s subsidiaries to CHS, which then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS. The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to the Company or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan. The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2015 totaled $623 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2015, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.3 billion and is included in patient accounts receivable on the condensed consolidated balance sheet. | ||||||
Loss from Early Extinguishment of Debt | ||||||
The financing transactions discussed above resulted in a loss from early extinguishment of debt of $8 million and $73 million for the three months ended March 31, 2015 and 2014, respectively, and an after-tax loss of $5 million and $45 million for the three months ended March 31, 2015 and 2014, respectively. | ||||||
Other Debt | ||||||
As of March 31, 2015, other debt consisted primarily of the mortgage obligation on the Company’s corporate headquarters and other obligations maturing in various installments through 2020. | ||||||
To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to seven separate interest swap agreements in effect at March 31, 2015, with an aggregate notional amount for currently effective swaps of $1.3 billion, and six forward-starting swap agreements with an aggregate notional amount of $1.7 billion. On each of these swaps, the Company receives a variable rate of interest based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. The Company currently pays, on a quarterly basis, interest on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 275 basis points. Loans in respect of the Term D Facility and the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 325 basis points. The Term D Facility is also subject to a 100 basis point LIBOR floor and a 200 basis point Alternate Base Rate floor. See Note 12 for additional information regarding these swaps. | ||||||
The Company paid interest of $300 million and $175 million on borrowings during the three months ended March 31, 2015 and 2014, respectively. Subsequent to the issuance of the Company’s 2014 Quarterly Report on Form 10-Q for the three-month period ended March 31, 2014, the Company determined that it had incorrectly reported cash paid for interest during the three months ended March 31, 2014 of $280 million instead of the correct amount of $175 million. The Company concluded that this error was immaterial to its previously reported consolidated financial statements and had no impact on its consolidated financial position, results of operations, or cash flows. Correct amounts were reported in all subsequent quarterly and annual financial reports during 2014. | ||||||
Fair_Value_of_Financial_Instru
Fair Value of Financial Instruments | 3 Months Ended | |||||||||||||||||||||
Mar. 31, 2015 | ||||||||||||||||||||||
Fair Value of Financial Instruments [Abstract] | ||||||||||||||||||||||
Fair Value of Financial Instruments Disclosure | ||||||||||||||||||||||
12. FAIR VALUE OF FINANCIAL INSTRUMENTS | ||||||||||||||||||||||
The fair value of financial instruments has been estimated by the Company using available market information as of March 31, 2015 and December 31, 2014, and valuation methodologies considered appropriate. The estimates presented are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): | ||||||||||||||||||||||
31-Mar-15 | 31-Dec-14 | |||||||||||||||||||||
Carrying | Estimated Fair | Carrying | Estimated Fair | |||||||||||||||||||
Amount | Value | Amount | Value | |||||||||||||||||||
Assets: | ||||||||||||||||||||||
Cash and cash equivalents | $ | 222 | $ | 222 | $ | 509 | $ | 509 | ||||||||||||||
Available-for-sale securities | 285 | 285 | 280 | 280 | ||||||||||||||||||
Trading securities | 58 | 58 | 55 | 55 | ||||||||||||||||||
Liabilities: | ||||||||||||||||||||||
Contingent Value Right | 6 | 6 | 6 | 6 | ||||||||||||||||||
Credit Facility | 7,231 | 7,249 | 7,165 | 7,143 | ||||||||||||||||||
8% Senior Notes | 2,017 | 2,129 | 2,018 | 2,139 | ||||||||||||||||||
7⅛% Senior Notes | 1,200 | 1,277 | 1,200 | 1,282 | ||||||||||||||||||
2018 Senior Secured Notes | 1,600 | 1,655 | 1,600 | 1,655 | ||||||||||||||||||
2021 Senior Secured Notes | 1,000 | 1,034 | 1,000 | 1,041 | ||||||||||||||||||
6⅞% Senior Notes | 3,000 | 3,211 | 3,000 | 3,194 | ||||||||||||||||||
Receivables Facility and other debt | 706 | 706 | 705 | 705 | ||||||||||||||||||
The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 13. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant. | ||||||||||||||||||||||
Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). | ||||||||||||||||||||||
Available-for-sale securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. | ||||||||||||||||||||||
Trading securities. Estimated fair value is based on closing price as quoted in public markets. | ||||||||||||||||||||||
Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded. | ||||||||||||||||||||||
Credit Facility. Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions. | ||||||||||||||||||||||
8% Senior Notes. Estimated fair value is based on the closing market price for these notes. | ||||||||||||||||||||||
7⅛% Senior Notes. Estimated fair value is based on the closing market price for these notes. | ||||||||||||||||||||||
2018 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes. | ||||||||||||||||||||||
2021 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes. | ||||||||||||||||||||||
6⅞% Senior Notes. Estimated fair value is based on the closing market price for these notes. | ||||||||||||||||||||||
Receivables Facility and other debt. The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations. | ||||||||||||||||||||||
Interest rate swaps. The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. | ||||||||||||||||||||||
The Company assesses the effectiveness of its hedge instruments on a quarterly basis. For the three months ended March 31, 2015 and 2014, the Company completed an assessment of the cash flow hedge instruments and determined the hedges to be highly effective. The Company has also determined that the ineffective portion of the hedges do not have a material effect on the Company’s consolidated financial position, operations or cash flows. The counterparties to the interest rate swap agreements expose the Company to credit risk in the event of nonperformance. However, at March 31, 2015, all of the swap agreements entered into by the Company were in a net liability position such that the Company would be required to make the net settlement payments to the counterparties; the Company does not anticipate nonperformance by those counterparties. The Company does not hold or issue derivative financial instruments for trading purposes. | ||||||||||||||||||||||
Interest rate swaps consisted of the following at March 31, 2015: | ||||||||||||||||||||||
Swap # | Notional Amount (in millions) | Fixed Interest Rate | Termination Date | Fair Value (in millions) | ||||||||||||||||||
1 | $ | 300 | 3.447 | % | 6-Aug-16 | $ | 12 | |||||||||||||||
2 | 100 | 3.401 | % | 19-Aug-16 | 4 | |||||||||||||||||
3 | 200 | 3.429 | % | 19-Aug-16 | 8 | |||||||||||||||||
4 | 200 | 3.500 | % | 30-Aug-16 | 8 | |||||||||||||||||
5 | 100 | 3.005 | % | 30-Nov-16 | 4 | |||||||||||||||||
6 | 200 | 2.055 | % | 25-Jul-19 | 5 | |||||||||||||||||
7 | 200 | 2.059 | % | 25-Jul-19 | 5 | |||||||||||||||||
8 | 400 | 1.882 | % | 30-Aug-19 | 1 | -1 | ||||||||||||||||
9 | 200 | 2.515 | % | 30-Aug-19 | 5 | -1 | ||||||||||||||||
10 | 200 | 2.613 | % | 30-Aug-19 | 6 | -2 | ||||||||||||||||
11 | 300 | 2.041 | % | 30-Aug-20 | 1 | -1 | ||||||||||||||||
12 | 300 | 2.738 | % | 30-Aug-20 | 10 | -1 | ||||||||||||||||
13 | 300 | 2.892 | % | 30-Aug-20 | 12 | -2 | ||||||||||||||||
___________________ | ||||||||||||||||||||||
(1) This interest rate swap becomes effective August 28, 2015. | ||||||||||||||||||||||
(2) This interest rate swap becomes effective August 30, 2015. | ||||||||||||||||||||||
The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Interest rate swaps are entered into to manage interest rate fluctuation risk associated with the term loans in the Credit Facility. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the condensed consolidated statement of financial position. The Company designates its interest rate swaps as cash flow hedges. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. | ||||||||||||||||||||||
Assuming no change in March 31, 2015 interest rates, approximately $48 million of interest expense resulting from the spread between the fixed and floating rates defined in each interest rate swap agreement will be recognized during the next 12 months. If interest rate swaps do not remain highly effective as a cash flow hedge, the derivatives’ gains or losses resulting from the change in fair value reported through OCI will be reclassified into earnings. | ||||||||||||||||||||||
The following tabular disclosure provides the amount of pre-tax loss recognized as a component of OCI during the three months ended March 31, 2015 and 2014 (in millions): | ||||||||||||||||||||||
Amount of Pre-Tax Loss Recognized in OCI (Effective Portion) | ||||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationships | Three Months Ended March 31, | |||||||||||||||||||||
2015 | 2014 | |||||||||||||||||||||
Interest rate swaps | $ | -22 | $ | -3 | ||||||||||||||||||
The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the condensed consolidated statements of income during the three months ended March 31, 2015 and 2014 (in millions): | ||||||||||||||||||||||
Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion) | ||||||||||||||||||||||
Location of Loss Reclassified from AOCL into Income (Effective Portion) | Three Months Ended March 31, | |||||||||||||||||||||
2015 | 2014 | |||||||||||||||||||||
Interest expense, net | $ | 9 | $ | 18 | ||||||||||||||||||
The fair values of derivative instruments in the condensed consolidated balance sheets as of March 31, 2015 and December 31, 2014 were as follows (in millions): | ||||||||||||||||||||||
Asset Derivatives | Liability Derivatives | |||||||||||||||||||||
31-Mar-15 | 31-Dec-14 | 31-Mar-15 | 31-Dec-14 | |||||||||||||||||||
Balance Sheet Location | Fair Value | Balance Sheet Location | Fair Value | Balance Sheet Location | Fair Value | Balance Sheet Location | Fair Value | |||||||||||||||
Derivatives designated as hedging instruments | Other assets, net | $ | - | Other assets, net | $ | - | Other long-term liabilities | $ | 81 | Other long-term liabilities | $ | 73 | ||||||||||
Fair_Value
Fair Value | 3 Months Ended | |||||||||||
Mar. 31, 2015 | ||||||||||||
Fair Value [Abstract] | ||||||||||||
Fair Value Disclosure | ||||||||||||
13. FAIR VALUE | ||||||||||||
Fair Value Hierarchy | ||||||||||||
Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). | ||||||||||||
The inputs used to measure fair value are classified into the following fair value hierarchy: | ||||||||||||
Level 1: Quoted market prices in active markets for identical assets or liabilities. | ||||||||||||
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. | ||||||||||||
Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. | ||||||||||||
In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during 2015 or 2014. | ||||||||||||
The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 (in millions): | ||||||||||||
31-Mar-15 | Level 1 | Level 2 | Level 3 | |||||||||
Available-for-sale securities | $ | 285 | $ | 156 | $ | 129 | $ | - | ||||
Trading securities | 58 | 58 | - | - | ||||||||
Total assets | $ | 343 | $ | 214 | $ | 129 | $ | - | ||||
Contingent Value Right (CVR) | $ | 6 | $ | 6 | $ | - | $ | - | ||||
CVR-related liability | 256 | - | - | 256 | ||||||||
Fair value of interest rate swap agreements | 81 | - | 81 | - | ||||||||
Total liabilities | $ | 343 | $ | 6 | $ | 81 | $ | 256 | ||||
31-Dec-14 | Level 1 | Level 2 | Level 3 | |||||||||
Available-for-sale securities | $ | 280 | $ | 151 | $ | 129 | $ | - | ||||
Trading securities | 55 | 55 | - | - | ||||||||
Total assets | $ | 335 | $ | 206 | $ | 129 | $ | - | ||||
Contingent Value Right (CVR) | $ | 6 | $ | 6 | $ | - | $ | - | ||||
CVR-related liability | 265 | - | - | 265 | ||||||||
Fair value of interest rate swap agreements | 68 | - | 68 | - | ||||||||
Total liabilities | $ | 339 | $ | 6 | $ | 68 | $ | 265 | ||||
Available-for-sale Securities | ||||||||||||
Available-for-sale securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale securities primarily consisted of: (i) bonds and notes issued by the United States government and its agencies, domestic and foreign corporations and foreign governments; and (ii) preferred securities issued by domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data. | ||||||||||||
Contingent Value Right (CVR) | ||||||||||||
The CVR represents the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVR is listed on the NASDAQ and the valuation at March 31, 2015 is based on the quoted trading price for the CVR on the last day of the period. Changes in the estimated fair value of the CVR are recorded through the condensed consolidated statement of income. | ||||||||||||
CVR-related Liability | ||||||||||||
The CVR-related legal liability represents the Company’s estimate of fair value at March 31, 2015 of the liability associated with the legal matters assumed in the HMA merger that were not previously accrued by HMA. In addition, a liability of $24 million is recorded in accrued liabilities in the accompanying condensed consolidated balance sheet in respect of claims that were previously recorded by HMA as a probable contingency. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability. The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company has classified the fair value measurement as a Level 3 measurement in the fair value hierarchy. | ||||||||||||
The fair value of the CVR-related legal liability will be measured each reporting period using similar measurement techniques, updated for the assumptions and facts existing at that date for each of the underlying legal matters. Changes in the fair value of the CVR related legal liability are recorded in future periods through the condensed consolidated statement of income. | ||||||||||||
Fair Value of Interest Rate Swap Agreements | ||||||||||||
The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged. | ||||||||||||
The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements at March 31, 2015 resulted in a decrease in the fair value of the related liability of $5 million and an after-tax adjustment of $3 million to OCI. The CVA on the Company’s interest rate swap agreements at December 31, 2014 resulted in a decrease in the fair value of the related liability of $4 million and an after-tax adjustment of $2 million to OCI. | ||||||||||||
The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy. | ||||||||||||
Segment_Information
Segment Information | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Segment Information [Abstract] | ||||||
Segment Information Disclosure | ||||||
14. SEGMENT INFORMATION | ||||||
The Company operates in two distinct operating segments, represented by hospital operations (which includes its general acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services) and home care agency operations (which provide in-home outpatient care). | ||||||
Only the hospital operations segment meets the criteria as a separate reportable segment. The financial information for the home care agency segment does not meet the quantitative thresholds for a separate identifiable reportable segment and is combined into the corporate and all other reportable segment. | ||||||
The distribution between reportable segments of the Company’s net operating revenues and income (loss) from continuing operations before income taxes is summarized in the following tables (in millions): | ||||||
Three Months Ended March 31, | ||||||
2015 | 2014 | |||||
Net operating revenues: | ||||||
Hospital operations | $ | 4,857 | $ | 4,124 | ||
Corporate and all other | 54 | 52 | ||||
Total | $ | 4,911 | $ | 4,176 | ||
Income (loss) from continuing operations before income taxes: | ||||||
Hospital operations | $ | 273 | $ | 38 | ||
Corporate and all other | -105 | -170 | ||||
Total | $ | 168 | $ | -132 | ||
Other_Comprehensive_Income
Other Comprehensive Income | 3 Months Ended | ||||||||||||
Mar. 31, 2015 | |||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||
Other Comprehensive Income Disclosure | |||||||||||||
15. OTHER COMPREHENSIVE INCOME | |||||||||||||
The following tables present information about items reclassified out of accumulated other comprehensive income (loss) by component for the three months ended March 31, 2015 and 2014 (in millions, net of tax): | |||||||||||||
Change in | |||||||||||||
Change in Fair | Change in Fair | Unrecognized | Accumulated Other | ||||||||||
Value of Interest | Value of Available | Pension Cost | Comprehensive | ||||||||||
Rate Swaps | for Sale Securities | Components | Income (Loss) | ||||||||||
Balance as of December 31, 2014 | $ | -43 | $ | 7 | $ | -27 | $ | -63 | |||||
Other comprehensive (loss) | |||||||||||||
income before reclassifications | -15 | 1 | - | -14 | |||||||||
Amounts reclassified from | |||||||||||||
accumulated other | |||||||||||||
comprehensive income (loss) | 6 | - | 1 | 7 | |||||||||
Net current-period other | |||||||||||||
comprehensive income | -9 | 1 | 1 | -7 | |||||||||
Balance as of March 31, 2015 | $ | -52 | $ | 8 | $ | -26 | $ | -70 | |||||
Change in | |||||||||||||
Change in Fair | Change in Fair | Unrecognized | Accumulated Other | ||||||||||
Value of Interest | Value of Available | Pension Cost | Comprehensive | ||||||||||
Rate Swaps | for Sale Securities | Components | Income (Loss) | ||||||||||
Balance as of December 31, 2013 | $ | -56 | $ | 7 | $ | -18 | $ | -67 | |||||
Other comprehensive (loss) | |||||||||||||
income before reclassifications | -2 | - | - | -2 | |||||||||
Amounts reclassified from | |||||||||||||
accumulated other | |||||||||||||
comprehensive income (loss) | 11 | - | - | 11 | |||||||||
Net current-period other | |||||||||||||
comprehensive income | 9 | - | - | 9 | |||||||||
Balance as of March 31, 2014 | $ | -47 | $ | 7 | $ | -18 | $ | -58 | |||||
The following tables present a subtotal for each significant reclassification to net income out of accumulated other comprehensive income (loss) and the line item affected in the accompanying condensed consolidated statement of income for the three months ended March 31, 2015 and 2014 (in millions): | |||||||||||||
Amount reclassified | |||||||||||||
from AOCL | Affected line item in the | ||||||||||||
Details about accumulated other | Three Months Ended | statement where net | |||||||||||
comprehensive income (loss) components | 31-Mar-15 | income is presented | |||||||||||
Gains and losses on cash flow hedges | |||||||||||||
Interest rate swaps | $ | -9 | Interest expense, net | ||||||||||
3 | Tax benefit | ||||||||||||
$ | -6 | Net of tax | |||||||||||
Amortization of defined benefit pension items | |||||||||||||
Prior service costs | $ | - | Salaries and benefits | ||||||||||
Actuarial losses | -1 | Salaries and benefits | |||||||||||
-1 | Total before tax | ||||||||||||
- | Tax benefit | ||||||||||||
$ | -1 | Net of tax | |||||||||||
Amount reclassified | |||||||||||||
from AOCL | Affected line item in the | ||||||||||||
Details about accumulated other | Three Months Ended | statement where net | |||||||||||
comprehensive income (loss) components | 31-Mar-14 | income is presented | |||||||||||
Gains and losses on cash flow hedges | |||||||||||||
Interest rate swaps | $ | -18 | Interest expense, net | ||||||||||
7 | Tax benefit | ||||||||||||
$ | -11 | Net of tax | |||||||||||
Amortization of defined benefit pension items | |||||||||||||
Prior service costs | $ | - | Salaries and benefits | ||||||||||
Actuarial losses | - | Salaries and benefits | |||||||||||
- | Total before tax | ||||||||||||
- | Tax benefit | ||||||||||||
$ | - | Net of tax | |||||||||||
Contingencies
Contingencies | 3 Months Ended | ||||||||||||
Mar. 31, 2015 | |||||||||||||
Contingencies [Abstract] | |||||||||||||
Commitments and Contingencies Disclosure | |||||||||||||
16. CONTINGENCIES | |||||||||||||
The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. | |||||||||||||
With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters. | |||||||||||||
HMA Legal Matters and Related CVR | |||||||||||||
The CVR agreement entitles the holder to receive a one-time cash payment of up to $1.00 per CVR, subject to downward adjustment based on the final resolution of certain litigation, investigations (whether formal or informal, including subpoenas), or other actions or proceedings related to HMA or its affiliates existing on or prior to July 29, 2013 (the date of the Company’s merger agreement with HMA) as more specifically provided in the CVR agreement (all such matters are referred to as the “HMA Legal Matters”), which include, but are not limited to, investigation and litigation matters as previously disclosed by HMA in public filings with the SEC and described in more detail below. The adjustment reducing the ultimate amount paid to holders of the CVR is determined based on the amount of losses incurred by the Company in connection with the HMA Legal Matters as more specifically provided in the CVR agreement, which generally includes the amount paid for damages, costs, fees and expenses (including, without limitation, attorneys’ fees and expenses), and all fines, penalties, settlement amounts, indemnification obligations and other liabilities (all such losses are referred to as “HMA Losses”). If the aggregate amount of HMA Losses exceeds a deductible of $18 million, then the amount payable in respect of each CVR shall be reduced (but not below zero) by an amount equal to the quotient obtained by dividing: (a) the product of (i) all losses in excess of the deductible and (ii) 90%; by (b) the number of CVRs outstanding on the date on which final resolution of the existing litigation occurs. There are 264,544,053 CVRs outstanding as of the date hereof. If total HMA Losses (including HMA Losses that have occurred to date as noted in the table below) exceed approximately $312 million, then the holders of the CVRs will not be entitled to any payment in respect of the CVRs. | |||||||||||||
The CVRs do not have a finite payment date. Any payments the Company makes under the CVR agreement will be payable within 60 days after the final resolution of the HMA Legal Matters. The CVRs are unsecured obligations of CHS and all payments under the CVRs will be subordinated in right of payment to the prior payment in full of all of the Company’s senior obligations (as defined in the CVR agreement), which include outstanding indebtedness of the Company (subject to certain exceptions set forth in the CVR agreement) and the HMA Losses. The CVR agreement permits the Company to acquire all or some of the CVRs, whether in open market transactions, private transactions or otherwise. As of March 31, 2015, the Company had acquired no CVRs. | |||||||||||||
The following table represents the impact of legal expenses paid or incurred to date and settlements paid or deemed final as of March 31, 2015 on the amounts owed to CVR holders (in millions): | |||||||||||||
Allocation of Expenses and Settlement Costs | |||||||||||||
Reduction to | |||||||||||||
Total Expenses | CHS | Amount Owed | |||||||||||
and Settlement | Responsibility | to CVR Holders | |||||||||||
Cost | Deductible | at 10% | at 90% | ||||||||||
As of December 31, 2014 | $ | 24 | $ | 18 | $ | - | $ | 6 | |||||
Settlements paid | - | - | - | - | |||||||||
Legal expenses incurred | |||||||||||||
and/or paid during | |||||||||||||
the three months ended | |||||||||||||
31-Mar-15 | 3 | - | 1 | 2 | |||||||||
As of March 31, 2015 | $ | 27 | $ | 18 | $ | 1 | $ | 8 | |||||
Amounts owed to CVR holders are dependent on the ultimate resolution of the HMA Legal Matters and determination of HMA Losses incurred. The settlement of any or all of the claims and expenses incurred on behalf of the Company in defending itself will (subject to the deductible) reduce the amounts owed to the CVR holders. | |||||||||||||
Underlying the CVR agreement are a number of claims included in the HMA Legal Matters asserted against HMA. The Company has recorded a liability in connection with those claims as part of the acquired assets and liabilities at the date of acquisition pursuant to the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 805 “Business Combinations.” For the estimate of the Company’s liabilities associated with the HMA Legal Matters that will be covered by the CVR and were not previously accrued by HMA, the Company recorded a liability of $284 million as part of the acquisition accounting for the HMA merger based on the Company’s estimate of fair value of such liabilities as of the date of acquisition. The decrease in this liability during the three months ended March 31, 2015 was approximately $9 million and the fair value of $256 million is recorded in other long-term liabilities on the accompanying condensed consolidated balance sheet. The remaining portion of the estimated liability for claims underlying the CVR agreement had been previously recorded by HMA, as a probable contingency, and was reflected in the purchase accounting for HMA as an acquired liability. This amount is $24 million at March 31, 2015 and is recorded in accrued liabilities on the accompanying condensed consolidated balance sheet. In addition, although legal fees are not included in the amounts currently accrued, such legal fees are taken into account in determining HMA Losses under the CVR agreement. Certain significant HMA Legal Matters underlying these liabilities are discussed in greater detail below. | |||||||||||||
HMA Matters Recorded at Fair Value | |||||||||||||
Medicare/Medicaid Billing Lawsuits | |||||||||||||
Beginning during the week of December 16, 2013, eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act. Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was recently settled; U.S. ex rel. Sandra Simmons, v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was recently partially settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions. On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation. On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, and again extended until May 27, 2015. The Company intends to defend against the allegations in these matters, but will also be cooperating with the government in the ongoing investigation of these allegations. The Company has been in discussions with the Civil Division of the United States Department of Justice (“DOJ”) regarding the resolutions of these matters. The Company has recently been told that the Criminal Division is continuing to investigate former executive-level employees of HMA, as well as considering whether any HMA entities should be held criminally liable for the acts of the former HMA employees. The Company is voluntarily cooperating with these inquiries and has not been served with any subpoenas or other legal process. | |||||||||||||
During September 2010, HMA received a letter from the DOJ indicating that an investigation was being conducted to determine whether certain HMA hospitals improperly submitted claims for the implantation of implantable cardioverter defibrillators (“ICDs”). The DOJ’s investigation covers the period commencing with Medicare’s expansion of coverage for ICDs in 2003 to the present. The letter from the DOJ further indicates that the claims submitted by HMA’s hospitals for ICDs and related services need to be reviewed to determine if Medicare coverage and payment was appropriate. During 2010, the DOJ sent similar letters and other requests to a large number of unrelated hospitals and hospital operators across the country as part of a nation-wide review of ICD billing under the Medicare program. The Company is cooperating with the DOJ in its ongoing investigation, which could potentially give rise to claims against HMA and/or certain of its subsidiary hospitals under the False Claims Act or other statutes, regulations or laws. Additionally, the Company is conducting an internal review of hospital medical records related to ICDs that are the subject of the DOJ investigation. The Company has reached an agreement in principle to settle this matter. | |||||||||||||
Probable Contingencies – HMA | |||||||||||||
OIG Investigation of Certain HMA Hospitals’ Relationships with Allegiance | |||||||||||||
On February 22, 2012 and February 24, 2012, the United States Department of Health and Human Services office of the Inspector General (“OIG”) served subpoenas on certain HMA hospitals relating to those hospitals’ relationships with Allegiance Health Management, Inc. (“Allegiance”). Allegiance, which is unrelated to HMA, is a post-acute healthcare management company that provides intensive outpatient psychiatric (“IOP”) services to patients. The HMA hospitals that were served subpoenas were: (i) Central Mississippi Medical Center in Jackson, Mississippi; (ii) Crossgates River Oaks Hospital in Brandon, Mississippi; (iii) Davis Regional Medical Center in Statesville, North Carolina; (iv) Lake Norman Regional Medical Center in Mooresville, North Carolina; (v) the Medical Center of Southeastern Oklahoma in Durant, Oklahoma; and (vi) Natchez Community Hospital in Natchez, Mississippi. Each of those hospitals has or had a contract with Allegiance. Among other things, the subpoenas seek: (i) documents related to the hospitals’ financial relationships with Allegiance; (ii) documents related to patients who received IOP services from Allegiance at the HMA hospitals, including their patient medical records; (iii) documents relating to complaints or concerns regarding Allegiance’s IOP services at the HMA hospitals; (iv) documents relating to employees, physicians and therapists who were involved with the IOP services provided by Allegiance at the HMA hospitals; and (v) other documents related to Allegiance, including leases, contracts, policies and procedures, training documents, budgets and financial analyses. The period of time covered by the subpoenas is January 1, 2008 through the date of subpoena compliance. The Company will continue to cooperate with the investigations. Prior to the HMA merger, HMA determined that a liability for this claim was probable and a liability was recorded by HMA during the quarter ended December 31, 2013, which liability was assumed as part of the HMA merger. The Company has reached an agreement in principle to settle this matter. | |||||||||||||
Department of Justice Investigation of Kyphoplasty Procedures at Certain HMA Hospitals | |||||||||||||
Several HMA hospitals received letters during 2009 requesting information in connection with a DOJ investigation relating to kyphoplasty procedures. Kyphoplasty is a minimally invasive spinal procedure used to treat vertebral compression fractures. The DOJ is currently investigating hospitals and hospital operators in multiple states to determine whether certain Medicare claims for kyphoplasty were incorrect when billed as an inpatient service rather than as an outpatient service. The DOJ’s investigation originated with a False Claims Act lawsuit against Kyphon, Inc., the company that developed the kyphoplasty procedure. The requested information has been provided to the DOJ and the Company is continuing to cooperate with the investigation. Prior to the HMA merger, HMA determined that a liability for this claim was probable and an incremental liability was recorded by HMA during the quarter ended December 31, 2013, which liability was assumed as part of the HMA merger. | |||||||||||||
Probable Contingencies - CHS | |||||||||||||
Implantable Cardioverter Defibrillators (“ICDs”). The Company was first made aware of this investigation in September 2010, when the Company received a letter from the Civil Division of the DOJ. The letter advised the Company that an investigation was being conducted to determine whether certain hospitals have improperly submitted claims for payment for ICDs. The period of time covered by the investigation was 2003 to 2010. The Company continues to fully cooperate with the government in this investigation and has provided requested records and documents. On August 30, 2012, the DOJ issued a document entitled, “Medical Review Guidelines/Resolution Model,” which sets out, for the purposes of this investigation, the patient conditions and criteria for the medical necessity of the implantation of ICDs in Medicare beneficiaries and how the DOJ will enforce the repayment obligations of hospitals. The Company has reached an agreement in principle to settle this matter. | |||||||||||||
Summary of Recorded Amounts | |||||||||||||
The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the three months ended March 31, 2015 with respect to the Company’s fair value determination in connection with HMA Legal Matters that were not previously accrued by HMA, the estimated liability in connection with HMA Legal Matters that were previously recorded by HMA as a probable contingency, and the remaining contingencies of the Company in respect of which an accrual has been recorded. In addition, future legal fees (which are expensed as incurred) and costs related to possible indemnification and criminal investigation matters associated with the HMA Legal Matters have not been accrued or included in the table below. Furthermore, although not accrued, such costs, if incurred, will be taken into account in determining the total amount of reductions applied to the amounts owed to CVR holders. | |||||||||||||
CVR Related | CVR Related Liability | Other | |||||||||||
Liability | for Probable | Probable | |||||||||||
at Fair Value | Contingencies | Contingencies | |||||||||||
Balance as of December 31, 2014 | $ | 265 | $ | 29 | $ | 125 | |||||||
Expense | -9 | -5 | 15 | ||||||||||
Cash payments | - | - | -92 | ||||||||||
Balance as of March 31, 2015 | $ | 256 | $ | 24 | $ | 48 | |||||||
With respect to the “Other Probable Contingencies” referenced in the chart above, in accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the condensed consolidated balance sheet and are included in the table above in the “Other Probable Contingencies” column. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount. | |||||||||||||
In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $4 million and $3 million for the three months ended March 31, 2015 and 2014, respectively, and are included in other operating expenses in the accompanying condensed consolidated statements of income. | |||||||||||||
Matters for which an Outcome Cannot be Assessed | |||||||||||||
For all of the legal matters below, the Company cannot at this time assess what the outcome may be and is further unable to determine any estimate of loss or range of loss. Because the matters below are at a preliminary stage and other factors, there are not sufficient facts available to make these assessments. | |||||||||||||
Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. The Company’s motion to dismiss this case has been fully briefed and remains pending before the court. Case management has been set for May 11, 2015. The Company believes this consolidated matter is without merit and will vigorously defend this case. | |||||||||||||
Shareholder Derivative Actions. Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. The Company’s motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part the Company’s motion to dismiss. On October 14, 2013, the Company filed for a Motion for Reconsideration of the Order Granting in Part and Denying in Part the Motion to Dismiss, a Motion to Stay Discovery, and an unopposed Motion for Extension of Time to File an Answer. The Company’s motion to stay was denied and the Company’s motion for reconsideration was denied on December 12, 2014. An initial case management order was entered on November 11, 2014, but no trial date has been set. The Company believes all of the plaintiffs’ claims are without merit and will vigorously defend them. | |||||||||||||
Subsequent_Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2015 | |
Subsequent Events [Abstract] | |
Subsequent Events Disclosure | |
17. SUBSEQUENT EVENTS | |
The Company evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the condensed consolidated financial statements. | |
Effective April 1, 2015, one or more subsidiaries of the Company sold Chesterfield General Hospital (59 licensed beds) in Cheraw, South Carolina and Marlboro Park Hospital (102 licensed beds) in Bennettsville, South Carolina, and related outpatient services to M/C Healthcare, LLC for approximately $4 million in cash, which was received at the closing on March 31, 2015. | |
Supplemental_Consolidating_Fin
Supplemental Consolidating Financial Information | 3 Months Ended | |||||||||||||||||
Mar. 31, 2015 | ||||||||||||||||||
Supplemental Condensed Consolidating Financial Information [Abstract] | ||||||||||||||||||
Supplemental Condensed Consolidating Financial Information Disclosure | ||||||||||||||||||
18. SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION | ||||||||||||||||||
The Senior Notes due 2019, 2020 and 2022, which are senior unsecured obligations of CHS, and the 5⅛% Senior Secured Notes due 2018 and 2021 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” | ||||||||||||||||||
The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below: | ||||||||||||||||||
•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. | ||||||||||||||||||
•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net. | ||||||||||||||||||
•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. | ||||||||||||||||||
•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances. | ||||||||||||||||||
The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 11. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation. | ||||||||||||||||||
From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods are revised to reflect the status of guarantors or non-guarantors as of March 31, 2015. | ||||||||||||||||||
Condensed Consolidating Statement of Income | ||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Operating revenues (net of contractual | ||||||||||||||||||
allowances and discounts) | $ | - | $ | -5 | $ | 3,488 | $ | 2,163 | $ | - | $ | 5,646 | ||||||
Provision for bad debts | - | - | 447 | 288 | - | 735 | ||||||||||||
Net operating revenues | - | -5 | 3,041 | 1,875 | - | 4,911 | ||||||||||||
Operating costs and expenses: | ||||||||||||||||||
Salaries and benefits | - | - | 1,222 | 1,035 | - | 2,257 | ||||||||||||
Supplies | - | - | 492 | 270 | - | 762 | ||||||||||||
Other operating expenses | - | - | 708 | 391 | - | 1,099 | ||||||||||||
Government settlement and related costs | - | - | 8 | - | - | 8 | ||||||||||||
Electronic health records incentive reimbursement | - | - | -17 | -9 | - | -26 | ||||||||||||
Rent | - | - | 61 | 55 | - | 116 | ||||||||||||
Depreciation and amortization | - | - | 200 | 96 | - | 296 | ||||||||||||
Total operating costs and expenses | - | - | 2,674 | 1,838 | - | 4,512 | ||||||||||||
Income from operations | - | -5 | 367 | 37 | - | 399 | ||||||||||||
Interest expense, net | - | 21 | 211 | 9 | - | 241 | ||||||||||||
Loss from early extinguishment of debt | - | 8 | - | - | - | 8 | ||||||||||||
Equity in earnings of unconsolidated affiliates | -79 | -104 | -5 | - | 170 | -18 | ||||||||||||
Income from continuing operations before income taxes | 79 | 70 | 161 | 28 | -170 | 168 | ||||||||||||
Provision for (benefit from) income taxes | - | -9 | 61 | 4 | - | 56 | ||||||||||||
Income from continuing operations | 79 | 79 | 100 | 24 | -170 | 112 | ||||||||||||
Discontinued operations, net of taxes: | ||||||||||||||||||
Loss from operations of entities sold or held for sale | - | - | - | -11 | - | -11 | ||||||||||||
Impairment of hospitals sold or held for sale | - | - | -1 | - | - | -1 | ||||||||||||
Loss on sale, net | - | - | 2 | -3 | - | -1 | ||||||||||||
Loss from discontinued operations, net of taxes | - | - | 1 | -14 | - | -13 | ||||||||||||
Net income | 79 | 79 | 101 | 10 | -170 | 99 | ||||||||||||
Less: Net income attributable to noncontrolling interests | - | - | - | 20 | - | 20 | ||||||||||||
Net income attributable to Community Health Systems, | ||||||||||||||||||
Inc. stockholders | $ | 79 | $ | 79 | $ | 101 | $ | -10 | $ | -170 | $ | 79 | ||||||
Condensed Consolidating Statement of Loss | ||||||||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Operating revenues (net of contractual | ||||||||||||||||||
allowances and discounts) | $ | - | $ | -4 | $ | 3,119 | $ | 1,760 | $ | - | $ | 4,875 | ||||||
Provision for bad debts | - | - | 476 | 223 | - | 699 | ||||||||||||
Net operating revenues | - | -4 | 2,643 | 1,537 | - | 4,176 | ||||||||||||
Operating costs and expenses: | ||||||||||||||||||
Salaries and benefits | - | - | 1,147 | 845 | - | 1,992 | ||||||||||||
Supplies | - | - | 417 | 215 | - | 632 | ||||||||||||
Other operating expenses | - | - | 663 | 356 | - | 1,019 | ||||||||||||
Electronic health records incentive reimbursement | - | - | -30 | -10 | - | -40 | ||||||||||||
Rent | - | - | 54 | 44 | - | 98 | ||||||||||||
Depreciation and amortization | - | - | 189 | 66 | - | 255 | ||||||||||||
Amortization of software to be abandoned | - | - | 26 | 16 | - | 42 | ||||||||||||
Total operating costs and expenses | - | - | 2,466 | 1,532 | - | 3,998 | ||||||||||||
Income from operations | - | -4 | 177 | 5 | - | 178 | ||||||||||||
Interest expense, net | - | 40 | 172 | 12 | - | 224 | ||||||||||||
Loss from early extinguishment of debt | - | 73 | - | - | - | 73 | ||||||||||||
Equity in earnings of unconsolidated affiliates | 112 | 27 | 23 | - | -173 | -11 | ||||||||||||
Impairment of long-lived assets | - | - | 24 | - | - | 24 | ||||||||||||
Income from continuing operations before income taxes | -112 | -144 | -42 | -7 | 173 | -132 | ||||||||||||
Provision for (benefit from) income taxes | - | -32 | -16 | -8 | - | -56 | ||||||||||||
Income from continuing operations | -112 | -112 | -26 | 1 | 173 | -76 | ||||||||||||
Discontinued operations, net of taxes: | ||||||||||||||||||
Loss from operations of entities sold or held for sale | - | - | -3 | -1 | - | -4 | ||||||||||||
Impairment of hospitals sold or held for sale | - | - | - | -18 | - | -18 | ||||||||||||
Loss from discontinued operations, net of taxes | - | - | -3 | -19 | - | -22 | ||||||||||||
Net loss | -112 | -112 | -29 | -18 | 173 | -98 | ||||||||||||
Less: Net income attributable to noncontrolling interests | - | - | - | 14 | - | 14 | ||||||||||||
Net loss attributable to Community Health | ||||||||||||||||||
Systems, Inc. stockholders | $ | -112 | $ | -112 | $ | -29 | $ | -32 | $ | 173 | $ | -112 | ||||||
Condensed Consolidating Statement of Comprehensive Income | ||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net income | $ | 79 | $ | 79 | $ | 101 | $ | 10 | $ | -170 | $ | 99 | ||||||
Other comprehensive income (loss), net of income taxes: | ||||||||||||||||||
Net change in fair value of interest rate swaps, net of tax | -9 | -9 | - | - | 9 | -9 | ||||||||||||
Net change in fair value of available-for-sale securities, net | ||||||||||||||||||
of tax | 1 | 1 | 1 | - | -2 | 1 | ||||||||||||
Amortization and recognition of unrecognized pension | ||||||||||||||||||
cost components, net of tax | 1 | 1 | 1 | - | -2 | 1 | ||||||||||||
Other comprehensive income (loss) | -7 | -7 | 2 | - | 5 | -7 | ||||||||||||
Comprehensive income | 72 | 72 | 103 | 10 | -165 | 92 | ||||||||||||
Less: Comprehensive income attributable to | ||||||||||||||||||
noncontrolling interests | - | - | - | 20 | - | 20 | ||||||||||||
Comprehensive income (loss) attributable to Community | ||||||||||||||||||
Health Systems, Inc. stockholders | $ | 72 | $ | 72 | $ | 103 | $ | -10 | $ | -165 | $ | 72 | ||||||
Condensed Consolidating Statement of Comprehensive Loss | ||||||||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net loss | $ | -112 | $ | -112 | $ | -29 | $ | -18 | $ | 173 | $ | -98 | ||||||
Other comprehensive income (loss), net of income taxes: | ||||||||||||||||||
Net change in fair value of interest rate swaps, net of tax | 9 | 9 | - | - | -9 | 9 | ||||||||||||
Net change in fair value of available-for-sale securities, net | ||||||||||||||||||
of tax | - | - | - | - | - | - | ||||||||||||
Amortization and recognition of unrecognized pension | ||||||||||||||||||
cost components, net of tax | - | - | - | - | - | - | ||||||||||||
Other comprehensive income (loss) | 9 | 9 | - | - | -9 | 9 | ||||||||||||
Comprehensive loss | -103 | -103 | -29 | -18 | 164 | -89 | ||||||||||||
Less: Comprehensive income attributable to | ||||||||||||||||||
noncontrolling interests | - | - | - | 14 | - | 14 | ||||||||||||
Comprehensive loss attributable to Community | ||||||||||||||||||
Health Systems, Inc. stockholders | $ | -103 | $ | -103 | $ | -29 | $ | -32 | $ | 164 | $ | -103 | ||||||
Condensed Consolidating Balance Sheet | ||||||||||||||||||
31-Mar-15 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
ASSETS | ||||||||||||||||||
Current assets: | ||||||||||||||||||
Cash and cash equivalents | $ | - | $ | - | $ | 37 | $ | 185 | $ | - | $ | 222 | ||||||
Patient accounts receivable, net of allowance | ||||||||||||||||||
for doubtful accounts | - | - | 1,430 | 2,176 | - | 3,606 | ||||||||||||
Supplies | - | - | 377 | 184 | - | 561 | ||||||||||||
Deferred income taxes | 341 | - | - | - | - | 341 | ||||||||||||
Prepaid expenses and taxes | - | - | 131 | 58 | - | 189 | ||||||||||||
Other current assets | - | - | 329 | 178 | - | 507 | ||||||||||||
Total current assets | 341 | - | 2,304 | 2,781 | - | 5,426 | ||||||||||||
Intercompany receivable | 1,257 | 16,512 | 3,314 | 6,131 | -27,214 | - | ||||||||||||
Property and equipment, net | - | - | 6,613 | 3,478 | - | 10,091 | ||||||||||||
Goodwill | - | - | 5,483 | 3,471 | - | 8,954 | ||||||||||||
Other assets, net | 6 | 303 | 1,817 | 1,164 | -642 | 2,648 | ||||||||||||
Net investment in subsidiaries | 3,361 | 18,435 | 7,643 | - | -29,439 | - | ||||||||||||
Total assets | $ | 4,965 | $ | 35,250 | $ | 27,174 | $ | 17,025 | $ | -57,295 | $ | 27,119 | ||||||
LIABILITIES AND EQUITY | ||||||||||||||||||
Current liabilities: | ||||||||||||||||||
Current maturities of long-term debt | $ | - | $ | 163 | $ | 54 | $ | 12 | $ | - | $ | 229 | ||||||
Accounts payable | - | 1 | 873 | 318 | - | 1,192 | ||||||||||||
Income tax payable | 13 | - | - | - | - | 13 | ||||||||||||
Deferred income taxes | 23 | - | - | - | - | 23 | ||||||||||||
Accrued interest | - | 155 | 1 | 1 | - | 157 | ||||||||||||
Accrued liabilities | 4 | - | 1,051 | 492 | - | 1,547 | ||||||||||||
Total current liabilities | 40 | 319 | 1,979 | 823 | - | 3,161 | ||||||||||||
Long-term debt | - | 15,885 | 127 | 728 | - | 16,740 | ||||||||||||
Intercompany payable | - | 14,822 | 20,071 | 14,117 | -49,010 | - | ||||||||||||
Deferred income taxes | 844 | - | - | - | - | 844 | ||||||||||||
Other long-term liabilities | - | 862 | 1,113 | 361 | -642 | 1,694 | ||||||||||||
Total liabilities | 884 | 31,888 | 23,290 | 16,029 | -49,652 | 22,439 | ||||||||||||
Redeemable noncontrolling interests in | ||||||||||||||||||
equity of consolidated subsidiaries | - | - | - | 520 | - | 520 | ||||||||||||
Equity: | ||||||||||||||||||
Community Health Systems, Inc. stockholders’ | ||||||||||||||||||
equity: | ||||||||||||||||||
Preferred stock | - | - | - | - | - | - | ||||||||||||
Common stock | 1 | - | - | - | - | 1 | ||||||||||||
Additional paid-in capital | 2,101 | 1,294 | 1,471 | 523 | -3,288 | 2,101 | ||||||||||||
Treasury stock, at cost | -7 | - | - | - | - | -7 | ||||||||||||
Accumulated other comprehensive loss | -70 | -70 | -17 | - | 87 | -70 | ||||||||||||
Retained earnings | 2,056 | 2,138 | 2,430 | -126 | -4,442 | 2,056 | ||||||||||||
Total Community Health Systems, Inc. | ||||||||||||||||||
stockholders’ equity | 4,081 | 3,362 | 3,884 | 397 | -7,643 | 4,081 | ||||||||||||
Noncontrolling interests in equity of | ||||||||||||||||||
consolidated subsidiaries | - | - | - | 79 | - | 79 | ||||||||||||
Total equity | 4,081 | 3,362 | 3,884 | 476 | -7,643 | 4,160 | ||||||||||||
Total liabilities and equity | $ | 4,965 | $ | 35,250 | $ | 27,174 | $ | 17,025 | $ | -57,295 | $ | 27,119 | ||||||
Condensed Consolidating Balance Sheet | ||||||||||||||||||
31-Dec-14 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
ASSETS | ||||||||||||||||||
Current assets: | ||||||||||||||||||
Cash and cash equivalents | $ | - | $ | - | $ | 368 | $ | 141 | $ | - | $ | 509 | ||||||
Patient accounts receivable, net of allowance | ||||||||||||||||||
for doubtful accounts | - | - | 1,272 | 2,137 | - | 3,409 | ||||||||||||
Supplies | - | - | 373 | 184 | - | 557 | ||||||||||||
Prepaid income taxes | 30 | - | - | - | - | 30 | ||||||||||||
Deferred income taxes | 341 | - | - | - | - | 341 | ||||||||||||
Prepaid expenses and taxes | - | - | 138 | 54 | - | 192 | ||||||||||||
Other current assets | - | - | 356 | 172 | - | 528 | ||||||||||||
Total current assets | 371 | - | 2,507 | 2,688 | - | 5,566 | ||||||||||||
Intercompany receivable | 1,199 | 16,560 | 2,532 | 7,877 | -28,168 | - | ||||||||||||
Property and equipment, net | - | - | 6,548 | 3,621 | - | 10,169 | ||||||||||||
Goodwill | - | - | 5,480 | 3,471 | - | 8,951 | ||||||||||||
Other assets, net | 15 | 302 | 1,874 | 1,179 | -635 | 2,735 | ||||||||||||
Net investment in subsidiaries | 3,290 | 18,229 | 7,399 | - | -28,918 | - | ||||||||||||
Total assets | $ | 4,875 | $ | 35,091 | $ | 26,340 | $ | 18,836 | $ | -57,721 | $ | 27,421 | ||||||
LIABILITIES AND EQUITY | ||||||||||||||||||
Current liabilities: | ||||||||||||||||||
Current maturities of long-term debt | $ | - | $ | 163 | $ | 61 | $ | 11 | $ | - | $ | 235 | ||||||
Accounts payable | - | - | 909 | 384 | - | 1,293 | ||||||||||||
Deferred income taxes | 23 | - | - | - | - | 23 | ||||||||||||
Accrued interest | - | 225 | 2 | - | - | 227 | ||||||||||||
Accrued liabilities | 4 | - | 1,249 | 558 | - | 1,811 | ||||||||||||
Total current liabilities | 27 | 388 | 2,221 | 953 | - | 3,589 | ||||||||||||
Long-term debt | - | 15,820 | 139 | 722 | - | 16,681 | ||||||||||||
Intercompany payable | - | 14,752 | 19,066 | 15,795 | -49,613 | - | ||||||||||||
Deferred income taxes | 845 | - | - | - | - | 845 | ||||||||||||
Other long-term liabilities | - | 841 | 1,140 | 346 | -635 | 1,692 | ||||||||||||
Total liabilities | 872 | 31,801 | 22,566 | 17,816 | -50,248 | 22,807 | ||||||||||||
Redeemable noncontrolling interests in | ||||||||||||||||||
equity of consolidated subsidiaries | - | - | - | 531 | - | 531 | ||||||||||||
Equity: | ||||||||||||||||||
Community Health Systems, Inc. stockholders’ | ||||||||||||||||||
equity: | ||||||||||||||||||
Preferred stock | - | - | - | - | - | - | ||||||||||||
Common stock | 1 | - | - | - | - | 1 | ||||||||||||
Additional paid-in capital | 2,095 | 1,208 | 1,369 | 528 | -3,105 | 2,095 | ||||||||||||
Treasury stock, at cost | -7 | - | - | - | - | -7 | ||||||||||||
Accumulated other comprehensive loss | -63 | -63 | -25 | 5 | 83 | -63 | ||||||||||||
Retained earnings | 1,977 | 2,145 | 2,430 | -124 | -4,451 | 1,977 | ||||||||||||
Total Community Health Systems, Inc. | ||||||||||||||||||
stockholders’ equity | 4,003 | 3,290 | 3,774 | 409 | -7,473 | 4,003 | ||||||||||||
Noncontrolling interests in equity of | ||||||||||||||||||
consolidated subsidiaries | - | - | - | 80 | - | 80 | ||||||||||||
Total equity | 4,003 | 3,290 | 3,774 | 489 | -7,473 | 4,083 | ||||||||||||
Total liabilities and equity | $ | 4,875 | $ | 35,091 | $ | 26,340 | $ | 18,836 | $ | -57,721 | $ | 27,421 | ||||||
Condensed Consolidating Statement of Cash Flows | ||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net cash (used in) provided by operating | ||||||||||||||||||
activities | $ | -10 | $ | -123 | $ | 23 | $ | 49 | $ | - | $ | -61 | ||||||
Cash flows from investing activities: | ||||||||||||||||||
Acquisitions of facilities and other related | ||||||||||||||||||
equipment | - | - | -11 | -2 | - | -13 | ||||||||||||
Purchases of property and equipment | - | - | -199 | -42 | - | -241 | ||||||||||||
Proceeds from disposition of hospitals | ||||||||||||||||||
and other ancillary operations | - | - | 4 | 58 | - | 62 | ||||||||||||
Proceeds from sale of property and equipment | - | - | - | 3 | - | 3 | ||||||||||||
Purchases of available-for-sale securities | - | - | -22 | -37 | - | -59 | ||||||||||||
Proceeds from sales of available-for-sale securities | - | - | 19 | 37 | - | 56 | ||||||||||||
Increase in other investments | - | - | -30 | -9 | - | -39 | ||||||||||||
Net cash used in investing activities | - | - | -239 | 8 | - | -231 | ||||||||||||
Cash flows from financing activities: | ||||||||||||||||||
Proceeds from exercise of stock options | 17 | - | - | - | - | 17 | ||||||||||||
Repurchase of restricted stock shares for payroll | ||||||||||||||||||
tax withholding requirements | -20 | - | - | - | - | -20 | ||||||||||||
Deferred financing costs and other | ||||||||||||||||||
debt-related costs | - | -20 | - | - | - | -20 | ||||||||||||
Redemption of noncontrolling investments in joint | ||||||||||||||||||
ventures | - | - | - | -7 | - | -7 | ||||||||||||
Distributions to noncontrolling investors in joint | ||||||||||||||||||
ventures | - | - | - | -23 | - | -23 | ||||||||||||
Changes in intercompany balances with | ||||||||||||||||||
affiliates, net | 13 | 77 | -101 | 11 | - | - | ||||||||||||
Borrowings under credit agreements | - | 1,250 | 1 | - | - | 1,251 | ||||||||||||
Issuance of long-term debt | - | - | - | - | - | - | ||||||||||||
Proceeds from receivables facility | - | - | - | 75 | - | 75 | ||||||||||||
Repayments of long-term indebtedness | - | -1,184 | -15 | -69 | - | -1,268 | ||||||||||||
Net cash provided by (used in) financing | ||||||||||||||||||
activities | 10 | 123 | -115 | -13 | - | 5 | ||||||||||||
Net change in cash and cash equivalents | - | - | -331 | 44 | - | -287 | ||||||||||||
Cash and cash equivalents at beginning of period | - | - | 368 | 141 | - | 509 | ||||||||||||
Cash and cash equivalents at end of period | $ | - | $ | - | $ | 37 | $ | 185 | $ | - | $ | 222 | ||||||
Condensed Consolidating Statement of Cash Flows | ||||||||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net cash (used in) provided by operating | ||||||||||||||||||
activities | $ | 73 | $ | 298 | $ | 62 | $ | -368 | $ | - | $ | 65 | ||||||
Cash flows from investing activities: | ||||||||||||||||||
Acquisitions of facilities and other related | ||||||||||||||||||
equipment | - | - | -2,760 | -14 | - | -2,774 | ||||||||||||
Purchases of property and equipment | - | - | -143 | -38 | - | -181 | ||||||||||||
Purchases of available-for-sale securities | - | - | - | -78 | - | -78 | ||||||||||||
Proceeds from sales of available-for-sale securities | - | - | - | 76 | - | 76 | ||||||||||||
Increase in other investments | - | - | -75 | -24 | - | -99 | ||||||||||||
Net cash used in investing activities | - | - | -2,978 | -78 | - | -3,056 | ||||||||||||
Cash flows from financing activities: | ||||||||||||||||||
Proceeds from exercise of stock options | 6 | - | - | - | - | 6 | ||||||||||||
Repurchase of restricted stock shares for payroll | ||||||||||||||||||
tax withholding requirements | -11 | - | - | - | - | -11 | ||||||||||||
Deferred financing costs and other | ||||||||||||||||||
debt-related costs | - | -269 | - | - | - | -269 | ||||||||||||
Excess tax benefit relating to | ||||||||||||||||||
stock-based compensation | 3 | - | - | - | - | 3 | ||||||||||||
Redemption of noncontrolling investments in joint | ||||||||||||||||||
ventures | - | - | - | -5 | - | -5 | ||||||||||||
Distributions to noncontrolling investors in joint | ||||||||||||||||||
ventures | - | - | - | -19 | - | -19 | ||||||||||||
Changes in intercompany balances with | ||||||||||||||||||
affiliates, net | -71 | -3,417 | 3,117 | 371 | - | - | ||||||||||||
Borrowings under credit agreements | - | 7,062 | 17 | - | - | 7,079 | ||||||||||||
Issuance of long-term debt | - | 4,000 | - | - | - | 4,000 | ||||||||||||
Proceeds from receivables facility | - | - | - | 133 | - | 133 | ||||||||||||
Repayments of long-term indebtedness | - | -7,674 | -7 | -5 | - | -7,686 | ||||||||||||
Net cash provided by (used in) financing | ||||||||||||||||||
activities | -73 | -298 | 3,127 | 475 | - | 3,231 | ||||||||||||
Net change in cash and cash equivalents | - | - | 211 | 29 | - | 240 | ||||||||||||
Cash and cash equivalents at beginning of period | - | - | 239 | 134 | - | 373 | ||||||||||||
Cash and cash equivalents at end of period | $ | - | $ | - | $ | 450 | $ | 163 | $ | - | $ | 613 | ||||||
Basis_of_Presentation_and_Sign1
Basis of Presentation and Significant Accounting Policies (Policies) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Basis of Presentation and Significant Accounting Policies [Abstract] | ||||||
Basis of Accounting, Policy | The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2015 and December 31, 2014 and for the three-month periods ended March 31, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of Health Management Associates, Inc. (“HMA”) are included from January 27, 2014, the date of the HMA merger. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2015. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2014, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2015. | |||||
Consolidation, Policy | Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets. | |||||
During the three months ended March 31, 2014, the Company made the decision to sell several smaller hospitals and entered into definitive agreements to sell two hospitals. Since March 31, 2014, the Company made the decision to sell two additional hospitals. The condensed consolidated statement of income for the three months ended March 31, 2014 has been restated to reclassify the results of operations for these hospitals that were owned or leased in 2014 to discontinued operations. | ||||||
Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc. | ||||||
Allowance for Doubtful Accounts, Policy | Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses. | |||||
The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. For all other non-self-pay payor categories, the Company reserves 100% of all accounts aging over 365 days from the date of discharge. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies. | ||||||
Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions. | ||||||
Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2015 and 2014, were as follows (in millions): | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Medicare | $ | 1,398 | $ | 1,261 | ||
Medicaid | 586 | 459 | ||||
Managed Care and other third-party payors | 2,946 | 2,450 | ||||
Self-pay | 716 | 705 | ||||
Total | $ | 5,646 | $ | 4,875 | ||
Electronic Health Records Incentive Reimbursement Policy | Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment. | |||||
Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. | ||||||
Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available. | ||||||
In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met. | ||||||
Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers. | ||||||
New Accounting Pronouncements, Policy | New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently decided to defer the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows. | |||||
Use_of_Estimates_Policies
Use of Estimates (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Use of Estimates [Abstract] | |
Use of Estimates, Policy | |
4. USE OF ESTIMATES | |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions. | |
Acquisitions_and_Divestitures_
Acquisitions and Divestitures (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Acquisitions And Divestitures [Abstract] | |
Business Combinations Policy | |
Acquisitions | |
The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition. Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired. | |
Goodwill_and_Other_Intangible_1
Goodwill and Other Intangible Assets (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Goodwill and Intangible Asset Impairment [Abstract] | |
Goodwill, Policy | Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2015, the hospital operations reporting unit, the home care agency operations reporting unit, and the hospital management services reporting unit had approximately $8.9 billion, $44 million and $33 million, respectively, of goodwill. |
Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2014. No impairment was indicated by this evaluation. The next annual goodwill evaluation will be performed during the fourth quarter of 2015. | |
The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions. | |
Fair_Value_of_Financial_Instru1
Fair Value of Financial Instruments (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Fair Value of Financial Instruments [Abstract] | |
Fair Value of Financial Instruments, Policy | The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 13. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant. |
Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). | |
Available-for-sale securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. | |
Trading securities. Estimated fair value is based on closing price as quoted in public markets. | |
Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded. | |
Credit Facility. Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions. | |
8% Senior Notes. Estimated fair value is based on the closing market price for these notes. | |
7⅛% Senior Notes. Estimated fair value is based on the closing market price for these notes. | |
2018 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes. | |
2021 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes. | |
6⅞% Senior Notes. Estimated fair value is based on the closing market price for these notes. | |
Receivables Facility and other debt. The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations. | |
Interest rate swaps. The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. | |
Fair_Value_Policies
Fair Value (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Fair Value [Abstract] | |
Fair Value Measurement, Policy | Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). |
The inputs used to measure fair value are classified into the following fair value hierarchy: | |
Level 1: Quoted market prices in active markets for identical assets or liabilities. | |
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. | |
Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. | |
In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during 2015 or 2014. | |
Contingencies_Policies
Contingencies (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Contingencies [Abstract] | |
Legal Costs, Policy | The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. |
With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters. | |
Supplemental_Condensed_Consoli
Supplemental Condensed Consolidating Financial Information (Policies) | 3 Months Ended |
Mar. 31, 2015 | |
Supplemental Condensed Consolidating Financial Information [Abstract] | |
Guarantor Financial Information Policy | These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” |
The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below: | |
•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. | |
•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net. | |
•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. | |
•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances. | |
The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 11. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation. | |
From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods are revised to reflect the status of guarantors or non-guarantors as of March 31, 2015. | |
Basis_of_Presentation_and_Sign2
Basis of Presentation and Significant Accounting Policies (Tables) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Basis of Presentation and Significant Accounting Policies [Abstract] | ||||||
Schedule of Operating Revenues, Net of Contractual Allowances and Discounts (But Before the Provision for Bad Debts) | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Medicare | $ | 1,398 | $ | 1,261 | ||
Medicaid | 586 | 459 | ||||
Managed Care and other third-party payors | 2,946 | 2,450 | ||||
Self-pay | 716 | 705 | ||||
Total | $ | 5,646 | $ | 4,875 | ||
Accounting_for_StockBased_Comp1
Accounting for Stock-Based Compensation (Tables) | 3 Months Ended | |||||||||
Mar. 31, 2015 | ||||||||||
Accounting for Stock-Based Compensation [Abstract] | ||||||||||
Schedule of Share-based Compensation Expense | ||||||||||
Three Months Ended | ||||||||||
March 31, | ||||||||||
2015 | 2014 | |||||||||
Effect on income from continuing operations before income taxes | $ | -14 | $ | -11 | ||||||
Effect on net income | $ | -8 | $ | -7 | ||||||
Schedule of Share-based Compensation, Stock Options, Activity | ||||||||||
Weighted- | Aggregate | |||||||||
Average | Intrinsic | |||||||||
Weighted- | Remaining | Value as of | ||||||||
Average | Contractual | March 31, | ||||||||
Shares | Exercise Price | Term | 2015 | |||||||
Outstanding at December 31, 2014 | 1,953,727 | $ | 32.94 | |||||||
Granted | - | - | ||||||||
Exercised | -452,959 | 38.77 | ||||||||
Forfeited and cancelled | - | - | ||||||||
Outstanding at March 31, 2015 | 1,500,768 | $ | 31.18 | 4.7 years | $ | 32 | ||||
Exercisable at March 31, 2015 | 1,498,764 | $ | 31.19 | 4.7 years | $ | 37 | ||||
Schedule of Share-based Compensation, Restricted Stock, Activity | ||||||||||
Weighted- | ||||||||||
Average Grant | ||||||||||
Shares | Date Fair Value | |||||||||
Unvested at December 31, 2014 | 2,760,639 | $ | 39.82 | |||||||
Granted | 1,223,500 | 47.72 | ||||||||
Vested | -1,115,006 | 37.45 | ||||||||
Forfeited | - | - | ||||||||
Unvested at March 31, 2015 | 2,869,133 | 44.11 | ||||||||
Schedule of Share-based Compensation, Restricted Stock Units Award, Activity | ||||||||||
Weighted- | ||||||||||
Average Grant | ||||||||||
Shares | Date Fair Value | |||||||||
Unvested at December 31, 2014 | 49,362 | $ | 36.07 | |||||||
Granted | 21,024 | 47.70 | ||||||||
Vested | -27,708 | 31.76 | ||||||||
Forfeited | - | - | ||||||||
Unvested at March 31, 2015 | 42,678 | 44.59 | ||||||||
Acquisitions_and_Divestitures_1
Acquisitions and Divestitures (Tables) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Acquisitions And Divestitures [Abstract] | ||||||
Schedule of Net Operating Revenues and Income (Loss) and Assets and Liabilities Classified as Discontinued Operations | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Net operating revenues | $ | 56 | $ | 89 | ||
Loss from operations of entities sold or held for sale | ||||||
before income taxes | -17 | -7 | ||||
Impairment of hospitals sold or held for sale | -1 | -22 | ||||
Loss on sale, net | -1 | - | ||||
Loss from discontinued operations, before taxes | -19 | -29 | ||||
Income tax benefit | -6 | -7 | ||||
Loss from discontinued operations, net of taxes | $ | -13 | $ | -22 | ||
Goodwill_and_Other_Intangible_2
Goodwill and Other Intangible Assets (Tables) | 3 Months Ended | |||
Mar. 31, 2015 | ||||
Goodwill and Other Intangible Assets [Abstract] | ||||
Schedule of Goodwill | ||||
Balance as of December 31, 2014 | $ | 8,951 | ||
Goodwill acquired as part of acquisitions during current year | 4 | |||
Consideration and purchase price allocation adjustments | ||||
for prior year’s acquisitions and other adjustments | -1 | |||
Balance as of March 31, 2015 | $ | 8,954 | ||
Earnings_Per_Share_Tables
Earnings Per Share (Tables) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Earnings Per Share [Abstract] | ||||||
Schedule of Calculation of Numerator and Denominator in Earnings Per Share | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Numerator: | ||||||
Income (loss) from continuing operations, net of taxes | $ | 112 | $ | -76 | ||
Less: Income from continuing operations attributable | ||||||
to noncontrolling interests, net of taxes | 20 | 14 | ||||
Income (loss) from continuing operations attributable to | ||||||
Community Health Systems, Inc. common | ||||||
stockholders — basic and diluted | $ | 92 | $ | -90 | ||
Loss from discontinued operations, net of taxes | $ | -13 | $ | -22 | ||
Less: Loss from discontinued operations attributable | ||||||
to noncontrolling interests, net of taxes | - | - | ||||
Loss from discontinued operations attributable to | ||||||
Community Health Systems, Inc. common | ||||||
stockholders — basic and diluted | $ | -13 | $ | -22 | ||
Denominator: | ||||||
Weighted-average number of shares outstanding — basic | 114,419,590 | 106,601,997 | ||||
Effect of dilutive securities: | ||||||
Restricted stock awards | 181,120 | - | ||||
Employee stock options | 452,659 | - | ||||
Other equity-based awards | 4,299 | - | ||||
Weighted-average number of shares outstanding — diluted | 115,057,668 | 106,601,997 | ||||
Schedule of Antidilutive Securities | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Dilutive securities outstanding not included in | ||||||
the computation of earnings per | ||||||
share because their effect is antidilutive: | ||||||
Employee stock options and restricted stock awards | - | 1,891,000 | ||||
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 3 Months Ended | ||||||||||||||||||||||||
Mar. 31, 2015 | |||||||||||||||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||||||||||||||
Schedule of Stockholders' Equity | |||||||||||||||||||||||||
Community Health Systems, Inc. Stockholders | |||||||||||||||||||||||||
Redeemable Noncontrolling Interest | Common Stock | Additional Paid-In Capital | Treasury Stock | Accumulated Other Comprehensive Income (Loss) | Retained Earnings | Noncontrolling Interest | Total Stockholders’ Equity | ||||||||||||||||||
Balance, December 31, 2014 | $ | 531 | $ | 1 | $ | 2,095 | $ | -7 | $ | -63 | $ | 1,977 | $ | 80 | $ | 4,083 | |||||||||
Comprehensive income | 16 | - | - | - | -7 | 79 | 4 | 76 | |||||||||||||||||
Distributions to noncontrolling | |||||||||||||||||||||||||
interests, net of contributions | -17 | - | - | - | - | - | -6 | -6 | |||||||||||||||||
Purchase of subsidiary shares | |||||||||||||||||||||||||
from noncontrolling interests | -7 | - | - | - | - | - | - | - | |||||||||||||||||
Disposition of less-than-wholly | |||||||||||||||||||||||||
owned hospital | -8 | - | - | - | - | - | - | - | |||||||||||||||||
Other reclassifications of | |||||||||||||||||||||||||
noncontrolling interests | -1 | - | - | - | - | - | 1 | 1 | |||||||||||||||||
Adjustment to redemption | |||||||||||||||||||||||||
value of redeemable | |||||||||||||||||||||||||
noncontrolling interests | 6 | - | -6 | - | - | - | - | -6 | |||||||||||||||||
Issuance of common stock | |||||||||||||||||||||||||
in connection with the | |||||||||||||||||||||||||
exercise of stock options | - | - | 18 | - | - | - | - | 18 | |||||||||||||||||
Cancellation of restricted | |||||||||||||||||||||||||
stock for tax withholdings | |||||||||||||||||||||||||
on vested shares | - | - | -20 | - | - | - | - | -20 | |||||||||||||||||
Share-based compensation | - | - | 14 | - | - | - | - | 14 | |||||||||||||||||
Balance, March 31, 2015 | $ | 520 | $ | 1 | $ | 2,101 | $ | -7 | $ | -70 | $ | 2,056 | $ | 79 | $ | 4,160 | |||||||||
Schedule of Impact of Noncontrolling Interest to Stockholders' Equity | |||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||
31-Mar-15 | |||||||||||||||||||||||||
Net income attributable to Community Health Systems, | |||||||||||||||||||||||||
Inc. stockholders | $ | 79 | |||||||||||||||||||||||
Transfers to the noncontrolling interests: | |||||||||||||||||||||||||
Net decrease in Community Health Systems, Inc. paid-in | |||||||||||||||||||||||||
capital for purchase of subsidiary partnership interests | - | ||||||||||||||||||||||||
Net transfers to the noncontrolling interests | - | ||||||||||||||||||||||||
Change to Community Health Systems, Inc. stockholders’ equity | |||||||||||||||||||||||||
from net income attributable to Community Health Systems, | |||||||||||||||||||||||||
Inc. stockholders and transfers to noncontrolling interests | $ | 79 | |||||||||||||||||||||||
Equity_Investments_Tables
Equity Investments (Tables) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Equity Investments [Abstract] | ||||||
Schedule of Financial Information Related to Unconsolidated Entities Included in Consolidated Statement of Income | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2015 | 2014 | |||||
Revenues | $ | 375 | $ | 332 | ||
Operating costs and expenses | 315 | 294 | ||||
Income from continuing operations before taxes | 60 | 39 | ||||
LongTerm_Debt_Tables
Long-Term Debt (Tables) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Debt Instrument [Line Items] | ||||||
Schedule of Debt | ||||||
March 31, | December 31, | |||||
2015 | 2014 | |||||
Credit Facility: | ||||||
Term A Loan | $ | 925 | $ | 950 | ||
Term D Loan | 4,544 | 4,555 | ||||
Term E Loan | - | 1,660 | ||||
Term F Loan | 1,700 | - | ||||
Revolving credit loans | 62 | - | ||||
8% Senior Notes due 2019 | 2,017 | 2,018 | ||||
7⅛% Senior Notes due 2020 | 1,200 | 1,200 | ||||
5⅛% Senior Secured Notes due 2018 | 1,600 | 1,600 | ||||
5⅛% Senior Secured Notes due 2021 | 1,000 | 1,000 | ||||
6⅞% Senior Notes due 2022 | 3,000 | 3,000 | ||||
Receivables Facility | 623 | 614 | ||||
Capital lease obligations | 215 | 228 | ||||
Other | 83 | 91 | ||||
Total debt | 16,969 | 16,916 | ||||
Less current maturities | -229 | -235 | ||||
Total long-term debt | $ | 16,740 | $ | 16,681 | ||
Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member] | ||||||
Debt Instrument [Line Items] | ||||||
Schedule of Early Redemption Prices on Notes | ||||||
Period | Redemption Price | |||||
November 15, 2015 to November 14, 2016 | 104.000 | % | ||||
November 15, 2016 to November 14, 2017 | 102.000 | % | ||||
November 15, 2017 to November 15, 2019 | 100.000 | % | ||||
Senior Notes at 7.125, Due 2020 [Member] | Senior Notes [Member] | ||||||
Debt Instrument [Line Items] | ||||||
Schedule of Early Redemption Prices on Notes | ||||||
Period | Redemption Price | |||||
July 15, 2016 to July 14, 2017 | 103.563 | % | ||||
July 15, 2017 to July 14, 2018 | 101.781 | % | ||||
July 15, 2018 to July 15, 2020 | 100.000 | % | ||||
Senior Secured Notes At 5.125 Due 2018 [Member] | Senior Secured Notes [Member] | ||||||
Debt Instrument [Line Items] | ||||||
Schedule of Early Redemption Prices on Notes | ||||||
Period | Redemption Price | |||||
August 15, 2015 to August 14, 2016 | 102.563 | % | ||||
August 15, 2016 to August 14, 2017 | 101.281 | % | ||||
August 15, 2017 to August 15, 2018 | 100.000 | % | ||||
Senior Secured Notes at 5.125, Due 2021 [Member] | Senior Secured Notes [Member] | ||||||
Debt Instrument [Line Items] | ||||||
Schedule of Early Redemption Prices on Notes | ||||||
Period | Redemption Price | |||||
February 1, 2017 to January 31, 2018 | 103.844 | % | ||||
February 1, 2018 to January 31, 2019 | 102.563 | % | ||||
February 1, 2019 to January 31, 2020 | 101.281 | % | ||||
February 1, 2020 to January 31, 2021 | 100.000 | % | ||||
Senior Notes at 6.875, Due 2022 [Member] | Senior Notes [Member] | ||||||
Debt Instrument [Line Items] | ||||||
Schedule of Early Redemption Prices on Notes | ||||||
Period | Redemption Price | |||||
February 1, 2018 to January 31, 2019 | 103.438 | % | ||||
February 1, 2019 to January 31, 2020 | 101.719 | % | ||||
February 1, 2020 to January 31, 2022 | 100.000 | % | ||||
Fair_Value_of_Financial_Instru2
Fair Value of Financial Instruments (Tables) | 3 Months Ended | |||||||||||||||||||||
Mar. 31, 2015 | ||||||||||||||||||||||
Fair Value of Financial Instruments [Abstract] | ||||||||||||||||||||||
Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping | ||||||||||||||||||||||
31-Mar-15 | 31-Dec-14 | |||||||||||||||||||||
Carrying | Estimated Fair | Carrying | Estimated Fair | |||||||||||||||||||
Amount | Value | Amount | Value | |||||||||||||||||||
Assets: | ||||||||||||||||||||||
Cash and cash equivalents | $ | 222 | $ | 222 | $ | 509 | $ | 509 | ||||||||||||||
Available-for-sale securities | 285 | 285 | 280 | 280 | ||||||||||||||||||
Trading securities | 58 | 58 | 55 | 55 | ||||||||||||||||||
Liabilities: | ||||||||||||||||||||||
Contingent Value Right | 6 | 6 | 6 | 6 | ||||||||||||||||||
Credit Facility | 7,231 | 7,249 | 7,165 | 7,143 | ||||||||||||||||||
8% Senior Notes | 2,017 | 2,129 | 2,018 | 2,139 | ||||||||||||||||||
7⅛% Senior Notes | 1,200 | 1,277 | 1,200 | 1,282 | ||||||||||||||||||
2018 Senior Secured Notes | 1,600 | 1,655 | 1,600 | 1,655 | ||||||||||||||||||
2021 Senior Secured Notes | 1,000 | 1,034 | 1,000 | 1,041 | ||||||||||||||||||
6⅞% Senior Notes | 3,000 | 3,211 | 3,000 | 3,194 | ||||||||||||||||||
Receivables Facility and other debt | 706 | 706 | 705 | 705 | ||||||||||||||||||
Schedule of Interest Rate Swaps | ||||||||||||||||||||||
Swap # | Notional Amount (in millions) | Fixed Interest Rate | Termination Date | Fair Value (in millions) | ||||||||||||||||||
1 | $ | 300 | 3.447 | % | 6-Aug-16 | $ | 12 | |||||||||||||||
2 | 100 | 3.401 | % | 19-Aug-16 | 4 | |||||||||||||||||
3 | 200 | 3.429 | % | 19-Aug-16 | 8 | |||||||||||||||||
4 | 200 | 3.500 | % | 30-Aug-16 | 8 | |||||||||||||||||
5 | 100 | 3.005 | % | 30-Nov-16 | 4 | |||||||||||||||||
6 | 200 | 2.055 | % | 25-Jul-19 | 5 | |||||||||||||||||
7 | 200 | 2.059 | % | 25-Jul-19 | 5 | |||||||||||||||||
8 | 400 | 1.882 | % | 30-Aug-19 | 1 | -1 | ||||||||||||||||
9 | 200 | 2.515 | % | 30-Aug-19 | 5 | -1 | ||||||||||||||||
10 | 200 | 2.613 | % | 30-Aug-19 | 6 | -2 | ||||||||||||||||
11 | 300 | 2.041 | % | 30-Aug-20 | 1 | -1 | ||||||||||||||||
12 | 300 | 2.738 | % | 30-Aug-20 | 10 | -1 | ||||||||||||||||
13 | 300 | 2.892 | % | 30-Aug-20 | 12 | -2 | ||||||||||||||||
___________________ | ||||||||||||||||||||||
(1) This interest rate swap becomes effective August 28, 2015. | ||||||||||||||||||||||
(2) This interest rate swap becomes effective August 30, 2015. | ||||||||||||||||||||||
Schedule of Pre-tax Gain (Loss) Recognized as a Component of Other Comprehensive Income | ||||||||||||||||||||||
Amount of Pre-Tax Loss Recognized in OCI (Effective Portion) | ||||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationships | Three Months Ended March 31, | |||||||||||||||||||||
2015 | 2014 | |||||||||||||||||||||
Interest rate swaps | $ | -22 | $ | -3 | ||||||||||||||||||
Schedule of Effective Portion of the Pre-tax Loss Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income | ||||||||||||||||||||||
Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion) | ||||||||||||||||||||||
Location of Loss Reclassified from AOCL into Income (Effective Portion) | Three Months Ended March 31, | |||||||||||||||||||||
2015 | 2014 | |||||||||||||||||||||
Interest expense, net | $ | 9 | $ | 18 | ||||||||||||||||||
Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet | ||||||||||||||||||||||
Asset Derivatives | Liability Derivatives | |||||||||||||||||||||
31-Mar-15 | 31-Dec-14 | 31-Mar-15 | 31-Dec-14 | |||||||||||||||||||
Balance Sheet Location | Fair Value | Balance Sheet Location | Fair Value | Balance Sheet Location | Fair Value | Balance Sheet Location | Fair Value | |||||||||||||||
Derivatives designated as hedging instruments | Other assets, net | $ | - | Other assets, net | $ | - | Other long-term liabilities | $ | 81 | Other long-term liabilities | $ | 73 | ||||||||||
Fair_Value_Tables
Fair Value (Tables) | 3 Months Ended | |||||||||||
Mar. 31, 2015 | ||||||||||||
Fair Value [Abstract] | ||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | ||||||||||||
31-Mar-15 | Level 1 | Level 2 | Level 3 | |||||||||
Available-for-sale securities | $ | 285 | $ | 156 | $ | 129 | $ | - | ||||
Trading securities | 58 | 58 | - | - | ||||||||
Total assets | $ | 343 | $ | 214 | $ | 129 | $ | - | ||||
Contingent Value Right (CVR) | $ | 6 | $ | 6 | $ | - | $ | - | ||||
CVR-related liability | 256 | - | - | 256 | ||||||||
Fair value of interest rate swap agreements | 81 | - | 81 | - | ||||||||
Total liabilities | $ | 343 | $ | 6 | $ | 81 | $ | 256 | ||||
31-Dec-14 | Level 1 | Level 2 | Level 3 | |||||||||
Available-for-sale securities | $ | 280 | $ | 151 | $ | 129 | $ | - | ||||
Trading securities | 55 | 55 | - | - | ||||||||
Total assets | $ | 335 | $ | 206 | $ | 129 | $ | - | ||||
Contingent Value Right (CVR) | $ | 6 | $ | 6 | $ | - | $ | - | ||||
CVR-related liability | 265 | - | - | 265 | ||||||||
Fair value of interest rate swap agreements | 68 | - | 68 | - | ||||||||
Total liabilities | $ | 339 | $ | 6 | $ | 68 | $ | 265 | ||||
Segment_Information_Tables
Segment Information (Tables) | 3 Months Ended | |||||
Mar. 31, 2015 | ||||||
Segment Information [Abstract] | ||||||
Schedule of Segment Reporting Information by Segment | ||||||
Three Months Ended March 31, | ||||||
2015 | 2014 | |||||
Net operating revenues: | ||||||
Hospital operations | $ | 4,857 | $ | 4,124 | ||
Corporate and all other | 54 | 52 | ||||
Total | $ | 4,911 | $ | 4,176 | ||
Income (loss) from continuing operations before income taxes: | ||||||
Hospital operations | $ | 273 | $ | 38 | ||
Corporate and all other | -105 | -170 | ||||
Total | $ | 168 | $ | -132 | ||
Other_Comprehensive_Income_Tab
Other Comprehensive Income (Tables) | 3 Months Ended | ||||||||||||
Mar. 31, 2015 | |||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||
Schedule of Changes in Accumulated Other Comprehensive Income by Component | |||||||||||||
Change in | |||||||||||||
Change in Fair | Change in Fair | Unrecognized | Accumulated Other | ||||||||||
Value of Interest | Value of Available | Pension Cost | Comprehensive | ||||||||||
Rate Swaps | for Sale Securities | Components | Income (Loss) | ||||||||||
Balance as of December 31, 2014 | $ | -43 | $ | 7 | $ | -27 | $ | -63 | |||||
Other comprehensive (loss) | |||||||||||||
income before reclassifications | -15 | 1 | - | -14 | |||||||||
Amounts reclassified from | |||||||||||||
accumulated other | |||||||||||||
comprehensive income (loss) | 6 | - | 1 | 7 | |||||||||
Net current-period other | |||||||||||||
comprehensive income | -9 | 1 | 1 | -7 | |||||||||
Balance as of March 31, 2015 | $ | -52 | $ | 8 | $ | -26 | $ | -70 | |||||
Change in | |||||||||||||
Change in Fair | Change in Fair | Unrecognized | Accumulated Other | ||||||||||
Value of Interest | Value of Available | Pension Cost | Comprehensive | ||||||||||
Rate Swaps | for Sale Securities | Components | Income (Loss) | ||||||||||
Balance as of December 31, 2013 | $ | -56 | $ | 7 | $ | -18 | $ | -67 | |||||
Other comprehensive (loss) | |||||||||||||
income before reclassifications | -2 | - | - | -2 | |||||||||
Amounts reclassified from | |||||||||||||
accumulated other | |||||||||||||
comprehensive income (loss) | 11 | - | - | 11 | |||||||||
Net current-period other | |||||||||||||
comprehensive income | 9 | - | - | 9 | |||||||||
Balance as of March 31, 2014 | $ | -47 | $ | 7 | $ | -18 | $ | -58 | |||||
Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Income | |||||||||||||
Amount reclassified | |||||||||||||
from AOCL | Affected line item in the | ||||||||||||
Details about accumulated other | Three Months Ended | statement where net | |||||||||||
comprehensive income (loss) components | 31-Mar-15 | income is presented | |||||||||||
Gains and losses on cash flow hedges | |||||||||||||
Interest rate swaps | $ | -9 | Interest expense, net | ||||||||||
3 | Tax benefit | ||||||||||||
$ | -6 | Net of tax | |||||||||||
Amortization of defined benefit pension items | |||||||||||||
Prior service costs | $ | - | Salaries and benefits | ||||||||||
Actuarial losses | -1 | Salaries and benefits | |||||||||||
-1 | Total before tax | ||||||||||||
- | Tax benefit | ||||||||||||
$ | -1 | Net of tax | |||||||||||
Amount reclassified | |||||||||||||
from AOCL | Affected line item in the | ||||||||||||
Details about accumulated other | Three Months Ended | statement where net | |||||||||||
comprehensive income (loss) components | 31-Mar-14 | income is presented | |||||||||||
Gains and losses on cash flow hedges | |||||||||||||
Interest rate swaps | $ | -18 | Interest expense, net | ||||||||||
7 | Tax benefit | ||||||||||||
$ | -11 | Net of tax | |||||||||||
Amortization of defined benefit pension items | |||||||||||||
Prior service costs | $ | - | Salaries and benefits | ||||||||||
Actuarial losses | - | Salaries and benefits | |||||||||||
- | Total before tax | ||||||||||||
- | Tax benefit | ||||||||||||
$ | - | Net of tax | |||||||||||
Contingencies_Tables
Contingencies (Tables) | 3 Months Ended | ||||||||||||
Mar. 31, 2015 | |||||||||||||
Contingencies [Abstract] | |||||||||||||
Impact of Legal Expenses Paid or Incurred to Date and Settlements Paid or Deemed Final | |||||||||||||
Allocation of Expenses and Settlement Costs | |||||||||||||
Reduction to | |||||||||||||
Total Expenses | CHS | Amount Owed | |||||||||||
and Settlement | Responsibility | to CVR Holders | |||||||||||
Cost | Deductible | at 10% | at 90% | ||||||||||
As of December 31, 2014 | $ | 24 | $ | 18 | $ | - | $ | 6 | |||||
Settlements paid | - | - | - | - | |||||||||
Legal expenses incurred | |||||||||||||
and/or paid during | |||||||||||||
the three months ended | |||||||||||||
31-Mar-15 | 3 | - | 1 | 2 | |||||||||
As of March 31, 2015 | $ | 27 | $ | 18 | $ | 1 | $ | 8 | |||||
Schedule Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies | |||||||||||||
CVR Related | CVR Related Liability | Other | |||||||||||
Liability | for Probable | Probable | |||||||||||
at Fair Value | Contingencies | Contingencies | |||||||||||
Balance as of December 31, 2014 | $ | 265 | $ | 29 | $ | 125 | |||||||
Expense | -9 | -5 | 15 | ||||||||||
Cash payments | - | - | -92 | ||||||||||
Balance as of March 31, 2015 | $ | 256 | $ | 24 | $ | 48 | |||||||
Supplemental_Condensed_Consoli1
Supplemental Condensed Consolidating Financial Information (Tables) | 3 Months Ended | |||||||||||||||||
Mar. 31, 2015 | ||||||||||||||||||
Supplemental Condensed Consolidating Financial Information [Abstract] | ||||||||||||||||||
Schedule of Condensed Consolidating Statement of Income (Loss) | ||||||||||||||||||
Condensed Consolidating Statement of Income | ||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Operating revenues (net of contractual | ||||||||||||||||||
allowances and discounts) | $ | - | $ | -5 | $ | 3,488 | $ | 2,163 | $ | - | $ | 5,646 | ||||||
Provision for bad debts | - | - | 447 | 288 | - | 735 | ||||||||||||
Net operating revenues | - | -5 | 3,041 | 1,875 | - | 4,911 | ||||||||||||
Operating costs and expenses: | ||||||||||||||||||
Salaries and benefits | - | - | 1,222 | 1,035 | - | 2,257 | ||||||||||||
Supplies | - | - | 492 | 270 | - | 762 | ||||||||||||
Other operating expenses | - | - | 708 | 391 | - | 1,099 | ||||||||||||
Government settlement and related costs | - | - | 8 | - | - | 8 | ||||||||||||
Electronic health records incentive reimbursement | - | - | -17 | -9 | - | -26 | ||||||||||||
Rent | - | - | 61 | 55 | - | 116 | ||||||||||||
Depreciation and amortization | - | - | 200 | 96 | - | 296 | ||||||||||||
Total operating costs and expenses | - | - | 2,674 | 1,838 | - | 4,512 | ||||||||||||
Income from operations | - | -5 | 367 | 37 | - | 399 | ||||||||||||
Interest expense, net | - | 21 | 211 | 9 | - | 241 | ||||||||||||
Loss from early extinguishment of debt | - | 8 | - | - | - | 8 | ||||||||||||
Equity in earnings of unconsolidated affiliates | -79 | -104 | -5 | - | 170 | -18 | ||||||||||||
Income from continuing operations before income taxes | 79 | 70 | 161 | 28 | -170 | 168 | ||||||||||||
Provision for (benefit from) income taxes | - | -9 | 61 | 4 | - | 56 | ||||||||||||
Income from continuing operations | 79 | 79 | 100 | 24 | -170 | 112 | ||||||||||||
Discontinued operations, net of taxes: | ||||||||||||||||||
Loss from operations of entities sold or held for sale | - | - | - | -11 | - | -11 | ||||||||||||
Impairment of hospitals sold or held for sale | - | - | -1 | - | - | -1 | ||||||||||||
Loss on sale, net | - | - | 2 | -3 | - | -1 | ||||||||||||
Loss from discontinued operations, net of taxes | - | - | 1 | -14 | - | -13 | ||||||||||||
Net income | 79 | 79 | 101 | 10 | -170 | 99 | ||||||||||||
Less: Net income attributable to noncontrolling interests | - | - | - | 20 | - | 20 | ||||||||||||
Net income attributable to Community Health Systems, | ||||||||||||||||||
Inc. stockholders | $ | 79 | $ | 79 | $ | 101 | $ | -10 | $ | -170 | $ | 79 | ||||||
Condensed Consolidating Statement of Loss | ||||||||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Operating revenues (net of contractual | ||||||||||||||||||
allowances and discounts) | $ | - | $ | -4 | $ | 3,119 | $ | 1,760 | $ | - | $ | 4,875 | ||||||
Provision for bad debts | - | - | 476 | 223 | - | 699 | ||||||||||||
Net operating revenues | - | -4 | 2,643 | 1,537 | - | 4,176 | ||||||||||||
Operating costs and expenses: | ||||||||||||||||||
Salaries and benefits | - | - | 1,147 | 845 | - | 1,992 | ||||||||||||
Supplies | - | - | 417 | 215 | - | 632 | ||||||||||||
Other operating expenses | - | - | 663 | 356 | - | 1,019 | ||||||||||||
Electronic health records incentive reimbursement | - | - | -30 | -10 | - | -40 | ||||||||||||
Rent | - | - | 54 | 44 | - | 98 | ||||||||||||
Depreciation and amortization | - | - | 189 | 66 | - | 255 | ||||||||||||
Amortization of software to be abandoned | - | - | 26 | 16 | - | 42 | ||||||||||||
Total operating costs and expenses | - | - | 2,466 | 1,532 | - | 3,998 | ||||||||||||
Income from operations | - | -4 | 177 | 5 | - | 178 | ||||||||||||
Interest expense, net | - | 40 | 172 | 12 | - | 224 | ||||||||||||
Loss from early extinguishment of debt | - | 73 | - | - | - | 73 | ||||||||||||
Equity in earnings of unconsolidated affiliates | 112 | 27 | 23 | - | -173 | -11 | ||||||||||||
Impairment of long-lived assets | - | - | 24 | - | - | 24 | ||||||||||||
Income from continuing operations before income taxes | -112 | -144 | -42 | -7 | 173 | -132 | ||||||||||||
Provision for (benefit from) income taxes | - | -32 | -16 | -8 | - | -56 | ||||||||||||
Income from continuing operations | -112 | -112 | -26 | 1 | 173 | -76 | ||||||||||||
Discontinued operations, net of taxes: | ||||||||||||||||||
Loss from operations of entities sold or held for sale | - | - | -3 | -1 | - | -4 | ||||||||||||
Impairment of hospitals sold or held for sale | - | - | - | -18 | - | -18 | ||||||||||||
Loss from discontinued operations, net of taxes | - | - | -3 | -19 | - | -22 | ||||||||||||
Net loss | -112 | -112 | -29 | -18 | 173 | -98 | ||||||||||||
Less: Net income attributable to noncontrolling interests | - | - | - | 14 | - | 14 | ||||||||||||
Net loss attributable to Community Health | ||||||||||||||||||
Systems, Inc. stockholders | $ | -112 | $ | -112 | $ | -29 | $ | -32 | $ | 173 | $ | -112 | ||||||
Schedule of Condensed Consolidating Statement of Comprehensive Income (Loss) | ||||||||||||||||||
Condensed Consolidating Statement of Comprehensive Income | ||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net income | $ | 79 | $ | 79 | $ | 101 | $ | 10 | $ | -170 | $ | 99 | ||||||
Other comprehensive income (loss), net of income taxes: | ||||||||||||||||||
Net change in fair value of interest rate swaps, net of tax | -9 | -9 | - | - | 9 | -9 | ||||||||||||
Net change in fair value of available-for-sale securities, net | ||||||||||||||||||
of tax | 1 | 1 | 1 | - | -2 | 1 | ||||||||||||
Amortization and recognition of unrecognized pension | ||||||||||||||||||
cost components, net of tax | 1 | 1 | 1 | - | -2 | 1 | ||||||||||||
Other comprehensive income (loss) | -7 | -7 | 2 | - | 5 | -7 | ||||||||||||
Comprehensive income | 72 | 72 | 103 | 10 | -165 | 92 | ||||||||||||
Less: Comprehensive income attributable to | ||||||||||||||||||
noncontrolling interests | - | - | - | 20 | - | 20 | ||||||||||||
Comprehensive income (loss) attributable to Community | ||||||||||||||||||
Health Systems, Inc. stockholders | $ | 72 | $ | 72 | $ | 103 | $ | -10 | $ | -165 | $ | 72 | ||||||
Condensed Consolidating Statement of Comprehensive Loss | ||||||||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||
Parent Guarantor | Issuer | Other Guarantors | Non - Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net loss | $ | -112 | $ | -112 | $ | -29 | $ | -18 | $ | 173 | $ | -98 | ||||||
Other comprehensive income (loss), net of income taxes: | ||||||||||||||||||
Net change in fair value of interest rate swaps, net of tax | 9 | 9 | - | - | -9 | 9 | ||||||||||||
Net change in fair value of available-for-sale securities, net | ||||||||||||||||||
of tax | - | - | - | - | - | - | ||||||||||||
Amortization and recognition of unrecognized pension | ||||||||||||||||||
cost components, net of tax | - | - | - | - | - | - | ||||||||||||
Other comprehensive income (loss) | 9 | 9 | - | - | -9 | 9 | ||||||||||||
Comprehensive loss | -103 | -103 | -29 | -18 | 164 | -89 | ||||||||||||
Less: Comprehensive income attributable to | ||||||||||||||||||
noncontrolling interests | - | - | - | 14 | - | 14 | ||||||||||||
Comprehensive loss attributable to Community | ||||||||||||||||||
Health Systems, Inc. stockholders | $ | -103 | $ | -103 | $ | -29 | $ | -32 | $ | 164 | $ | -103 | ||||||
Schedule of Condensed Consolidating Balance Sheet | ||||||||||||||||||
Condensed Consolidating Balance Sheet | ||||||||||||||||||
31-Mar-15 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
ASSETS | ||||||||||||||||||
Current assets: | ||||||||||||||||||
Cash and cash equivalents | $ | - | $ | - | $ | 37 | $ | 185 | $ | - | $ | 222 | ||||||
Patient accounts receivable, net of allowance | ||||||||||||||||||
for doubtful accounts | - | - | 1,430 | 2,176 | - | 3,606 | ||||||||||||
Supplies | - | - | 377 | 184 | - | 561 | ||||||||||||
Deferred income taxes | 341 | - | - | - | - | 341 | ||||||||||||
Prepaid expenses and taxes | - | - | 131 | 58 | - | 189 | ||||||||||||
Other current assets | - | - | 329 | 178 | - | 507 | ||||||||||||
Total current assets | 341 | - | 2,304 | 2,781 | - | 5,426 | ||||||||||||
Intercompany receivable | 1,257 | 16,512 | 3,314 | 6,131 | -27,214 | - | ||||||||||||
Property and equipment, net | - | - | 6,613 | 3,478 | - | 10,091 | ||||||||||||
Goodwill | - | - | 5,483 | 3,471 | - | 8,954 | ||||||||||||
Other assets, net | 6 | 303 | 1,817 | 1,164 | -642 | 2,648 | ||||||||||||
Net investment in subsidiaries | 3,361 | 18,435 | 7,643 | - | -29,439 | - | ||||||||||||
Total assets | $ | 4,965 | $ | 35,250 | $ | 27,174 | $ | 17,025 | $ | -57,295 | $ | 27,119 | ||||||
LIABILITIES AND EQUITY | ||||||||||||||||||
Current liabilities: | ||||||||||||||||||
Current maturities of long-term debt | $ | - | $ | 163 | $ | 54 | $ | 12 | $ | - | $ | 229 | ||||||
Accounts payable | - | 1 | 873 | 318 | - | 1,192 | ||||||||||||
Income tax payable | 13 | - | - | - | - | 13 | ||||||||||||
Deferred income taxes | 23 | - | - | - | - | 23 | ||||||||||||
Accrued interest | - | 155 | 1 | 1 | - | 157 | ||||||||||||
Accrued liabilities | 4 | - | 1,051 | 492 | - | 1,547 | ||||||||||||
Total current liabilities | 40 | 319 | 1,979 | 823 | - | 3,161 | ||||||||||||
Long-term debt | - | 15,885 | 127 | 728 | - | 16,740 | ||||||||||||
Intercompany payable | - | 14,822 | 20,071 | 14,117 | -49,010 | - | ||||||||||||
Deferred income taxes | 844 | - | - | - | - | 844 | ||||||||||||
Other long-term liabilities | - | 862 | 1,113 | 361 | -642 | 1,694 | ||||||||||||
Total liabilities | 884 | 31,888 | 23,290 | 16,029 | -49,652 | 22,439 | ||||||||||||
Redeemable noncontrolling interests in | ||||||||||||||||||
equity of consolidated subsidiaries | - | - | - | 520 | - | 520 | ||||||||||||
Equity: | ||||||||||||||||||
Community Health Systems, Inc. stockholders’ | ||||||||||||||||||
equity: | ||||||||||||||||||
Preferred stock | - | - | - | - | - | - | ||||||||||||
Common stock | 1 | - | - | - | - | 1 | ||||||||||||
Additional paid-in capital | 2,101 | 1,294 | 1,471 | 523 | -3,288 | 2,101 | ||||||||||||
Treasury stock, at cost | -7 | - | - | - | - | -7 | ||||||||||||
Accumulated other comprehensive loss | -70 | -70 | -17 | - | 87 | -70 | ||||||||||||
Retained earnings | 2,056 | 2,138 | 2,430 | -126 | -4,442 | 2,056 | ||||||||||||
Total Community Health Systems, Inc. | ||||||||||||||||||
stockholders’ equity | 4,081 | 3,362 | 3,884 | 397 | -7,643 | 4,081 | ||||||||||||
Noncontrolling interests in equity of | ||||||||||||||||||
consolidated subsidiaries | - | - | - | 79 | - | 79 | ||||||||||||
Total equity | 4,081 | 3,362 | 3,884 | 476 | -7,643 | 4,160 | ||||||||||||
Total liabilities and equity | $ | 4,965 | $ | 35,250 | $ | 27,174 | $ | 17,025 | $ | -57,295 | $ | 27,119 | ||||||
Condensed Consolidating Balance Sheet | ||||||||||||||||||
31-Dec-14 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
ASSETS | ||||||||||||||||||
Current assets: | ||||||||||||||||||
Cash and cash equivalents | $ | - | $ | - | $ | 368 | $ | 141 | $ | - | $ | 509 | ||||||
Patient accounts receivable, net of allowance | ||||||||||||||||||
for doubtful accounts | - | - | 1,272 | 2,137 | - | 3,409 | ||||||||||||
Supplies | - | - | 373 | 184 | - | 557 | ||||||||||||
Prepaid income taxes | 30 | - | - | - | - | 30 | ||||||||||||
Deferred income taxes | 341 | - | - | - | - | 341 | ||||||||||||
Prepaid expenses and taxes | - | - | 138 | 54 | - | 192 | ||||||||||||
Other current assets | - | - | 356 | 172 | - | 528 | ||||||||||||
Total current assets | 371 | - | 2,507 | 2,688 | - | 5,566 | ||||||||||||
Intercompany receivable | 1,199 | 16,560 | 2,532 | 7,877 | -28,168 | - | ||||||||||||
Property and equipment, net | - | - | 6,548 | 3,621 | - | 10,169 | ||||||||||||
Goodwill | - | - | 5,480 | 3,471 | - | 8,951 | ||||||||||||
Other assets, net | 15 | 302 | 1,874 | 1,179 | -635 | 2,735 | ||||||||||||
Net investment in subsidiaries | 3,290 | 18,229 | 7,399 | - | -28,918 | - | ||||||||||||
Total assets | $ | 4,875 | $ | 35,091 | $ | 26,340 | $ | 18,836 | $ | -57,721 | $ | 27,421 | ||||||
LIABILITIES AND EQUITY | ||||||||||||||||||
Current liabilities: | ||||||||||||||||||
Current maturities of long-term debt | $ | - | $ | 163 | $ | 61 | $ | 11 | $ | - | $ | 235 | ||||||
Accounts payable | - | - | 909 | 384 | - | 1,293 | ||||||||||||
Deferred income taxes | 23 | - | - | - | - | 23 | ||||||||||||
Accrued interest | - | 225 | 2 | - | - | 227 | ||||||||||||
Accrued liabilities | 4 | - | 1,249 | 558 | - | 1,811 | ||||||||||||
Total current liabilities | 27 | 388 | 2,221 | 953 | - | 3,589 | ||||||||||||
Long-term debt | - | 15,820 | 139 | 722 | - | 16,681 | ||||||||||||
Intercompany payable | - | 14,752 | 19,066 | 15,795 | -49,613 | - | ||||||||||||
Deferred income taxes | 845 | - | - | - | - | 845 | ||||||||||||
Other long-term liabilities | - | 841 | 1,140 | 346 | -635 | 1,692 | ||||||||||||
Total liabilities | 872 | 31,801 | 22,566 | 17,816 | -50,248 | 22,807 | ||||||||||||
Redeemable noncontrolling interests in | ||||||||||||||||||
equity of consolidated subsidiaries | - | - | - | 531 | - | 531 | ||||||||||||
Equity: | ||||||||||||||||||
Community Health Systems, Inc. stockholders’ | ||||||||||||||||||
equity: | ||||||||||||||||||
Preferred stock | - | - | - | - | - | - | ||||||||||||
Common stock | 1 | - | - | - | - | 1 | ||||||||||||
Additional paid-in capital | 2,095 | 1,208 | 1,369 | 528 | -3,105 | 2,095 | ||||||||||||
Treasury stock, at cost | -7 | - | - | - | - | -7 | ||||||||||||
Accumulated other comprehensive loss | -63 | -63 | -25 | 5 | 83 | -63 | ||||||||||||
Retained earnings | 1,977 | 2,145 | 2,430 | -124 | -4,451 | 1,977 | ||||||||||||
Total Community Health Systems, Inc. | ||||||||||||||||||
stockholders’ equity | 4,003 | 3,290 | 3,774 | 409 | -7,473 | 4,003 | ||||||||||||
Noncontrolling interests in equity of | ||||||||||||||||||
consolidated subsidiaries | - | - | - | 80 | - | 80 | ||||||||||||
Total equity | 4,003 | 3,290 | 3,774 | 489 | -7,473 | 4,083 | ||||||||||||
Total liabilities and equity | $ | 4,875 | $ | 35,091 | $ | 26,340 | $ | 18,836 | $ | -57,721 | $ | 27,421 | ||||||
Schedule of Condensed Consolidating Statement of Cash Flows | ||||||||||||||||||
Condensed Consolidating Statement of Cash Flows | ||||||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net cash (used in) provided by operating | ||||||||||||||||||
activities | $ | -10 | $ | -123 | $ | 23 | $ | 49 | $ | - | $ | -61 | ||||||
Cash flows from investing activities: | ||||||||||||||||||
Acquisitions of facilities and other related | ||||||||||||||||||
equipment | - | - | -11 | -2 | - | -13 | ||||||||||||
Purchases of property and equipment | - | - | -199 | -42 | - | -241 | ||||||||||||
Proceeds from disposition of hospitals | ||||||||||||||||||
and other ancillary operations | - | - | 4 | 58 | - | 62 | ||||||||||||
Proceeds from sale of property and equipment | - | - | - | 3 | - | 3 | ||||||||||||
Purchases of available-for-sale securities | - | - | -22 | -37 | - | -59 | ||||||||||||
Proceeds from sales of available-for-sale securities | - | - | 19 | 37 | - | 56 | ||||||||||||
Increase in other investments | - | - | -30 | -9 | - | -39 | ||||||||||||
Net cash used in investing activities | - | - | -239 | 8 | - | -231 | ||||||||||||
Cash flows from financing activities: | ||||||||||||||||||
Proceeds from exercise of stock options | 17 | - | - | - | - | 17 | ||||||||||||
Repurchase of restricted stock shares for payroll | ||||||||||||||||||
tax withholding requirements | -20 | - | - | - | - | -20 | ||||||||||||
Deferred financing costs and other | ||||||||||||||||||
debt-related costs | - | -20 | - | - | - | -20 | ||||||||||||
Redemption of noncontrolling investments in joint | ||||||||||||||||||
ventures | - | - | - | -7 | - | -7 | ||||||||||||
Distributions to noncontrolling investors in joint | ||||||||||||||||||
ventures | - | - | - | -23 | - | -23 | ||||||||||||
Changes in intercompany balances with | ||||||||||||||||||
affiliates, net | 13 | 77 | -101 | 11 | - | - | ||||||||||||
Borrowings under credit agreements | - | 1,250 | 1 | - | - | 1,251 | ||||||||||||
Issuance of long-term debt | - | - | - | - | - | - | ||||||||||||
Proceeds from receivables facility | - | - | - | 75 | - | 75 | ||||||||||||
Repayments of long-term indebtedness | - | -1,184 | -15 | -69 | - | -1,268 | ||||||||||||
Net cash provided by (used in) financing | ||||||||||||||||||
activities | 10 | 123 | -115 | -13 | - | 5 | ||||||||||||
Net change in cash and cash equivalents | - | - | -331 | 44 | - | -287 | ||||||||||||
Cash and cash equivalents at beginning of period | - | - | 368 | 141 | - | 509 | ||||||||||||
Cash and cash equivalents at end of period | $ | - | $ | - | $ | 37 | $ | 185 | $ | - | $ | 222 | ||||||
Condensed Consolidating Statement of Cash Flows | ||||||||||||||||||
Three Months Ended March 31, 2014 | ||||||||||||||||||
Parent | Other | Non - | ||||||||||||||||
Guarantor | Issuer | Guarantors | Guarantors | Eliminations | Consolidated | |||||||||||||
(In millions) | ||||||||||||||||||
Net cash (used in) provided by operating | ||||||||||||||||||
activities | $ | 73 | $ | 298 | $ | 62 | $ | -368 | $ | - | $ | 65 | ||||||
Cash flows from investing activities: | ||||||||||||||||||
Acquisitions of facilities and other related | ||||||||||||||||||
equipment | - | - | -2,760 | -14 | - | -2,774 | ||||||||||||
Purchases of property and equipment | - | - | -143 | -38 | - | -181 | ||||||||||||
Purchases of available-for-sale securities | - | - | - | -78 | - | -78 | ||||||||||||
Proceeds from sales of available-for-sale securities | - | - | - | 76 | - | 76 | ||||||||||||
Increase in other investments | - | - | -75 | -24 | - | -99 | ||||||||||||
Net cash used in investing activities | - | - | -2,978 | -78 | - | -3,056 | ||||||||||||
Cash flows from financing activities: | ||||||||||||||||||
Proceeds from exercise of stock options | 6 | - | - | - | - | 6 | ||||||||||||
Repurchase of restricted stock shares for payroll | ||||||||||||||||||
tax withholding requirements | -11 | - | - | - | - | -11 | ||||||||||||
Deferred financing costs and other | ||||||||||||||||||
debt-related costs | - | -269 | - | - | - | -269 | ||||||||||||
Excess tax benefit relating to | ||||||||||||||||||
stock-based compensation | 3 | - | - | - | - | 3 | ||||||||||||
Redemption of noncontrolling investments in joint | ||||||||||||||||||
ventures | - | - | - | -5 | - | -5 | ||||||||||||
Distributions to noncontrolling investors in joint | ||||||||||||||||||
ventures | - | - | - | -19 | - | -19 | ||||||||||||
Changes in intercompany balances with | ||||||||||||||||||
affiliates, net | -71 | -3,417 | 3,117 | 371 | - | - | ||||||||||||
Borrowings under credit agreements | - | 7,062 | 17 | - | - | 7,079 | ||||||||||||
Issuance of long-term debt | - | 4,000 | - | - | - | 4,000 | ||||||||||||
Proceeds from receivables facility | - | - | - | 133 | - | 133 | ||||||||||||
Repayments of long-term indebtedness | - | -7,674 | -7 | -5 | - | -7,686 | ||||||||||||
Net cash provided by (used in) financing | ||||||||||||||||||
activities | -73 | -298 | 3,127 | 475 | - | 3,231 | ||||||||||||
Net change in cash and cash equivalents | - | - | 211 | 29 | - | 240 | ||||||||||||
Cash and cash equivalents at beginning of period | - | - | 239 | 134 | - | 373 | ||||||||||||
Cash and cash equivalents at end of period | $ | - | $ | - | $ | 450 | $ | 163 | $ | - | $ | 613 | ||||||
Basis_of_Presentation_and_Sign3
Basis of Presentation and Significant Accounting Policies (Narrative) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Allowance for Doubtful Accounts, Policy [Abstract] | ||
Percentage reserved for all non-self-pay payors accounts aging over 365 days from the date of discharge | 100.00% | |
Number of days from the date of discharge over which all accounts are reserved 100% | 365 days | |
Electronic Health Records Reimbursement, Policy [Abstract] | ||
Electronic health records incentive reimbursement under HITECH | $26 | $40 |
Electronic Health Records Incentive Reimbursement, Cash Received | 54 | 62 |
Electronic Health Records Incentive Reimbursements [Member] | ||
Electronic Health Records Reimbursement, Policy [Abstract] | ||
Deferred Revenue | $75 | $93 |
Basis_of_Presentation_and_Sign4
Basis of Presentation and Significant Accounting Policies (Schedule of Operating Revenue, Net of Contractual Allowances and Discounts (But Before the Provision for Bad Debts)) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Health Care Organization, Receivable and Revenue Disclosures [Line Items] | ||
Operating revenues (net of contractual allowances and discounts) | $5,646 | $4,875 |
Medicare [Member] | ||
Health Care Organization, Receivable and Revenue Disclosures [Line Items] | ||
Operating revenues (net of contractual allowances and discounts) | 1,398 | 1,261 |
Medicaid [Member] | ||
Health Care Organization, Receivable and Revenue Disclosures [Line Items] | ||
Operating revenues (net of contractual allowances and discounts) | 586 | 459 |
Managed Care And Other Third Party Payors [Member] | ||
Health Care Organization, Receivable and Revenue Disclosures [Line Items] | ||
Operating revenues (net of contractual allowances and discounts) | 2,946 | 2,450 |
Self-Pay [Member] | ||
Health Care Organization, Receivable and Revenue Disclosures [Line Items] | ||
Operating revenues (net of contractual allowances and discounts) | $716 | $705 |
Accounting_for_StockBased_Comp2
Accounting for Stock-Based Compensation (Narrative) (Details) (USD $) | 3 Months Ended | ||||
In Millions, except Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Mar. 01, 2015 | Mar. 01, 2014 | Feb. 27, 2013 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Employee Service Share-based Compensation, Unrecognized Compensation Costs on Nonvested Awards | $103 | ||||
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition | 29 months | ||||
Aggregate intrinsic value of options exercised | $5 | $1 | |||
Common Class A [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share Price | $52.28 | ||||
Employee Stock Option [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | 0 | |||
Restricted Stock Units (RSUs) [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | one-third increments on each of the first three anniversaries of the award date | ||||
Restricted Stock [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | one-third increments on each of the first three anniversaries of the award date | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 835,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period | 2 years | ||||
Restricted Stock, Performance-Based Units [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | one-third increments on each of the first three anniversaries of the award date | ||||
Plan 2000 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | one-third increments on each of the first three anniversaries of the award date | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0 | ||||
Plan 2009 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | one-third increments on each of the first three anniversaries of the award date | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 3,192,176 | ||||
Plan 2009 [Member] | Restricted Stock Units (RSUs) [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation, Number of Shares Received by Each Director | 3,504 | 3,614 | 3,596 | ||
Contractual Term of Option Granted Prior to 2005 [Member] | Plan 2000 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share Based Compensation Contractual Term of Option Granted | 10 years | ||||
Contractual Term of Option Granted From 2005 Through 2007 [Member] | Plan 2000 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share Based Compensation Contractual Term of Option Granted | 8 years | ||||
Contractual Term Of Option Granted From 2008 Through 2011 [Member] | Plan 2000 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share Based Compensation Contractual Term of Option Granted | 10 years | ||||
Contractual Term of Option Granted in 2011 or Later [Member] | Plan 2009 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share Based Compensation Contractual Term of Option Granted | 10 years |
Accounting_for_StockBased_Comp3
Accounting for Stock-Based Compensation (Schedule of Share-based Compensation Expense) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Accounting for Stock-Based Compensation [Abstract] | ||
Effect on income from continuing operations before income taxes | ($14) | ($11) |
Effect on net income | ($8) | ($7) |
Accounting_for_StockBased_Comp4
Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Stock Options, Activity) (Details) (Employee Stock Option [Member], USD $) | 3 Months Ended | |
In Millions, except Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Employee Stock Option [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Beginning Balance, shares | 1,953,727 | |
Granted, Shares | 0 | 0 |
Exercised, Shares | -452,959 | |
Ending Balance, shares | 1,500,768 | |
Beginning of Period, Weighted Average Exercise Price | $32.94 | |
Exercised, Weighted Average Exercise Price | $38.77 | |
End of Period, Weighted Average Exercise Price | $31.18 | |
Weighted Average Remaining Contractual Term | 4 years 8 months 12 days | |
Aggregate Intrinsic Value | $32 | |
Exercisable, Shares | 1,498,764 | |
Exercisable, Weighted Average Exercise Price | $31.19 | |
Exercisable, Weighted Average Remaining Contractual Term | 4 years 8 months 12 days | |
Exercisable, Aggregate Intrinsic Value | $37 |
Accounting_for_StockBased_Comp5
Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Restricted Stock, Activity) (Details) (Restricted Stock [Member], USD $) | 3 Months Ended |
Mar. 31, 2015 | |
Restricted Stock [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Beginning Balance, Unvested Shares | 2,760,639 |
Granted, Shares | 1,223,500 |
Vested, Shares | -1,115,006 |
Ending Balance, Unvested Shares | 2,869,133 |
Beginning of Period, Weighted Average Grant Date Fair Value | $39.82 |
Granted, Weighted Average Grant Date Fair Value | $47.72 |
Vested, Weighted Average Grant Date Fair Value | $37.45 |
End of Period, Weighted Average Grant Date Fair Value | $44.11 |
Accounting_for_Stock_Based_Com
Accounting for Stock Based Compensation (Schedule of Share-based Compensation, Restricted Stock Units, Activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $) | 3 Months Ended |
Mar. 31, 2015 | |
Restricted Stock Units (RSUs) [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Beginning Balance, Unvested Shares | 49,362 |
Granted, Shares | 21,024 |
Vested, Shares | -27,708 |
Ending Balance, Unvested Shares | 42,678 |
Beginning of Period, Weighted Average Grant Date Fair Value | $36.07 |
Granted, Weighted Average Grant Date Fair Value | $47.70 |
Vested, Weighted Average Grant Date Fair Value | $31.76 |
End of Period, Weighted Average Grant Date Fair Value | $44.59 |
Cost_of_Revenue_Details
Cost of Revenue (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Cost of Revenue [Abstract] | ||
Corporate Office Costs | $77 | $77 |
Share-based Compensation | $14 | $11 |
Acquisitions_and_Divestitures_2
Acquisitions and Divestitures (Acquisitions Narrative) (Details) (USD $) | 3 Months Ended | 0 Months Ended | 1 Months Ended | ||||
Mar. 31, 2015 | Mar. 31, 2014 | Nov. 03, 2014 | Oct. 01, 2014 | Apr. 01, 2014 | Jan. 27, 2014 | Dec. 31, 2014 | |
item | |||||||
state | |||||||
Business Acquisition [Line Items] | |||||||
Business Combination, Acquisition Related Costs | $3,000,000 | $57,000,000 | |||||
Business Acquisition, Purchase Price Allocation, Goodwill | 8,954,000,000 | 8,951,000,000 | |||||
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share | $1 | ||||||
Senior Secured Notes at 5.125, Due 2021 [Member] | Senior Secured Notes [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Debt Instrument, Face Amount | 1,000,000,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.13% | ||||||
Senior Notes at 6.875, Due 2022 [Member] | Senior Notes [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Debt Instrument, Face Amount | 3,000,000,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.88% | ||||||
Lake Norman [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent | 150,000,000 | ||||||
Business Acquisition, Percentage of Voting Interests Acquired | 30.00% | ||||||
Upstate Carolina Medical Center [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Number of Licensed Hospital or Facility Beds | 125 | ||||||
Business Acquisition, Cost of Acquired Entity, Purchase Price | 4,000,000 | ||||||
Business Acquisition, Purchase Price Allocation, Goodwill | 0 | ||||||
Novant [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Effective Date of Acquisition | 3-Nov-14 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | 5,000,000 | ||||||
Natchez Regional Medical Center [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Effective Date of Acquisition | 1-Oct-14 | ||||||
Business Acquisition, Number of Licensed Hospital or Facility Beds | 179 | ||||||
Business Acquisition, Cost of Acquired Entity, Purchase Price | 10,000,000 | ||||||
Prepayment of future property taxes | 8,000,000 | ||||||
Period of prepayment for future property taxes will be applied to the tax liability | 17 years | ||||||
Business Acquisition, Purchase Price Allocation, Goodwill | 0 | ||||||
Sharon Regional Health System [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Effective Date of Acquisition | 1-Apr-14 | ||||||
Business Acquisition, Number of Licensed Hospital or Facility Beds | 258 | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid for Fixed Assets | 67,000,000 | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid for Working Capital | 1,000,000 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | 9,000,000 | ||||||
Business Acquisition, Cost of Acquired Entity, Purchase Price | 77,000,000 | ||||||
Business Acquisition, Purchase Price Allocation, Goodwill | 8,000,000 | ||||||
Munroe Regional Medical Center [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Effective Date of Acquisition | 1-Apr-14 | ||||||
Business Acquisition, Number of Licensed Hospital or Facility Beds | 421 | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid for Fixed Assets | 192,000,000 | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid for Working Capital | 4,000,000 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | 11,000,000 | ||||||
Business Acquisition, Cost of Acquired Entity, Purchase Price | 207,000,000 | ||||||
Business Acquisition, Purchase Price Allocation, Goodwill | 11,000,000 | ||||||
Business Acquisition, Percentage of Voting Interests Acquired | 95.00% | ||||||
Business Combination, Assumed Noncontrolling Interest, Fair Value | 10,000,000 | ||||||
Munroe Regional Medical Center [Member] | Affiliate of Regional Not-for-Profit Healthcare System [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 5.00% | ||||||
Health Management Associates, Inc. [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Effective Date of Acquisition | 27-Jan-14 | ||||||
Business Acquisition, Purchase Price Allocation, Goodwill | 4,500,000,000 | ||||||
Business Combination Consideration Transferred And Existing Indebtedness Assumed | 7,300,000,000 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | 3,800,000,000 | ||||||
Payments to Acquire Businesses, Gross, Per Share | $10.50 | ||||||
Business Combination Consideration Transferred Equity Interests Issued, Per Share | 0.06942 | ||||||
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Number Per Share | 1 | ||||||
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share | $1 | ||||||
Business Acquisition, Number of Hospitals Acquired | 71 | ||||||
Number of States in which Entity Operates | 15 | ||||||
Physician Practices Clinics and Other Ancillary Businesses [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 12,000,000 | ||||||
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment | 8,000,000 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | $4,000,000 |
Acquisitions_and_Divestitures_3
Acquisitions and Divestitures (Divestitures Narrative) (Details) (USD $) | 3 Months Ended | 0 Months Ended | |||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 01, 2015 | Dec. 31, 2014 | Feb. 01, 2015 | Jan. 01, 2015 |
item | item | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Number of Hospitals Sold | 4 | ||||
Proceeds from Divestiture of Businesses, Net of Cash Divested | $62 | ||||
Riverview Regional Medical Center [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Date | 1-Mar-15 | ||||
Number of licensed beds | 281 | ||||
Proceeds from Divestiture of Businesses, Net of Cash Divested | 25 | ||||
Carolina Pines Regional Medical Center [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Date | 1-Jan-15 | ||||
Number of licensed beds | 116 | ||||
Proceeds from Divestiture of Businesses, Net of Cash Divested | 74 | ||||
Williamson Memorial Hospital [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Number of licensed beds | 76 | ||||
Harris Hospital [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Date | 1-Feb-15 | ||||
Number of licensed beds | 133 | ||||
Proceeds from Divestiture of Businesses, Net of Cash Divested | 5 | ||||
Dallas Regional Medical Center [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Date | 1-Mar-15 | ||||
Number of licensed beds | 202 | ||||
Proceeds from Divestiture of Businesses, Net of Cash Divested | $25 |
Acquisitions_and_Divestitures_4
Acquisitions and Divestitures (Schedule of Net Operating Revenues and Income (Loss) and Assets and Liabilities Classified as Discontinued Operations) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Acquisitions And Divestitures [Abstract] | ||
Net operating revenues | $56 | $89 |
Loss from operations of entities sold or held for sale before income taxes | -17 | -7 |
Impairment of hospitals held for sale before income taxes | -1 | -22 |
Loss on sale, net | -1 | |
Loss from discontinued operations, before taxes | -19 | -29 |
Income tax benefit | -6 | -7 |
Loss from discontinued operations, net of taxes | ($13) | ($22) |
Income_Taxes_Income_Tax_Contin
Income Taxes (Income Tax Contingency and Taxes Paid Narrative) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Income Tax Contingency [Abstract] | ||
Unrecognized benefit that would affect the effective tax rate | $5 | |
Amount of interest and penalties included in liabilities for uncertain tax positions | 2 | |
Effective Income Tax Rate, Continuing Operations | 33.20% | 42.50% |
Cash Paid for Income Taxes, Net of Refunds Received [Abstract] | ||
Cash paid for income taxes (refunds received), net | $1 | ($79) |
Goodwill_and_Other_Intangible_3
Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 |
Goodwill [Roll Forward] | |
Goodwill, Beginning Balance | $8,951 |
Goodwill acquired as part of acquisitions during current year | 4 |
Consideration and purchase price allocation adjustments for prior year's acquisitions and other adjustments | -1 |
Goodwill, Ending Balance | $8,954 |
Goodwill_and_Other_Intangible_4
Goodwill and Other Intangible Assets (Goodwill Narrative) (Details) (USD $) | 3 Months Ended | |
Mar. 31, 2015 | Dec. 31, 2014 | |
Goodwill [Line Items] | ||
Goodwill | $8,954,000,000 | $8,951,000,000 |
Goodwill, Impairment Loss | 0 | |
Hospital operations [Member] | ||
Goodwill [Line Items] | ||
Goodwill | 8,900,000,000 | |
Home Care Agency Operations Reporting Unit [Member] | ||
Goodwill [Line Items] | ||
Goodwill | 44,000,000 | |
Hospital Management Services Reporting Unit [Member] | ||
Goodwill [Line Items] | ||
Goodwill | $33,000,000 |
Goodwill_and_Other_Intangible_5
Goodwill and Other Intangible Assets (Other Intangible Assets Narrative) (Details) (USD $) | 3 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 | |
Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets acquired during the year | $0 | ||
Finite-Lived Intangible Assets, Gross | 76,000,000 | 76,000,000 | |
Finite-Lived Intangible Assets, Net | 35,000,000 | 39,000,000 | |
Indefinite-Lived Intangible Assets (Excluding Goodwill) | 128,000,000 | 131,000,000 | |
Capitalized Computer Software, Gross | 1,400,000,000 | 1,500,000,000 | |
Capitalized Computer Software, Net | 769,000,000 | 790,000,000 | |
Capitalized Computer Software, Development Stage Costs | 33,000,000 | ||
Impairment of long-lived assets | 24,000,000 | ||
Amortization of software to be abandoned | 42,000,000 | ||
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Weighted-Average Useful Life | 4 years | ||
Acquired Finite-lived Intangible Asset, Residual Value | 0 | ||
Amortization expense | 3,000,000 | 1,000,000 | |
Amortization expense for remainder 2015 | 10,000,000 | ||
Amortization expense for 2016 | 13,000,000 | ||
Amortization expense for 2017 | 3,000,000 | ||
Amortization expense for 2018 | 2,000,000 | ||
Amortization expense for 2019 | 2,000,000 | ||
Amortization expense for 2020 | 2,000,000 | ||
Amortization expense thereafter | 3,000,000 | ||
Capitalized Internal Use Software [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Acquired Finite-lived Intangible Asset, Residual Value | 0 | ||
Amortization expense | 53,000,000 | 84,000,000 | |
Amortization expense for remainder 2015 | 146,000,000 | ||
Amortization expense for 2016 | 167,000,000 | ||
Amortization expense for 2017 | 103,000,000 | ||
Amortization expense for 2018 | 75,000,000 | ||
Amortization expense for 2019 | 68,000,000 | ||
Amortization expense for 2020 | 65,000,000 | ||
Amortization expense thereafter | $145,000,000 | ||
Capitalized Internal Use Software, Except Significant System Conversions [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Weighted-Average Useful Life | 3 years | ||
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Weighted-Average Useful Life | 8 years | ||
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Weighted-Average Useful Life | 10 years |
Earnings_Per_Share_Schedule_of
Earnings Per Share (Schedule of Calculation of Numerator and Denominator in Earnings Per Share) (Details) (USD $) | 3 Months Ended | |
In Millions, except Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Numerator: | ||
Income (loss) from continuing operations, net of taxes | $112 | ($76) |
Less: Income from continuing operations attributable to noncontrolling interests | 20 | 14 |
Income (loss) from continuing operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted | 92 | -90 |
Loss from discontinued operations, net of taxes | -13 | -22 |
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted | ($13) | ($22) |
Denominator: | ||
Weighted-average number of shares outstanding - basic | 114,419,590 | 106,601,997 |
Effect of dilutive securities: | ||
Restricted stock awards | 181,120 | |
Employee stock options | 452,659 | |
Other equity-based awards | 4,299 | |
Weighted-average number of shares outstanding - diluted | 115,057,668 | 106,601,997 |
Earnings_Per_Share_Narrative_D
Earnings Per Share (Narrative) (Details) | 3 Months Ended |
Mar. 31, 2014 | |
Earnings Per Share [Abstract] | |
Increase in number of shares to diluted shares calculation if income from continuing operations would have been generated | 578,587 |
Earnings_Per_Share_Schedule_of1
Earnings Per Share (Schedule of Antidilutive Securities (Details) | 3 Months Ended |
Mar. 31, 2014 | |
Earnings Per Share [Abstract] | |
Employee stock options and restricted stock awards | 1,891,000 |
Stockholders_Equity_Narrative_
Stockholders' Equity (Narrative) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2015 | Dec. 31, 2012 | Dec. 31, 2014 | |
Class of Stock [Line Items] | |||
Total capital stock, shares authorized | 400,000,000 | 400,000,000 | |
Common stock, shares authorized | 300,000,000 | 300,000,000 | |
Preferred stock, shares authorized | 100,000,000 | 100,000,000 | |
Common stock, par value per share | $0.01 | $0.01 | |
Preferred stock, par value per share | $0.01 | $0.01 | |
Preferred stock, shares outstanding | 0 | ||
Common Stock, Dividends, Per Share, Cash Paid | $0.25 | ||
Maximum amount of dividends or stock repurchases permissable under the Credit Facility | $200,000,000 | ||
Annual amount of dividends or stock repurchases permissable under the Credit Facility | 25,000,000 | ||
Amount available for dividend payments, stock repurchases or Senior Notes repurchases at period end | 461,000,000 | ||
Open Market Repurchase Program for Common Stock, Adopted December 10, 2014 [Member] | |||
Class of Stock [Line Items] | |||
Maximum number of shares authorized for repurchase | 5,000,000 | ||
Maximum value of shares authorized under repurchase program | $150,000,000 |
Stockholders_Equity_Schedule_o
Stockholders' Equity (Schedule of Stockholders' Equity) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Dec. 31, 2014 |
Equity, beginning balance | $4,083 | |
Redeemable Noncontrolling Interests, beginning balance | 531 | |
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests | 76 | |
Distributions to noncontrolling interests, net of contributions | -6 | |
Other reclassifications of noncontrolling interests | 1 | |
Adjustment to redemption value of redeemable noncontrolling interests | -6 | |
Issuance of common stock in connection with the exercise of stock options | 18 | |
Cancellation of restricted stock for tax withholdings on vested shares | -20 | |
Share-based compensation | 14 | |
Equity, ending balance | 4,160 | |
Redeemable Noncontrolling Interests, ending balance | 520 | |
Redeemable Noncontrolling Interests (Non- Equity) [Member] | ||
Redeemable Noncontrolling Interests, beginning balance | 531 | |
Comprehensive income (loss) attributable to redeemable noncontrolling interest | 16 | |
Distributions to redeemable noncontrolling interests, net of contributions | -17 | |
Purchase of subsidiary shares from noncontrolling interests | -7 | |
Disposition of less-than-wholly owned hospital owned hospital | -8 | |
Other reclassifications of redeemable noncontrolling interests | -1 | |
Adjustment to redemption value of redeemable noncontrolling interests | 6 | |
Redeemable Noncontrolling Interests, ending balance | 520 | |
Common Stock [Member] | ||
Equity, beginning balance | 1 | |
Equity, ending balance | 1 | 1 |
Additional Paid-in Capital [Member] | ||
Equity, beginning balance | 2,095 | |
Adjustment to redemption value of redeemable noncontrolling interests | -6 | |
Issuance of common stock in connection with the exercise of stock options | 18 | |
Cancellation of restricted stock for tax withholdings on vested shares | -20 | |
Share-based compensation | 14 | |
Equity, ending balance | 2,101 | |
Treasury Stock [Member] | ||
Equity, beginning balance | -7 | |
Equity, ending balance | -7 | -7 |
Accumulated Other Comprehensive (Loss) Income [Member] | ||
Equity, beginning balance | -63 | |
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests | -7 | |
Equity, ending balance | -70 | |
Retained Earnings [Member] | ||
Equity, beginning balance | 1,977 | |
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests | 79 | |
Equity, ending balance | 2,056 | |
Noncontrolling Interests [Member] | ||
Equity, beginning balance | 80 | |
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests | 4 | |
Distributions to noncontrolling interests, net of contributions | -6 | |
Other reclassifications of noncontrolling interests | 1 | |
Equity, ending balance | $79 |
Stockholders_Equity_Schedule_o1
Stockholders' Equity (Schedule of Impact of Noncontrolling Interest to Stockholders' Equity) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Stockholders' Equity [Abstract] | ||
Net loss attributable to Community Health Systems, Inc. stockholders | $79 | ($112) |
Change to Community Health Systems, Inc. stockholders' equity from net loss attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests | $79 |
Equity_Investments_Narrative_D
Equity Investments (Narrative) (Details) (USD $) | 3 Months Ended | ||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 |
Schedule of Equity Method Investments [Line Items] | |||
Equity Method Investments | $488 | $470 | |
Equity in earnings of unconsolidated affiliates | $18 | $11 | |
Four Hospitals in Las Vegas, Nevada [Member] | |||
Schedule of Equity Method Investments [Line Items] | |||
Equity Method Investment, Ownership Percentage | 27.50% | ||
One Hospital in Las Vegas, Nevada [Member] | |||
Schedule of Equity Method Investments [Line Items] | |||
Equity Method Investment, Ownership Percentage | 26.10% | ||
Three Hospitals in Macon Georgia, [Member] | |||
Schedule of Equity Method Investments [Line Items] | |||
Equity Method Investment, Ownership Percentage | 38.00% | ||
HealthTrust [Member] | |||
Schedule of Equity Method Investments [Line Items] | |||
Equity Method Investment, Ownership Percentage | 25.10% |
Equity_Investments_Schedule_of
Equity Investments (Schedule of Financial Information Related to Unconsolidated Entities Included in Consolidated Statement of Income) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Equity Investments [Abstract] | ||
Revenues | $375 | $332 |
Operating costs and expenses | 315 | 294 |
Income from continuing operations before taxes | $60 | $39 |
LongTerm_Debt_Schedule_of_Debt
Long-Term Debt (Schedule of Debt) (Details) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Debt Instrument [Line Items] | ||
Debt | $16,969 | $16,916 |
Current maturities of long-term debt | -229 | -235 |
Long-term debt | 16,740 | 16,681 |
Secured Debt [Member] | Credit Facility, Term Loan A [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 925 | 950 |
Secured Debt [Member] | Credit Facility, Term Loan D [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 4,544 | 4,555 |
Secured Debt [Member] | Credit Facility, Term Loan E [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 1,660 | |
Secured Debt [Member] | Credit Facility, Term Loan F [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 1,700 | |
Line of Credit [Member] | Credit Facility, Revolving Credit Loans [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 62 | |
Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 2,017 | 2,018 |
Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 1,200 | 1,200 |
Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 3,000 | 3,000 |
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 1,600 | 1,600 |
Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 1,000 | 1,000 |
Receivables Facility [Member] | Receivables Facility, Name [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 623 | 614 |
Capital Lease Obligations [Member] | ||
Debt Instrument [Line Items] | ||
Debt | 215 | 228 |
Unsecured Debt [Member] | ||
Debt Instrument [Line Items] | ||
Debt | $83 | $91 |
LongTerm_Debt_Credit_Facility_
Long-Term Debt (Credit Facility as Amended, Amendments and Modifications Narrative) (Details) (USD $) | Jan. 26, 2014 | Jan. 27, 2014 |
Credit Facility, Term Loan B, Initial Funding [Member] | Secured Debt [Member] | ||
Debt Instrument [Line Items] | ||
Balance of Remaining Non-extended Term Loans | $60,000,000 | |
Credit Facility, Term Loan A, March 6, 2012 Amendment [Member] | Secured Debt [Member] | ||
Debt Instrument [Line Items] | ||
Balance of Remaining Non-extended Term Loans | 637,000,000 | |
Credit Facility, Revolving Credit Loans, Third Amendment and Restatement [Member] | Line of Credit [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit Facility, Maximum Borrowing Capacity | 1,000,000,000 | |
Credit Facility, Term Loan A, Third Amendment and Restatement [Member] | Secured Debt [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Face Amount | 1,000,000,000 | |
Credit Facility, Term Loan D, Third Amendment and Restatement [Member] | Secured Debt [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Face Amount | 4,600,000,000 | |
Credit Facility, Term Loan E, Third Amendment and Restatement [Member] | Secured Debt [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Face Amount | $1,700,000,000 |
LongTerm_Debt_Credit_Facility_1
Long-Term Debt (Credit Facility Terms Narrative) (Details) | 3 Months Ended |
Mar. 31, 2015 | |
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member] | |
Debt Instrument [Line Items] | |
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.50% |
Credit Facility, Term Loans [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Equivalent Percentage of Term Loan Facility Related to Net Cash Proceeds of Certain Asset Sales and Dispositions by Company and Its Subsidiaries | 100.00% |
Equivalent Percentage of Term Loan Facility Related to Net Cash Proceeds of Issuance of Certain Debt Obligations or Receivables Based Financing by Company and Its Subsidiaries | 100.00% |
Equivalent Percentage of Term Loan Facility Subject to Reduction to Lower Percentage Based on Company Leverage Ratio | 50.00% |
Alternate Base Rate [Member] | Credit Facility, Term Loan A [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Debt Instrument, Basis Spread on Variable Rate | 1.75% |
Alternate Base Rate [Member] | Credit Facility, Term Loan D [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Derivative, Floor Interest Rate | 2.00% |
Alternate Base Rate [Member] | Credit Facility, Term Loan F [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Debt Instrument, Basis Spread on Variable Rate | 2.25% |
Federal Funds Effective Rate [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Debt Instrument, Basis Spread on Variable Rate | 0.50% |
LIBOR [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member] | |
Debt Instrument [Line Items] | |
Debt Instrument, Basis Spread on Variable Rate | 1.00% |
LIBOR [Member] | Credit Facility, Term Loan A [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Debt Instrument, Basis Spread on Variable Rate | 2.75% |
LIBOR [Member] | Credit Facility, Term Loan D [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Derivative, Floor Interest Rate | 1.00% |
LIBOR [Member] | Credit Facility, Term Loan F [Member] | Secured Debt [Member] | |
Debt Instrument [Line Items] | |
Debt Instrument, Basis Spread on Variable Rate | 3.25% |
LongTerm_Debt_Credit_Facility_2
Long-Term Debt (Credit Facility End of Period Disclosures Narrative) (Details) (USD $) | 3 Months Ended |
Mar. 31, 2015 | |
item | |
Line of Credit [Member] | |
Debt Instrument [Line Items] | |
Line of credit outstanding amount | $62,000,000 |
Credit Facility, Name [Member] | Credit Facility, Type of Debt [Member] | |
Debt Instrument [Line Items] | |
Minimum Number of Additional Tranches Available in Future | 1 |
Aggregate Principal Amount of Each Tranche Available in Future | 1,500,000,000 |
Debt, Weighted Average Interest Rate | 4.40% |
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member] | |
Debt Instrument [Line Items] | |
Line of Credit Facility, Remaining Borrowing Capacity | 1,000,000,000 |
Letters of Credit Outstanding, Amount | $83,000,000 |
LongTerm_Debt_Schedule_of_Earl
Long-Term Debt (Schedule of Early Redemption Prices on 8.0% Senior Notes) (Details) (Senior Notes at 8.0, Due 2019 [Member], Senior Notes [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Debt Instrument, Redemption, Period Three [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 104.00% |
Debt Instrument, Redemption Period, Start Date | 15-Nov-15 |
Debt Instrument, Redemption Period, End Date | 14-Nov-16 |
Debt Instrument, Redemption, Period Four [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 102.00% |
Debt Instrument, Redemption Period, Start Date | 15-Nov-16 |
Debt Instrument, Redemption Period, End Date | 14-Nov-17 |
Debt Instrument, Redemption, Period Five [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 100.00% |
Debt Instrument, Redemption Period, Start Date | 15-Nov-17 |
Debt Instrument, Redemption Period, End Date | 15-Nov-19 |
LongTerm_Debt_Schedule_of_Earl1
Long-Term Debt (Schedule of Early Redemption Prices on 7.125% Senior Notes) (Details) (Senior Notes at 7.125, Due 2020 [Member], Senior Notes [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Debt Instrument, Redemption, Period Three [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 103.56% |
Debt Instrument, Redemption Period, Start Date | 15-Jul-16 |
Debt Instrument, Redemption Period, End Date | 14-Jul-17 |
Debt Instrument, Redemption, Period Four [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 101.78% |
Debt Instrument, Redemption Period, Start Date | 15-Jul-17 |
Debt Instrument, Redemption Period, End Date | 14-Jul-18 |
Debt Instrument, Redemption, Period Five [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 100.00% |
Debt Instrument, Redemption Period, Start Date | 15-Jul-18 |
Debt Instrument, Redemption Period, End Date | 15-Jul-20 |
LongTerm_Debt_Schedule_of_Earl2
Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2018) (Details) (Senior Secured Notes At 5.125 Due 2018 [Member], Senior Secured Notes [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Debt Instrument, Redemption, Period Three [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 102.56% |
Debt Instrument, Redemption Period, Start Date | 15-Aug-15 |
Debt Instrument, Redemption Period, End Date | 14-Aug-16 |
Debt Instrument, Redemption, Period Four [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 101.28% |
Debt Instrument, Redemption Period, Start Date | 15-Aug-16 |
Debt Instrument, Redemption Period, End Date | 14-Aug-17 |
Debt Instrument, Redemption, Period Five [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 100.00% |
Debt Instrument, Redemption Period, Start Date | 15-Aug-17 |
Debt Instrument, Redemption Period, End Date | 15-Aug-18 |
LongTerm_Debt_Schedule_of_Earl3
Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2021) (Details) (Senior Secured Notes at 5.125, Due 2021 [Member], Senior Secured Notes [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Debt Instrument, Redemption, Period Three [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 103.84% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-17 |
Debt Instrument, Redemption Period, End Date | 31-Jan-18 |
Debt Instrument, Redemption, Period Four [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 102.56% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-18 |
Debt Instrument, Redemption Period, End Date | 31-Jan-19 |
Debt Instrument, Redemption, Period Five [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 101.28% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-19 |
Debt Instrument, Redemption Period, End Date | 31-Jan-20 |
Debt Instrument, Redemption, Period Six [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 100.00% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-20 |
Debt Instrument, Redemption Period, End Date | 31-Jan-21 |
LongTerm_Debt_Schedule_of_Earl4
Long-Term Debt (Schedule of Early Redemption Prices on 6.785% Senior Notes) (Details) (Senior Notes at 6.875, Due 2022 [Member], Senior Notes [Member]) | 3 Months Ended |
Mar. 31, 2015 | |
Debt Instrument, Redemption, Period Three [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 103.44% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-18 |
Debt Instrument, Redemption Period, End Date | 31-Jan-19 |
Debt Instrument, Redemption, Period Four [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 101.72% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-19 |
Debt Instrument, Redemption Period, End Date | 31-Jan-20 |
Debt Instrument, Redemption, Period Five [Member] | |
Debt Instrument, Redemption [Line Items] | |
Debt Instrument Redemption Price Percentage | 100.00% |
Debt Instrument, Redemption Period, Start Date | 1-Feb-20 |
Debt Instrument, Redemption Period, End Date | 31-Jan-22 |
LongTerm_Debt_80_Senior_Notes_
Long-Term Debt (8.0% Senior Notes, Due 2019 Narrative) (Details) (USD $) | 1 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | |
Jul. 18, 2012 | Mar. 21, 2012 | Dec. 31, 2011 | Mar. 31, 2015 | Nov. 22, 2011 | |
Senior Notes at 8.875, Due 2015 [Member] | Senior Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Extinguishment of Debt, Amount | $934,000,000 | $850,000,000 | $1,000,000,000 | ||
Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Offering Date | 22-Nov-11 | ||||
Debt Instrument, Maturity Date | 15-Nov-19 | ||||
Debt Instrument, Face Amount | 1,000,000,000 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||
Debt Instrument, Earliest Redemption Date | 15-Nov-15 | ||||
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member] | Senior Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Offering Date | 21-Mar-12 | ||||
Debt Instrument, Face Amount | $1,000,000,000 | ||||
Debt Instrument, Premium Percentage | 102.50% | ||||
Debt Instrument, Redemption, Period Two [Member] | Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument Redemption Price Percentage | 100.00% | ||||
Debt Instrument, Redemption Period, Start Date | 15-Nov-14 | ||||
Debt Instrument, Redemption Period, End Date | 15-Nov-15 | ||||
Debt Instrument, Redemption, Description | plus a "make-whole" premium, as described in the 8% Senior Notes indenture | ||||
Minimum Period Notice for Redemption of Debt | 30 days | ||||
Maximum Period Notice for Redemption of Debt | 60 days |
LongTerm_Debt_7125_Senior_Note
Long-Term Debt (7.125% Senior Notes, Due 2020 Narrative) (Details) (Senior Notes [Member], USD $) | 1 Months Ended | 12 Months Ended | 3 Months Ended | |
Jul. 18, 2012 | Mar. 21, 2012 | Dec. 31, 2011 | Mar. 31, 2015 | |
Senior Notes at 8.875, Due 2015 [Member] | ||||
Debt Instrument [Line Items] | ||||
Extinguishment of Debt, Amount | $934,000,000 | $850,000,000 | $1,000,000,000 | |
Senior Notes at 7.125, Due 2020 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt Instrument, Offering Date | 18-Jul-12 | |||
Debt Instrument, Face Amount | $1,200,000,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 7.13% | |||
Debt Instrument, Earliest Redemption Date | 15-Jul-16 | |||
Debt Instrument, Redemption, Period One [Member] | Senior Notes at 7.125, Due 2020 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt Instrument Redemption Price Percentage | 107.13% | |||
Debt Instrument, Redemption Period, End Date | 15-Jul-15 | |||
Debt Instrument, Redemption, Description | with the proceeds from certain public equity offerings | |||
Debt Instrument, Redemption, Period Two [Member] | Senior Notes at 7.125, Due 2020 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt Instrument Redemption Price Percentage | 100.00% | |||
Debt Instrument, Redemption Period, Start Date | 15-Jul-15 | |||
Debt Instrument, Redemption Period, End Date | 15-Jul-16 | |||
Debt Instrument, Redemption, Description | plus a "make-whole" premium, as described in the 7b% Senior Notes indenture | |||
Minimum Period Notice for Redemption of Debt | 30 days | |||
Maximum Period Notice for Redemption of Debt | 60 days | |||
Maximum [Member] | Debt Instrument, Redemption, Period One [Member] | Senior Notes at 7.125, Due 2020 [Member] | ||||
Debt Instrument [Line Items] | ||||
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount | 35.00% |
LongTerm_Debt_5125_Senior_Note
Long-Term Debt (5.125% Senior Notes, Due 2018 Narrative) (Details) (USD $) | 1 Months Ended | 3 Months Ended |
Aug. 17, 2012 | Mar. 31, 2015 | |
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Offering Date | 17-Aug-12 | |
Debt Instrument, Face Amount | 1,600,000,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.13% | |
Debt Instrument, Earliest Redemption Date | 15-Aug-15 | |
Secured Debt [Member] | Credit Facility, Term Loan B, Initial Funding [Member] | ||
Debt Instrument [Line Items] | ||
Extinguishment of Debt, Amount | 1,600,000,000 | |
Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument Redemption Price Percentage | 105.13% | |
Debt Instrument, Redemption Period, End Date | 15-Aug-15 | |
Debt Instrument, Redemption, Description | with the proceeds from certain public equity offerings | |
Debt Instrument, Redemption, Period Two [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument Redemption Price Percentage | 100.00% | |
Debt Instrument, Redemption Period, Start Date | 15-Aug-15 | |
Debt Instrument, Redemption Period, End Date | 15-Aug-15 | |
Debt Instrument, Redemption, Description | plus a "make-whole" premium, as described in the 2018 Senior Secured Notes indenture | |
Minimum Period Notice for Redemption of Debt | 30 days | |
Maximum Period Notice for Redemption of Debt | 60 days | |
Maximum [Member] | Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Debt Instrument [Line Items] | ||
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount | 35.00% |
LongTerm_Debt_5125_Senior_Note1
Long-Term Debt (5.125% Senior Notes, Due 2021 Narrative) (Details) (Senior Secured Notes [Member], Senior Secured Notes at 5.125, Due 2021 [Member], USD $) | 1 Months Ended | 3 Months Ended |
Jan. 27, 2014 | Mar. 31, 2015 | |
Debt Instrument [Line Items] | ||
Debt Instrument, Offering Date | 27-Jan-14 | |
Debt Instrument, Face Amount | 1,000,000,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.13% | |
Debt Instrument, Earliest Redemption Date | 1-Feb-17 | |
Debt Instrument, Redemption, Period One [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument Redemption Price Percentage | 105.13% | |
Debt Instrument, Redemption Period, End Date | 1-Feb-17 | |
Debt Instrument, Redemption, Description | proceeds from certain equity offerings | |
Debt Instrument, Redemption, Period Two [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument Redemption Price Percentage | 100.00% | |
Debt Instrument, Redemption Period, Start Date | 1-Feb-16 | |
Debt Instrument, Redemption Period, End Date | 1-Feb-17 | |
Debt Instrument, Redemption, Description | plus a "make-whole" premium, as described in the 2021 Senior Secured Notes indenture | |
Minimum Period Notice for Redemption of Debt | 30 days | |
Maximum Period Notice for Redemption of Debt | 60 days | |
Maximum [Member] | Debt Instrument, Redemption, Period One [Member] | ||
Debt Instrument [Line Items] | ||
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount | 40.00% |
LongTerm_Debt_6785_Senior_Note
Long-Term Debt (6.785% Senior Notes, Due 2022 Narrative) (Details) (Senior Notes [Member], Senior Notes at 6.875, Due 2022 [Member], USD $) | 1 Months Ended | 3 Months Ended |
Jan. 27, 2014 | Mar. 31, 2015 | |
Debt Instrument [Line Items] | ||
Debt Instrument, Offering Date | 27-Jan-14 | |
Debt Instrument, Face Amount | 3,000,000,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 6.88% | |
Debt Instrument, Earliest Redemption Date | 1-Feb-18 | |
Debt Instrument, Redemption, Period One [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument Redemption Price Percentage | 106.88% | |
Debt Instrument, Redemption Period, End Date | 1-Feb-18 | |
Debt Instrument, Redemption, Description | proceeds from certain public equity offerings | |
Debt Instrument, Redemption, Period Two [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument Redemption Price Percentage | 100.00% | |
Debt Instrument, Redemption Period, Start Date | 1-Feb-17 | |
Debt Instrument, Redemption Period, End Date | 1-Feb-18 | |
Debt Instrument, Redemption, Description | plus a "make-whole" premium, as described in the 6b% Senior Notes indenture | |
Minimum Period Notice for Redemption of Debt | 30 days | |
Maximum Period Notice for Redemption of Debt | 60 days | |
Maximum [Member] | Debt Instrument, Redemption, Period One [Member] | ||
Debt Instrument [Line Items] | ||
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount | 40.00% |
LongTerm_Debt_Receivables_Faci
Long-Term Debt (Receivables Facility Narrative) (Details) (USD $) | 3 Months Ended | |||
Mar. 31, 2015 | Dec. 31, 2014 | Mar. 21, 2012 | Mar. 07, 2013 | |
Debt Instrument [Line Items] | ||||
Debt | $16,969,000,000 | $16,916,000,000 | ||
Receivables Facility, Name [Member] | Receivables Facility [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt Instrument, Issuance Date | 21-Mar-12 | |||
Maximum Borrowing Capacity of Receivables Facility | 300,000,000 | |||
Debt | 623,000,000 | 614,000,000 | ||
Receivables Facility, March 7, 2013 Amendment [Member] | Receivables Facility [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt Instrument, Issuance Date | 7-Mar-13 | |||
Debt Instrument, Maturity Date | 21-Mar-17 | |||
Maximum Borrowing Capacity of Receivables Facility | 500,000,000 | |||
Receivables Facility, March 31, 2014 Amendment [Member] | Receivables Facility [Member] | ||||
Debt Instrument [Line Items] | ||||
Maximum Borrowing Capacity of Receivables Facility | 700,000,000 | |||
Debt | 623,000,000 | |||
Receivables included in the Receivables Facility | $1,300,000,000 |
LongTerm_Debt_Loss_from_Early_
Long-Term Debt (Loss from Early Extinguishment of Debt Narrative) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Extinguishment of Debt Disclosures [Abstract] | ||
Loss from early extinguishment of debt | $8 | $73 |
Loss on Extinguishment of Debt, Net of Tax | $5 | $45 |
LongTerm_Debt_Other_Debt_and_I
Long-Term Debt (Other Debt and Interest Payments Narrative) (Details) (USD $) | 3 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Debt Instrument [Line Items] | ||
Interest Paid on borrowing | $300,000,000 | $175,000,000 |
Scenario, Previously Reported [Member] | ||
Debt Instrument [Line Items] | ||
Interest Paid on borrowing | 280,000,000 | |
Interest Rate Swap [Member] | ||
Debt Instrument [Line Items] | ||
Derivative Liability, Number of Instruments Held | 7 | |
Interest Rate Swap, Currently Effective [Member] | ||
Debt Instrument [Line Items] | ||
Notional Amount, Liability | 1,300,000,000 | |
Interest Rate Swap, Not Yet Effective [Member] | ||
Debt Instrument [Line Items] | ||
Derivative Liability, Number of Instruments Held | 6 | |
Notional Amount, Liability | $1,700,000,000 | |
Credit Facility, Revolving Credit Loans [Member] | LIBOR [Member] | ||
Debt Instrument [Line Items] | ||
Derivative, Basis Spread on Variable Rate | 2.75% | |
Credit Facility, Term Loan A [Member] | LIBOR [Member] | ||
Debt Instrument [Line Items] | ||
Derivative, Basis Spread on Variable Rate | 2.75% | |
Credit Facility, Term Loan D [Member] | LIBOR [Member] | ||
Debt Instrument [Line Items] | ||
Derivative, Basis Spread on Variable Rate | 3.25% | |
Credit Facility, Term Loan F [Member] | LIBOR [Member] | ||
Debt Instrument [Line Items] | ||
Derivative, Basis Spread on Variable Rate | 3.25% | |
Secured Debt [Member] | Credit Facility, Term Loan D [Member] | LIBOR [Member] | ||
Debt Instrument [Line Items] | ||
Derivative, Floor Interest Rate | 1.00% | |
Secured Debt [Member] | Credit Facility, Term Loan D [Member] | Alternate Base Rate [Member] | ||
Debt Instrument [Line Items] | ||
Derivative, Floor Interest Rate | 2.00% |
Fair_Value_of_Financial_Instru3
Fair Value of Financial Instruments (Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping) (Details) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Assets: | ||
Available-for-sale securities | $285 | $280 |
Trading securities | 58 | 55 |
Liabilities: | ||
Contingent Value Right, Fair Value Disclosure | 6 | 6 |
Carrying Amount Measurement [Member] | ||
Assets: | ||
Cash and cash equivalents | 222 | 509 |
Available-for-sale securities | 285 | 280 |
Trading securities | 58 | 55 |
Liabilities: | ||
Contingent Value Right, Fair Value Disclosure | 6 | 6 |
Carrying Amount Measurement [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member] | ||
Liabilities: | ||
Credit Facility, Fair Value Disclosure | 7,231 | 7,165 |
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 2,017 | 2,018 |
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 1,200 | 1,200 |
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 3,000 | 3,000 |
Carrying Amount Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 1,600 | 1,600 |
Carrying Amount Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 1,000 | 1,000 |
Carrying Amount Measurement [Member] | Receivables Facility and Other Debt, Type [Member] | Receivables Facility and Unsecured Debt [Member] | ||
Liabilities: | ||
Other Liabilities, Fair Value Disclosure | 706 | 705 |
Estimate of Fair Value Measurement [Member] | ||
Assets: | ||
Cash and cash equivalents | 222 | 509 |
Available-for-sale securities | 285 | 280 |
Trading securities | 58 | 55 |
Liabilities: | ||
Contingent Value Right, Fair Value Disclosure | 6 | 6 |
Estimate of Fair Value Measurement [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member] | ||
Liabilities: | ||
Credit Facility, Fair Value Disclosure | 7,249 | 7,143 |
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 2,129 | 2,139 |
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 1,277 | 1,282 |
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 3,211 | 3,194 |
Estimate of Fair Value Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 1,655 | 1,655 |
Estimate of Fair Value Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member] | ||
Liabilities: | ||
Notes Payable, Fair Value Disclosure | 1,034 | 1,041 |
Estimate of Fair Value Measurement [Member] | Receivables Facility and Other Debt, Type [Member] | Receivables Facility and Unsecured Debt [Member] | ||
Liabilities: | ||
Other Liabilities, Fair Value Disclosure | $706 | $705 |
Fair_Value_of_Financial_Instru4
Fair Value of Financial Instruments (Schedule of Interest Rate Swaps) (Details) (Interest Rate Swap [Member], USD $) | 3 Months Ended | |
Mar. 31, 2015 | ||
Interest Rate Swaps One [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | $300,000,000 | |
Fixed Interest Rate | 3.45% | |
Termination Date | 6-Aug-16 | |
Fair Value of Liability | 12,000,000 | |
Interest Rate Swaps Two [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 100,000,000 | |
Fixed Interest Rate | 3.40% | |
Termination Date | 19-Aug-16 | |
Fair Value of Liability | 4,000,000 | |
Interest Rate Swaps Three [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 200,000,000 | |
Fixed Interest Rate | 3.43% | |
Termination Date | 19-Aug-16 | |
Fair Value of Liability | 8,000,000 | |
Interest Rate Swaps Four [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 200,000,000 | |
Fixed Interest Rate | 3.50% | |
Termination Date | 30-Aug-16 | |
Fair Value of Liability | 8,000,000 | |
Interest Rate Swaps Five [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 100,000,000 | |
Fixed Interest Rate | 3.01% | |
Termination Date | 30-Nov-16 | |
Fair Value of Liability | 4,000,000 | |
Interest Rate Swaps Six [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 200,000,000 | |
Fixed Interest Rate | 2.06% | |
Termination Date | 25-Jul-19 | |
Fair Value of Liability | 5,000,000 | |
Interest Rate Swaps Seven [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 200,000,000 | |
Fixed Interest Rate | 2.06% | |
Termination Date | 25-Jul-19 | |
Fair Value of Liability | 5,000,000 | |
Interest Rate Swaps Eight [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 400,000,000 | |
Fixed Interest Rate | 1.88% | |
Termination Date | 30-Aug-19 | |
Fair Value of Liability | 1,000,000 | [1] |
Interest Rate Swaps Nine [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 200,000,000 | |
Fixed Interest Rate | 2.52% | |
Termination Date | 30-Aug-19 | |
Fair Value of Liability | 5,000,000 | [1] |
Interest Rate Swaps Ten [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 200,000,000 | |
Fixed Interest Rate | 2.61% | |
Termination Date | 30-Aug-19 | |
Fair Value of Liability | 6,000,000 | [2] |
Interest Rate Swaps Eleven [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 300,000,000 | |
Fixed Interest Rate | 2.04% | |
Termination Date | 30-Aug-20 | |
Fair Value of Liability | 1,000,000 | [1] |
Interest Rate Swaps Twelve [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 300,000,000 | |
Fixed Interest Rate | 2.74% | |
Termination Date | 30-Aug-20 | |
Fair Value of Liability | 10,000,000 | [1] |
Interest Rate Swaps Thirteen [Member] | ||
Derivative [Line Items] | ||
Notional Amount, Liability | 300,000,000 | |
Fixed Interest Rate | 2.89% | |
Termination Date | 30-Aug-20 | |
Fair Value of Liability | $12,000,000 | [2] |
[1] | This interest rate swap becomes effective August 28, 2015. | |
[2] | This interest rate swap becomes effective August 30, 2015. |
Fair_Value_of_Financial_Instru5
Fair Value of Financial Instruments (Narrative) (Details) (USD $) | Mar. 31, 2015 |
In Millions, unless otherwise specified | |
Fair Value of Financial Instruments [Abstract] | |
Interest expense arising from spread in fixed and floating rates of interest rate swap agreements that will be recognized in next 12 months | $48 |
Fair_Value_of_Financial_Instru6
Fair Value of Financial Instruments (Schedule of Pre-tax Gain (Loss) Recognized as a Component of Other Comprehensive Income) (Details) (Cash Flow Hedging [Member], Interest Rate Swap [Member], USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Cash Flow Hedging [Member] | Interest Rate Swap [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Amount of Pre-Tax Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) | ($22) | ($3) |
Fair_Value_of_Financial_Instru7
Fair Value of Financial Instruments (Schedule of Effective Portion of the Pre-tax Loss Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income) (Details) (Interest Expense [Member], USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Interest Expense [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion) | $9 | $18 |
Fair_Value_of_Financial_Instru8
Fair Value of Financial Instruments (Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet) (Details) (Designated as Hedging Instrument [Member], Other Long-term Liabilities [Member], USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Liability derivatives designated as hedging instruments | $81 | $73 |
Fair_Value_Schedule_of_Fair_Va
Fair Value (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 |
In Millions, unless otherwise specified | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale securities | $285 | $280 |
Trading securities | 58 | 55 |
Total assets | 343 | 335 |
Contingent Value Right (CVR) | 6 | 6 |
CVR-related legal liability | 256 | 265 |
Fair value of interest rate swap agreements | 81 | 68 |
Total liabilities | 343 | 339 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale securities | 156 | 151 |
Trading securities | 58 | 55 |
Total assets | 214 | 206 |
Contingent Value Right (CVR) | 6 | 6 |
Total liabilities | 6 | 6 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale securities | 129 | 129 |
Total assets | 129 | 129 |
Fair value of interest rate swap agreements | 81 | 68 |
Total liabilities | 81 | 68 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
CVR-related legal liability | 256 | 265 |
Total liabilities | $256 | $265 |
Fair_Value_Narrative_Details
Fair Value (Narrative) (Details) (USD $) | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2014 |
In Millions, unless otherwise specified | |||
Fair Value Disclosures [Line Items] | |||
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount | $0 | $0 | |
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount | 0 | 0 | |
CVR-related legal liability | 24 | ||
Interest Rate Swap [Member] | |||
Fair Value Disclosures [Line Items] | |||
Credit risk valuation adjustment, decrease in fair value of liability | 5 | 4 | |
Credit risk valuation adjustment, decrease in fair value of liability, net of tax | $3 | $2 |
Segment_Information_Narrative_
Segment Information (Narrative) (Details) | 3 Months Ended |
Mar. 31, 2015 | |
segment | |
Segment Information [Abstract] | |
Number of Operating Segments | 2 |
Segment_Information_Schedule_o
Segment Information (Schedule of Segment Reporting Information by Segment) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Segment Reporting Information [Line Items] | ||
Net operating revenues | $4,911 | $4,176 |
Income (loss) from continuing operations before income taxes | 168 | -132 |
Hospital operations [Member] | ||
Segment Reporting Information [Line Items] | ||
Net operating revenues | 4,857 | 4,124 |
Income (loss) from continuing operations before income taxes | 273 | 38 |
Corporate and All Other Reporting Units [Member] | ||
Segment Reporting Information [Line Items] | ||
Net operating revenues | 54 | 52 |
Income (loss) from continuing operations before income taxes | ($105) | ($170) |
Other_Comprehensive_Income_Sch
Other Comprehensive Income (Schedule of Changes in Accumulated Other Comprehensive Income by Component) (Details) (USD $) | 3 Months Ended | ||
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Dec. 31, 2013 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated Other Comprehensive Income (Loss), Beginning Balance | ($63) | ($67) | |
Other Comprehensive Income (Loss), before Reclassifications | -14 | -2 | |
Amounts reclassified from accumulated other comprehensive income (loss) | 7 | 11 | |
Other comprehensive (loss) income | -7 | 9 | |
Accumulated Other Comprehensive Income (Loss), Ending Balance | -70 | -58 | |
Change in Fair Value of Interest Rate Swaps [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated Other Comprehensive Income (Loss), Beginning Balance | -43 | -56 | |
Other Comprehensive Income (Loss), before Reclassifications | -15 | -2 | |
Amounts reclassified from accumulated other comprehensive income (loss) | 6 | 11 | |
Other comprehensive (loss) income | -9 | 9 | |
Accumulated Other Comprehensive Income (Loss), Ending Balance | -52 | -47 | |
Change in Fair Value of Available for Sale Securities [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated Other Comprehensive Income (Loss), Beginning Balance | 7 | 7 | |
Other Comprehensive Income (Loss), before Reclassifications | 1 | ||
Other comprehensive (loss) income | 1 | ||
Accumulated Other Comprehensive Income (Loss), Ending Balance | 8 | 7 | 7 |
Change in Unrecognized Pension Cost Components [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated Other Comprehensive Income (Loss), Beginning Balance | -27 | -18 | |
Amounts reclassified from accumulated other comprehensive income (loss) | 1 | ||
Other comprehensive (loss) income | 1 | ||
Accumulated Other Comprehensive Income (Loss), Ending Balance | ($26) | ($18) | ($18) |
Other_Comprehensive_Income_Sch1
Other Comprehensive Income (Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Income) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||
Interest expense, net | $241 | $224 |
Income (loss) from continuing operations before income taxes | 168 | -132 |
Tax benefit | -56 | 56 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | 79 | -112 |
Change in Fair Value of Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||
Interest expense, net | -9 | -18 |
Tax benefit | 3 | 7 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | -6 | -11 |
Change in Unrecognized Pension Cost Components [Member] | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||
Amortization of defined benefit pension items - Actuarial losses | -1 | |
Change in Unrecognized Pension Cost Components [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||
Income (loss) from continuing operations before income taxes | -1 | |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | ($1) |
Contingencies_Contingencies_Na
Contingencies (Contingencies Narrative) (Details) (USD $) | 3 Months Ended | ||
In Millions, except Per Share data, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 | Jan. 27, 2014 |
item | |||
Loss Contingencies [Line Items] | |||
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share | $1 | ||
Deductible related to litigation and contingent value right | $18 | ||
Contingent value right, percentage multiplier | 90.00% | ||
Number of contingent value rights outstanding | 264,544,053 | ||
Amount which CVR holders are no longer entitled to payment | 312 | ||
Contingent value right, period payable after final resolution | 60 days | ||
Business Combination, Contingent Consideration, Liability, Noncurrent | 256 | 284 | |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | -9 | ||
Business Combination, Contingent Consideration, Liability, Current | 24 | ||
Pending Litigation [Member] | Legal Matters Where Negative Outcome is Known or Probable [Member] | |||
Loss Contingencies [Line Items] | |||
Legal Fees | $4 | $3 | |
Class Action Shareholder Federal Securities Cases [Member] | Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member] | |||
Loss Contingencies [Line Items] | |||
Number of legal cases filed | 3 | ||
Shareholder Derivative Actions [Member] | Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member] | |||
Loss Contingencies [Line Items] | |||
Number of legal cases filed | 3 |
Contingencies_Impact_of_Legal_
Contingencies (Impact of Legal Expenses Paid or Incurred to Date and Settlements Paid or Deemed Final) (Details) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 |
Loss Contingencies [Line Items] | |
Beginning balance | $24 |
Settlements paid | |
Legal expenses incurred and/or paid during the three months ended March 31, 2015 | 3 |
Ending balance | 27 |
Deductible [Member] | |
Loss Contingencies [Line Items] | |
Beginning balance | 18 |
Settlements paid | |
Ending balance | 18 |
CHS Responsibility at 10% [Member] | |
Loss Contingencies [Line Items] | |
Settlements paid | |
Legal expenses incurred and/or paid during the three months ended March 31, 2015 | 1 |
Ending balance | 1 |
Reduction to Amount Owed to CVR Holders at 90% [Member] | |
Loss Contingencies [Line Items] | |
Beginning balance | 6 |
Settlements paid | |
Legal expenses incurred and/or paid during the three months ended March 31, 2015 | 2 |
Ending balance | $8 |
Contingencies_Schedule_of_the_
Contingencies (Schedule of the Reconciliation of Accrued Liability Balances for Probable Contingencies) (Details) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 |
Loss Contingency Accrual [Roll Forward] | |
Expense | $8 |
Pending Litigation [Member] | CVR Related Liability at Fair Value [Member] | |
Loss Contingency Accrual [Roll Forward] | |
Beginning Balance | 265 |
Expense | -9 |
Ending Balance | 256 |
Pending Litigation [Member] | CVR Related Liability for Probably Contingencies [Member] | |
Loss Contingency Accrual [Roll Forward] | |
Beginning Balance | 29 |
Expense | -5 |
Ending Balance | 24 |
Pending Litigation [Member] | Legal Matters Where Negative Outcome is Known or Probable [Member] | |
Loss Contingency Accrual [Roll Forward] | |
Beginning Balance | 125 |
Expense | 15 |
Cash payments | -92 |
Ending Balance | $48 |
Subsequent_Events_Narrative_De
Subsequent Events (Narrative) (Details) (USD $) | 3 Months Ended | 0 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2015 | Apr. 01, 2015 |
Subsequent Event [Line Items] | ||
Proceeds from Divestiture of Businesses, Net of Cash Divested | $62 | |
Chesterfield General Hospital and Marlboro Park Hospital [Member] | ||
Subsequent Event [Line Items] | ||
Disposal Date | 1-Apr-15 | |
Subsequent Event [Member] | Chesterfield General Hospital [Member] | ||
Subsequent Event [Line Items] | ||
Number of licensed beds sold | 59 | |
Subsequent Event [Member] | Marlboro Park Hospital [Member] | ||
Subsequent Event [Line Items] | ||
Number of licensed beds sold | 102 | |
Subsequent Event [Member] | Chesterfield General Hospital and Marlboro Park Hospital [Member] | ||
Subsequent Event [Line Items] | ||
Proceeds from Divestiture of Businesses, Net of Cash Divested | $4 |
Supplemental_Condensed_Consoli2
Supplemental Condensed Consolidating Financial Information (Narrative) (Details) | 3 Months Ended |
Mar. 31, 2015 | |
Supplemental Condensed Consolidating Financial Information [Abstract] | |
Percentage of owned domestic subsidiaries which guaranteed senior notes | 100.00% |
Supplemental_Condensed_Consoli3
Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Income (Loss)) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Condensed Consolidating Statements of Income (Unaudited) | ||
Operating revenues (net of contractual allowances and discounts) | $5,646 | $4,875 |
Provision for bad debts | 735 | 699 |
Net operating revenues | 4,911 | 4,176 |
Operating costs and expenses: | ||
Salaries and benefits | 2,257 | 1,992 |
Supplies | 762 | 632 |
Other operating expenses | 1,099 | 1,019 |
Government settlement and related costs | 8 | |
Electronic health records incentive reimbursement | -26 | -40 |
Rent | 116 | 98 |
Depreciation and amortization | 296 | 255 |
Amortization of software to be abandoned | 42 | |
Total operating costs and expenses | 4,512 | 3,998 |
Income from operations | 399 | 178 |
Interest expense, net | 241 | 224 |
Loss from early extinguishment of debt | 8 | 73 |
Equity in earnings of unconsolidated affiliates | -18 | -11 |
Impairment of long-lived assets | 24 | |
Income (loss) from continuing operations before income taxes | 168 | -132 |
Provision for (benefit from) income taxes | 56 | -56 |
Income (loss) from continuing operations | 112 | -76 |
Discontinued operations, net of taxes: | ||
Loss from operations of entities sold or held for sale | -11 | -4 |
Impairment of hospitals sold or held for sale | -1 | -18 |
Loss on sale, net | -1 | |
Loss from discontinued operations, net of taxes | -13 | -22 |
Net income (loss) | 99 | -98 |
Less: Net income attributable to noncontrolling interests | 20 | 14 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | 79 | -112 |
Parent Company [Member] | ||
Operating costs and expenses: | ||
Equity in earnings of unconsolidated affiliates | -79 | 112 |
Income (loss) from continuing operations before income taxes | 79 | -112 |
Income (loss) from continuing operations | 79 | -112 |
Discontinued operations, net of taxes: | ||
Net income (loss) | 79 | -112 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | 79 | -112 |
Subsidiary Issuer [Member] | ||
Condensed Consolidating Statements of Income (Unaudited) | ||
Operating revenues (net of contractual allowances and discounts) | -5 | -4 |
Net operating revenues | -5 | -4 |
Operating costs and expenses: | ||
Income from operations | -5 | -4 |
Interest expense, net | 21 | 40 |
Loss from early extinguishment of debt | 8 | 73 |
Equity in earnings of unconsolidated affiliates | -104 | 27 |
Income (loss) from continuing operations before income taxes | 70 | -144 |
Provision for (benefit from) income taxes | -9 | -32 |
Income (loss) from continuing operations | 79 | -112 |
Discontinued operations, net of taxes: | ||
Net income (loss) | 79 | -112 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | 79 | -112 |
Guarantor Subsidiaries [Member] | ||
Condensed Consolidating Statements of Income (Unaudited) | ||
Operating revenues (net of contractual allowances and discounts) | 3,488 | 3,119 |
Provision for bad debts | 447 | 476 |
Net operating revenues | 3,041 | 2,643 |
Operating costs and expenses: | ||
Salaries and benefits | 1,222 | 1,147 |
Supplies | 492 | 417 |
Other operating expenses | 708 | 663 |
Government settlement and related costs | 8 | |
Electronic health records incentive reimbursement | -17 | -30 |
Rent | 61 | 54 |
Depreciation and amortization | 200 | 189 |
Amortization of software to be abandoned | 26 | |
Total operating costs and expenses | 2,674 | 2,466 |
Income from operations | 367 | 177 |
Interest expense, net | 211 | 172 |
Equity in earnings of unconsolidated affiliates | -5 | 23 |
Impairment of long-lived assets | 24 | |
Income (loss) from continuing operations before income taxes | 161 | -42 |
Provision for (benefit from) income taxes | 61 | -16 |
Income (loss) from continuing operations | 100 | -26 |
Discontinued operations, net of taxes: | ||
Loss from operations of entities sold or held for sale | -3 | |
Impairment of hospitals sold or held for sale | -1 | |
Loss on sale, net | 2 | |
Loss from discontinued operations, net of taxes | 1 | -3 |
Net income (loss) | 101 | -29 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | 101 | -29 |
Non-Guarantor Subsidiaries [Member] | ||
Condensed Consolidating Statements of Income (Unaudited) | ||
Operating revenues (net of contractual allowances and discounts) | 2,163 | 1,760 |
Provision for bad debts | 288 | 223 |
Net operating revenues | 1,875 | 1,537 |
Operating costs and expenses: | ||
Salaries and benefits | 1,035 | 845 |
Supplies | 270 | 215 |
Other operating expenses | 391 | 356 |
Electronic health records incentive reimbursement | -9 | -10 |
Rent | 55 | 44 |
Depreciation and amortization | 96 | 66 |
Amortization of software to be abandoned | 16 | |
Total operating costs and expenses | 1,838 | 1,532 |
Income from operations | 37 | 5 |
Interest expense, net | 9 | 12 |
Income (loss) from continuing operations before income taxes | 28 | -7 |
Provision for (benefit from) income taxes | 4 | -8 |
Income (loss) from continuing operations | 24 | 1 |
Discontinued operations, net of taxes: | ||
Loss from operations of entities sold or held for sale | -11 | -1 |
Impairment of hospitals sold or held for sale | -18 | |
Loss on sale, net | -3 | |
Loss from discontinued operations, net of taxes | -14 | -19 |
Net income (loss) | 10 | -18 |
Less: Net income attributable to noncontrolling interests | 20 | 14 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | -10 | -32 |
Consolidation, Eliminations [Member] | ||
Operating costs and expenses: | ||
Equity in earnings of unconsolidated affiliates | 170 | -173 |
Income (loss) from continuing operations before income taxes | -170 | 173 |
Income (loss) from continuing operations | -170 | 173 |
Discontinued operations, net of taxes: | ||
Net income (loss) | -170 | 173 |
Net income (loss) attributable to Community Health Systems, Inc. stockholders | ($170) | $173 |
Supplemental_Condensed_Consoli4
Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Comprehensive Income (Loss)) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Condensed Consolidating Statement of Comprehensive Income (Unaudited) | ||
Net income (loss) | $99 | ($98) |
Other comprehensive (loss) income, net of income taxes: | ||
Net change in fair value of interest rate swaps, net of tax | -9 | 9 |
Net change in fair value of available-for-sale securities, net of tax | 1 | |
Amortization and recognition of unrecognized pension cost components, net of tax | 1 | |
Other comprehensive (loss) income | -7 | 9 |
Comprehensive income (loss) | 92 | -89 |
Less: Comprehensive income attributable to noncontrolling interests | 20 | 14 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | 72 | -103 |
Parent Company [Member] | ||
Condensed Consolidating Statement of Comprehensive Income (Unaudited) | ||
Net income (loss) | 79 | -112 |
Other comprehensive (loss) income, net of income taxes: | ||
Net change in fair value of interest rate swaps, net of tax | -9 | 9 |
Net change in fair value of available-for-sale securities, net of tax | 1 | |
Amortization and recognition of unrecognized pension cost components, net of tax | 1 | |
Other comprehensive (loss) income | -7 | 9 |
Comprehensive income (loss) | 72 | -103 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | 72 | -103 |
Subsidiary Issuer [Member] | ||
Condensed Consolidating Statement of Comprehensive Income (Unaudited) | ||
Net income (loss) | 79 | -112 |
Other comprehensive (loss) income, net of income taxes: | ||
Net change in fair value of interest rate swaps, net of tax | -9 | 9 |
Net change in fair value of available-for-sale securities, net of tax | 1 | |
Amortization and recognition of unrecognized pension cost components, net of tax | 1 | |
Other comprehensive (loss) income | -7 | 9 |
Comprehensive income (loss) | 72 | -103 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | 72 | -103 |
Guarantor Subsidiaries [Member] | ||
Condensed Consolidating Statement of Comprehensive Income (Unaudited) | ||
Net income (loss) | 101 | -29 |
Other comprehensive (loss) income, net of income taxes: | ||
Net change in fair value of available-for-sale securities, net of tax | 1 | |
Amortization and recognition of unrecognized pension cost components, net of tax | 1 | |
Other comprehensive (loss) income | 2 | |
Comprehensive income (loss) | 103 | -29 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | 103 | -29 |
Non-Guarantor Subsidiaries [Member] | ||
Condensed Consolidating Statement of Comprehensive Income (Unaudited) | ||
Net income (loss) | 10 | -18 |
Other comprehensive (loss) income, net of income taxes: | ||
Comprehensive income (loss) | 10 | -18 |
Less: Comprehensive income attributable to noncontrolling interests | 20 | 14 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | -10 | -32 |
Consolidation, Eliminations [Member] | ||
Condensed Consolidating Statement of Comprehensive Income (Unaudited) | ||
Net income (loss) | -170 | 173 |
Other comprehensive (loss) income, net of income taxes: | ||
Net change in fair value of interest rate swaps, net of tax | 9 | -9 |
Net change in fair value of available-for-sale securities, net of tax | -2 | |
Amortization and recognition of unrecognized pension cost components, net of tax | -2 | |
Other comprehensive (loss) income | 5 | -9 |
Comprehensive income (loss) | -165 | 164 |
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders | ($165) | $164 |
Supplemental_Condensed_Consoli5
Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Balance Sheet) (Details) (USD $) | Mar. 31, 2015 | Dec. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 |
In Millions, unless otherwise specified | ||||
Current assets: | ||||
Cash and cash equivalents | $222 | $509 | $613 | $373 |
Patient accounts receivable, net of allowance for doubtful accounts | 3,606 | 3,409 | ||
Supplies | 561 | 557 | ||
Prepaid income taxes | 30 | |||
Deferred income taxes | 341 | 341 | ||
Prepaid expenses and taxes | 189 | 192 | ||
Other current assets | 507 | 528 | ||
Total current assets | 5,426 | 5,566 | ||
Property and equipment, net | 10,091 | 10,169 | ||
Goodwill | 8,954 | 8,951 | ||
Other assets, net | 2,648 | 2,735 | ||
Total assets | 27,119 | 27,421 | ||
Current liabilities: | ||||
Current maturities of long-term debt | 229 | 235 | ||
Accounts payable | 1,192 | 1,293 | ||
Income tax payable | 13 | |||
Deferred income taxes | 23 | 23 | ||
Accrued interest | 157 | 227 | ||
Accrued liabilities | 1,547 | 1,811 | ||
Total current liabilities | 3,161 | 3,589 | ||
Long-term debt | 16,740 | 16,681 | ||
Deferred income taxes | 844 | 845 | ||
Other long-term liabilities | 1,694 | 1,692 | ||
Total liabilities | 22,439 | 22,807 | ||
Redeemable noncontrolling interests in equity of consolidated subsidiaries | 520 | 531 | ||
Community Health Systems, Inc. stockholders' equity: | ||||
Preferred stock | ||||
Common stock | 1 | 1 | ||
Additional paid-in capital | 2,101 | 2,095 | ||
Treasury stock, at cost | -7 | -7 | ||
Accumulated other comprehensive loss | -70 | -63 | -58 | -67 |
Retained earnings | 2,056 | 1,977 | ||
Total Community Health Systems, Inc. stockholders' equity | 4,081 | 4,003 | ||
Noncontrolling interests in equity of consolidated subsidiaries | 79 | 80 | ||
Total equity | 4,160 | 4,083 | ||
Total liabilities and equity | 27,119 | 27,421 | ||
Parent Company [Member] | ||||
Current assets: | ||||
Prepaid income taxes | 30 | |||
Deferred income taxes | 341 | 341 | ||
Total current assets | 341 | 371 | ||
Intercompany receivable | 1,257 | 1,199 | ||
Other assets, net | 6 | 15 | ||
Net investment in subsidiaries | 3,361 | 3,290 | ||
Total assets | 4,965 | 4,875 | ||
Current liabilities: | ||||
Income tax payable | 13 | |||
Deferred income taxes | 23 | 23 | ||
Accrued liabilities | 4 | 4 | ||
Total current liabilities | 40 | 27 | ||
Deferred income taxes | 844 | 845 | ||
Total liabilities | 884 | 872 | ||
Community Health Systems, Inc. stockholders' equity: | ||||
Common stock | 1 | 1 | ||
Additional paid-in capital | 2,101 | 2,095 | ||
Treasury stock, at cost | -7 | -7 | ||
Accumulated other comprehensive loss | -70 | -63 | ||
Retained earnings | 2,056 | 1,977 | ||
Total Community Health Systems, Inc. stockholders' equity | 4,081 | 4,003 | ||
Total equity | 4,081 | 4,003 | ||
Total liabilities and equity | 4,965 | 4,875 | ||
Subsidiary Issuer [Member] | ||||
Current assets: | ||||
Intercompany receivable | 16,512 | 16,560 | ||
Other assets, net | 303 | 302 | ||
Net investment in subsidiaries | 18,435 | 18,229 | ||
Total assets | 35,250 | 35,091 | ||
Current liabilities: | ||||
Current maturities of long-term debt | 163 | 163 | ||
Accounts payable | 1 | |||
Accrued interest | 155 | 225 | ||
Total current liabilities | 319 | 388 | ||
Long-term debt | 15,885 | 15,820 | ||
Intercompany payable | 14,822 | 14,752 | ||
Other long-term liabilities | 862 | 841 | ||
Total liabilities | 31,888 | 31,801 | ||
Community Health Systems, Inc. stockholders' equity: | ||||
Additional paid-in capital | 1,294 | 1,208 | ||
Accumulated other comprehensive loss | -70 | -63 | ||
Retained earnings | 2,138 | 2,145 | ||
Total Community Health Systems, Inc. stockholders' equity | 3,362 | 3,290 | ||
Total equity | 3,362 | 3,290 | ||
Total liabilities and equity | 35,250 | 35,091 | ||
Guarantor Subsidiaries [Member] | ||||
Current assets: | ||||
Cash and cash equivalents | 37 | 368 | 450 | 239 |
Patient accounts receivable, net of allowance for doubtful accounts | 1,430 | 1,272 | ||
Supplies | 377 | 373 | ||
Prepaid expenses and taxes | 131 | 138 | ||
Other current assets | 329 | 356 | ||
Total current assets | 2,304 | 2,507 | ||
Intercompany receivable | 3,314 | 2,532 | ||
Property and equipment, net | 6,613 | 6,548 | ||
Goodwill | 5,483 | 5,480 | ||
Other assets, net | 1,817 | 1,874 | ||
Net investment in subsidiaries | 7,643 | 7,399 | ||
Total assets | 27,174 | 26,340 | ||
Current liabilities: | ||||
Current maturities of long-term debt | 54 | 61 | ||
Accounts payable | 873 | 909 | ||
Accrued interest | 1 | 2 | ||
Accrued liabilities | 1,051 | 1,249 | ||
Total current liabilities | 1,979 | 2,221 | ||
Long-term debt | 127 | 139 | ||
Intercompany payable | 20,071 | 19,066 | ||
Other long-term liabilities | 1,113 | 1,140 | ||
Total liabilities | 23,290 | 22,566 | ||
Community Health Systems, Inc. stockholders' equity: | ||||
Additional paid-in capital | 1,471 | 1,369 | ||
Accumulated other comprehensive loss | -17 | -25 | ||
Retained earnings | 2,430 | 2,430 | ||
Total Community Health Systems, Inc. stockholders' equity | 3,884 | 3,774 | ||
Total equity | 3,884 | 3,774 | ||
Total liabilities and equity | 27,174 | 26,340 | ||
Non-Guarantor Subsidiaries [Member] | ||||
Current assets: | ||||
Cash and cash equivalents | 185 | 141 | 163 | 134 |
Patient accounts receivable, net of allowance for doubtful accounts | 2,176 | 2,137 | ||
Supplies | 184 | 184 | ||
Prepaid expenses and taxes | 58 | 54 | ||
Other current assets | 178 | 172 | ||
Total current assets | 2,781 | 2,688 | ||
Intercompany receivable | 6,131 | 7,877 | ||
Property and equipment, net | 3,478 | 3,621 | ||
Goodwill | 3,471 | 3,471 | ||
Other assets, net | 1,164 | 1,179 | ||
Total assets | 17,025 | 18,836 | ||
Current liabilities: | ||||
Current maturities of long-term debt | 12 | 11 | ||
Accounts payable | 318 | 384 | ||
Accrued interest | 1 | |||
Accrued liabilities | 492 | 558 | ||
Total current liabilities | 823 | 953 | ||
Long-term debt | 728 | 722 | ||
Intercompany payable | 14,117 | 15,795 | ||
Other long-term liabilities | 361 | 346 | ||
Total liabilities | 16,029 | 17,816 | ||
Redeemable noncontrolling interests in equity of consolidated subsidiaries | 520 | 531 | ||
Community Health Systems, Inc. stockholders' equity: | ||||
Additional paid-in capital | 523 | 528 | ||
Accumulated other comprehensive loss | 5 | |||
Retained earnings | -126 | -124 | ||
Total Community Health Systems, Inc. stockholders' equity | 397 | 409 | ||
Noncontrolling interests in equity of consolidated subsidiaries | 79 | 80 | ||
Total equity | 476 | 489 | ||
Total liabilities and equity | 17,025 | 18,836 | ||
Consolidation, Eliminations [Member] | ||||
Current assets: | ||||
Intercompany receivable | -27,214 | -28,168 | ||
Other assets, net | -642 | -635 | ||
Net investment in subsidiaries | -29,439 | -28,918 | ||
Total assets | -57,295 | -57,721 | ||
Current liabilities: | ||||
Intercompany payable | -49,010 | -49,613 | ||
Other long-term liabilities | -642 | -635 | ||
Total liabilities | -49,652 | -50,248 | ||
Community Health Systems, Inc. stockholders' equity: | ||||
Additional paid-in capital | -3,288 | -3,105 | ||
Accumulated other comprehensive loss | 87 | 83 | ||
Retained earnings | -4,442 | -4,451 | ||
Total Community Health Systems, Inc. stockholders' equity | -7,643 | -7,473 | ||
Total equity | -7,643 | -7,473 | ||
Total liabilities and equity | ($57,295) | ($57,721) |
Supplemental_Condensed_Consoli6
Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Cash Flows) (Details) (USD $) | 3 Months Ended | |
In Millions, unless otherwise specified | Mar. 31, 2015 | Mar. 31, 2014 |
Cash flows from operating activities: | ||
Net cash (used in) provided by operating activities | ($61) | $65 |
Cash flows from investing activities: | ||
Acquisitions of facilities and other related equipment | -13 | -2,774 |
Purchases of property and equipment | -241 | -181 |
Proceeds from disposition of hospitals and other ancillary operations | 62 | |
Proceeds from sale of property and equipment | 3 | |
Purchases of available-for-sale securities | -59 | -78 |
Proceeds from sales of available-for-sale securities | 56 | 76 |
Increase in other investments | -39 | -99 |
Net cash used in investing activities | -231 | -3,056 |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 17 | 6 |
Repurchase of restricted stock shares for payroll tax withholding requirements | -20 | -11 |
Deferred financing costs and other debt-related costs | -20 | -269 |
Excess tax benefit relating to stock-based compensation | 3 | |
Redemption of noncontrolling investments in joint ventures | -7 | -5 |
Distributions to noncontrolling investors in joint ventures | -23 | -19 |
Borrowings under credit agreements | 1,251 | 7,079 |
Issuance of long-term debt | 4,000 | |
Proceeds from receivables facility | 75 | 133 |
Repayments of long-term indebtedness | -1,268 | -7,686 |
Net cash provided by financing activities | 5 | 3,231 |
Net change in cash and cash equivalents | -287 | 240 |
Cash and cash equivalents at beginning of period | 509 | 373 |
Cash and cash equivalents at end of period | 222 | 613 |
Parent Company [Member] | ||
Cash flows from operating activities: | ||
Net cash (used in) provided by operating activities | -10 | 73 |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 17 | 6 |
Repurchase of restricted stock shares for payroll tax withholding requirements | -20 | -11 |
Excess tax benefit relating to stock-based compensation | 3 | |
Changes in intercompany balances with affiliates, net | 13 | -71 |
Net cash provided by financing activities | 10 | -73 |
Subsidiary Issuer [Member] | ||
Cash flows from operating activities: | ||
Net cash (used in) provided by operating activities | -123 | 298 |
Cash flows from financing activities: | ||
Deferred financing costs and other debt-related costs | -20 | -269 |
Changes in intercompany balances with affiliates, net | 77 | -3,417 |
Borrowings under credit agreements | 1,250 | 7,062 |
Issuance of long-term debt | 4,000 | |
Repayments of long-term indebtedness | -1,184 | -7,674 |
Net cash provided by financing activities | 123 | -298 |
Guarantor Subsidiaries [Member] | ||
Cash flows from operating activities: | ||
Net cash (used in) provided by operating activities | 23 | 62 |
Cash flows from investing activities: | ||
Acquisitions of facilities and other related equipment | -11 | -2,760 |
Purchases of property and equipment | -199 | -143 |
Proceeds from disposition of hospitals and other ancillary operations | 4 | |
Purchases of available-for-sale securities | -22 | |
Proceeds from sales of available-for-sale securities | 19 | |
Increase in other investments | -30 | -75 |
Net cash used in investing activities | -239 | -2,978 |
Cash flows from financing activities: | ||
Changes in intercompany balances with affiliates, net | -101 | 3,117 |
Borrowings under credit agreements | 1 | 17 |
Repayments of long-term indebtedness | -15 | -7 |
Net cash provided by financing activities | -115 | 3,127 |
Net change in cash and cash equivalents | -331 | 211 |
Cash and cash equivalents at beginning of period | 368 | 239 |
Cash and cash equivalents at end of period | 37 | 450 |
Non-Guarantor Subsidiaries [Member] | ||
Cash flows from operating activities: | ||
Net cash (used in) provided by operating activities | 49 | -368 |
Cash flows from investing activities: | ||
Acquisitions of facilities and other related equipment | -2 | -14 |
Purchases of property and equipment | -42 | -38 |
Proceeds from disposition of hospitals and other ancillary operations | 58 | |
Proceeds from sale of property and equipment | 3 | |
Purchases of available-for-sale securities | -37 | -78 |
Proceeds from sales of available-for-sale securities | 37 | 76 |
Increase in other investments | -9 | -24 |
Net cash used in investing activities | 8 | -78 |
Cash flows from financing activities: | ||
Redemption of noncontrolling investments in joint ventures | -7 | -5 |
Distributions to noncontrolling investors in joint ventures | -23 | -19 |
Changes in intercompany balances with affiliates, net | 11 | 371 |
Proceeds from receivables facility | 75 | 133 |
Repayments of long-term indebtedness | -69 | -5 |
Net cash provided by financing activities | -13 | 475 |
Net change in cash and cash equivalents | 44 | 29 |
Cash and cash equivalents at beginning of period | 141 | 134 |
Cash and cash equivalents at end of period | $185 | $163 |